ARCADIUM LITHIUM PLC, 10-K filed on 2/27/2025
Annual Report
v3.25.0.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2024
Feb. 25, 2025
Jun. 30, 2024
Entity Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-38694    
Entity Registrant Name ARCADIUM LITHIUM PLC    
Entity Incorporation, State or Country Code Y9    
Entity Tax Identification Number 98-1737136    
Entity Address, Address Line One 1818 Market Street    
Entity Address, Address Line Two Suite 2550    
Entity Address, City or Town Philadelphia    
Entity Address, State or Province PA    
Entity Address, Country US    
Entity Address, Postal Zip Code 19103    
City Area Code 215    
Local Phone Number 299-5900    
Title of 12(b) Security Ordinary Shares, $1.00 par value per share    
Trading Symbol ALTM    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction false    
Entity Shell Company false    
Entity Public Float     $ 3,608,469,742
Entity Common Stock, Shares Outstanding   1,076,858,925  
Documents Incorporated by Reference
Portions of the registrant's definitive proxy statement to be filed with the Securities and Exchange Commission in connection with the registrant's annual meeting of shareholders or on an amendment on Form 10-K/A are incorporated by reference in Part III.
    
Entity Central Index Key 0001977303    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Amendment Flag false    
Other Address      
Entity Information [Line Items]      
Entity Address, Address Line One Suite 12, Gateway Hub    
Entity Address, Address Line Two Shannon Airport House    
Entity Address, City or Town Shannon, Co. Clare    
Entity Address, Country IE    
Entity Address, Postal Zip Code V14 E370    
City Area Code 353-1    
Local Phone Number 6875238    
v3.25.0.1
Audit Information
 12 Months Ended
Dec. 31, 2024
Audit Information [Abstract]  
Auditor Name KPMG LLP
Auditor Location Philadelphia, PA
Auditor Firm ID 185
v3.25.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]      
Revenue $ 1,007.8 $ 882.5 $ 813.2
Costs and expenses:      
Cost of sales 719.2 344.1 [1] 410.7 [1]
Gross margin 288.6 538.4 [1] 402.5 [1]
Impairment charges 51.7 0.0 [1],[2] 0.0 [1],[2]
Selling, general and administrative expenses 126.8 63.2 [1] 55.2 [1]
Research and development expenses 6.4 5.8 [1] 3.9 [1]
Restructuring and other charges 157.2 56.9 [1] 7.3 [1]
Separation-related costs 0.0 0.0 [1] 0.7 [1]
Total costs and expenses 1,061.3 470.0 [1] 477.8 [1]
(Loss)/income from operations before equity in net loss of unconsolidated affiliates, interest income, net, loss on debt extinguishment and other (gains)/losses (53.5) 412.5 [1] 335.4 [1]
Equity in net loss of unconsolidated affiliates 7.5 23.1 [1],[2] 15.1 [1],[2]
Interest income, net (20.3) 0.0 [1] 0.0 [1]
Loss on debt extinguishment 1.1 0.0 [1] 0.1 [1]
Other (gains)/losses (252.4) 0.4 [1] (15.2) [1]
Income from operations before income taxes 210.6 389.0 [1] 335.4 [1]
Income tax expense 78.9 58.9 [1] 61.9 [1]
Net income 131.7 330.1 [2] 273.5 [2]
Net loss attributable to noncontrolling interests 28.5 0.0 [1] 0.0 [1]
Net income attributable to Arcadium Lithium plc $ 103.2 $ 330.1 [1],[3] $ 273.5 [1],[3]
Basic earnings per ordinary share (in dollars per share) $ 0.10 $ 0.76 [1] $ 0.66 [1]
Diluted earnings per ordinary share (in dollars per share) $ 0.09 $ 0.66 [1] $ 0.56 [1]
Weighted average ordinary shares outstanding - basic (in shares) 1,069.8 432.4 [1] 413.4 [1]
Weighted average ordinary shares outstanding - diluted (in shares) 1,138.7 503.4 [1] 485.2 [1]
[1] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
[2] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
[3] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)
Jan. 04, 2024
Dec. 31, 2023
Dec. 31, 2022
Exchange ratio   2.406 2.406
Allkem Livent Merger      
Exchange ratio 2.406    
v3.25.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
 [2]
Dec. 31, 2022
 [2]
Statement of Comprehensive Income [Abstract]      
Net income $ 103.2 $ 330.1 [1] $ 273.5 [1]
Foreign currency adjustments:      
Foreign currency translation (loss)/income arising during the period (40.6) 1.2 (7.9)
Total foreign currency translation adjustments (40.6) 1.2 (7.9)
Derivative instruments:      
Unrealized hedging losses, net of tax of zero, zero and $0.2 (0.6) (0.5) (0.9)
Reclassification of deferred hedging losses included in net income, net of tax of zero, zero and $(0.2) [3] 0.6 0.5 0.7
Total derivative instruments 0.0 0.0 (0.2)
Other comprehensive (loss)/income, net of tax (40.6) 1.2 (8.1)
Comprehensive income 62.6 331.3 265.4
Comprehensive loss attributable to the noncontrolling interest (13.2) 0.0 0.0
Comprehensive income attributable to Arcadium Lithium plc $ 75.8 $ 331.3 $ 265.4
[1] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
[2] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
[3] For more detail on the components of these reclassifications and the affected line item in the consolidated statements of operations, see Note 19 within these consolidated financial statements.
v3.25.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Statement of Comprehensive Income [Abstract]      
Unrealized hedging (losses)/gains, net of tax $ 0 $ 0 $ 200,000
Reclassification of deferred hedging losses/(gains) included in net income, net of tax $ 0 $ 0 $ (200,000)
v3.25.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
 [1]
Current assets    
Cash and cash equivalents $ 93.2 $ 237.6
Trade receivables, net of allowance of less than $0.1 in 2024 and $0.3 in 2023 130.3 106.7
Inventories, net 417.6 217.5
Prepaid and other current assets 218.7 86.4
Total current assets 859.8 648.2
Investments 36.9 34.8
Property, plant and equipment, net of accumulated depreciation of $351.2 in 2024 and $269.1 in 2023 7,371.2 2,237.1
Goodwill 1,362.9 120.7
Other intangibles, net 62.2 53.4
Deferred income taxes 37.8 1.4
Right of use assets - operating leases, net 47.0 6.8
Other assets 412.3 127.7
Total assets 10,190.1 3,230.1
Current liabilities    
Short-term debt and current portion of long-term debt 288.9 2.4
Accounts payable, trade and other 205.6 115.4
Accrued and other liabilities 189.8 136.8
Contract liability - short-term 42.3 4.4
Operating lease liabilities - current 5.9 1.3
Income taxes 56.5 8.3
Total current liabilities 789.0 268.6
Long-term debt 671.7 299.6
Operating lease liabilities - long-term 40.9 5.6
Environmental liabilities 6.9 7.0
Deferred income taxes 1,151.0 126.4
Contract liability - long-term 238.1 217.8
Other long-term liabilities 111.7 21.3
Commitments and contingent liabilities (Note 22) 0.0 0.0
Total current and long-term liabilities 3,009.3 946.3
Arcadium Lithium plc shareholders' equity:    
Ordinary shares; $1.00 par value; 5 billion shares authorized; 1,076,519,022 and 433,059,946 shares issued; 1,076,258,878 and 432,796,277 outstanding at December 31, 2024 and 2023, respectively 0.1 0.1
Capital in excess of par value of ordinary shares 5,585.4 1,170.4
Retained earnings 767.7 664.5
Accumulated other comprehensive loss (90.4) (49.8)
Treasury shares, ordinary, at cost; 260,144 and 263,669 shares at December 31, 2024 and 2023, respectively (0.9) (1.0)
Total Arcadium Lithium plc shareholders’ equity 6,261.9 1,784.2
Noncontrolling interest 918.9 499.6
Total equity 7,180.8 2,283.8 [2]
Total liabilities and equity $ 10,190.1 $ 3,230.1
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
[2] Represents the financial position of predecessor Livent as of December 31, 2023, 2022 and 2021 which does not include the financial position of Allkem.
v3.25.0.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Current assets    
Allowance for trade receivable $ 0.1 $ 0.3
Accumulated depreciation $ 351.2 $ 269.1
Arcadium Lithium plc shareholders' equity:    
Common stock, par value (in dollars per share) $ 1.00 $ 1.00
Common stock, authorized (in shares) 5,000,000,000 5,000,000,000
Common stock, issued (in shares) 1,076,519,022 433,059,946
Common stock, outstanding (in shares) 1,076,258,878 432,796,277
Treasury stock, issued (in shares) 260,144 263,669
v3.25.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash (used in)/provided by operating activities:      
Net income $ 131.7 $ 330.1 [1] $ 273.5 [1]
Adjustments to reconcile net income to cash (used in)/provided by operating activities:      
Depreciation and amortization 124.0 29.6 [1] 27.7 [1]
Restructuring and other (income)/charges (34.9) 28.1 [1] 4.0 [1]
Impairment charges 51.7 0.0 [1],[2] 0.0 [1],[2]
Deferred income taxes (249.2) (4.4) [1] 3.8 [1]
Share-based compensation 12.2 8.4 [1] 6.8 [1]
Change in investments in trust fund securities (0.6) (0.2) [1] (0.5) [1]
Equity in net loss of unconsolidated affiliates 7.5 23.1 [1],[2] 15.1 [1],[2]
Other gain, Blue Chip Swap (67.8) (68.5) [1] (22.2) [1]
Other non-cash adjustments (0.3) 0.0 [1] 1.3 [1]
Changes in operating assets and liabilities:      
Trade receivables, net 39.5 34.7 [1] (51.1) [1]
Changes in deferred compensation 1.5 1.8 [1] (0.3) [1]
Inventories (75.1) (68.9) [1] (22.9) [1]
Accounts payable, trade and other (120.5) (17.2) [1] 18.9 [1]
Contract liability - short-term 37.9 (11.1) [1] 15.5 [1]
Contract liability - long-term (33.0) 0.0 [1] 198.0 [1]
Income taxes (31.1) (4.7) [1] 10.5 [1]
Change in prepaid and other current assets and other assets (68.0) 32.5 [1] (31.1) [1]
Change in accrued and other liabilities and other long-term liabilities 98.5 (16.0) [1] 7.7 [1]
Net cash (used in)/provided by operating activities (176.0) 297.3 [1] 454.7 [1]
Cash used in investing activities:      
Capital expenditures [3] (1,043.0) (327.1) [1] (336.9) [1]
Investment in-transit - Nemaska Lithium [4] (96.7) 0.0 [1] 0.0 [1]
Proceeds from Blue Chip Swap, net of purchases 67.8 68.5 [1] 22.2 [1]
Investments in unconsolidated affiliates (40.7) (88.7) [1] (47.1) [1]
Other investing activities (14.1) (14.5) [1] (2.9) [1]
Net cash used in investing activities (445.3) (228.3) [1] (364.7) [1]
Cash provided by/(used in) financing activities:      
Proceeds from Revolving Credit Facility 467.0 0.0 [1] 13.0 [1]
Repayments of Revolving Credit Facility (123.0) 0.0 [1] (13.0) [1]
Repayment of QLP Note 0.0 0.0 [1] (13.5) [1]
Repayments of project loan facilities (83.2) 0.0 [1] 0.0 [1]
Proceeds from Nemaska supply agreement prepayment 150.0 0.0 [1] 0.0 [1]
Capital contribution from noncontrolling interest - Nemaska Lithium 83.0 0.0 [1] 0.0 [1]
Payment of deposit to customs authorities 0.0 (21.7) [1] 0.0 [1]
Other financing activities (1.4) 1.3 [1] 1.0 [1]
Net cash provided by/(used in) financing activities 492.4 (20.4) [1] (12.5) [1]
Effect of exchange rate changes on cash and cash equivalents (15.5) 0.0 [1] (1.5) [1]
(Decrease)/increase in Cash and cash equivalents and Restricted Cash (144.4) 48.6 [1] 76.0 [1]
Cash and cash equivalents, beginning of period [1] 237.6 189.0 113.0
Cash and cash equivalents, end of period 93.2 237.6 [1] 189.0 [1]
Supplemental disclosure for cash flow:      
Cash payments for income taxes, net of refunds [5] 145.5 65.9 [1] 43.1 [1]
Cash payments for interest [3] 29.0 11.7 [1] 12.3 [1]
Cash payments for Restructuring and other charges 192.1 28.7 [1] 3.5 [1]
Cash payments for Separation-related charges 0.0 0.0 [1] 0.9 [1]
Accrued capital expenditures 205.4 56.2 [1] 16.5 [1]
Accrued investment in unconsolidated affiliates 0.0 27.0 [1] 0.2 [1]
Non-cash assumption of QLP Note 0.0 0.0 [1] 13.5 [1]
Non-cash investment in unconsolidated affiliate 0.0 0.0 [1] 387.1 [1]
Operating lease right-of-use assets and lease liabilities recorded for ASC 842 2.2 0.9 [1] 0.0 [1]
Acquired cash & cash equivalents - Allkem Livent Merger      
Changes in operating assets and liabilities:      
Income taxes (49.3)    
Cash used in investing activities:      
Cash & cash equivalents 681.4 0.0 [1] 0.0 [1]
Nemaska - cash & cash equivalents      
Cash used in investing activities:      
Cash & cash equivalents [6] $ 0.0 $ 133.5 [1] $ 0.0 [1]
[1] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
[2] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
[3] For the years ended December 31, 2024, 2023, and 2022, $24.9 million, $16.8 million and $15.8 million of interest was capitalized, respectively. For the years ended December 31, 2024, 2023 and 2022, cash payments for interest capitalized were $20.6 million, $11.7 million and $12.3 million, respectively.
[4] Represents the Company's cash contributed to Nemaska Lithium in the fourth quarter of 2024 which, due to one-quarter lag reporting, is not yet recorded in our consolidation of Nemaska. The balance is recorded to Other assets - noncurrent because the cash is expected to be used by Nemaska primarily for capital expenditures. See Note 9 for details.
[5] The year ended December 31, 2024 includes refunds of $1.4 million relating to U.S. state taxes. The years ended December 31, 2023 and 2022 include refunds of $1.0 million relating to U.S. foreign and state taxes, respectively.
[6] On October 18, 2023 we began consolidating Nemaska Lithium, see Note 9 for details.
v3.25.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Capitalized interest costs $ 24.9 $ 16.8 $ 15.8
Interest paid, capitalized, investing activities 20.6 11.7 12.3
Domestic Tax Jurisdiction      
Income tax refunds $ 1.4    
State and Foreign Tax Authority      
Income tax refunds   $ 1.0 $ 1.0
v3.25.0.1
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Millions
Total
Common Stock
Capital In Excess of Par
Retained Earnings
Accumulated Other Comprehensive Loss
Treasury Shares
Noncontrolling Interest
Beginning balance at Dec. 31, 2021 [1] $ 795.4 $ 0.1 $ 778.1 $ 60.9 $ (42.9) $ (0.8) $ 0.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 273.5 [2]     273.5      
Share compensation plans 6.9   6.9        
Shares withheld for taxes - ordinary share issuances (1.7)   (1.7)        
Issuance of ordinary shares 373.9   373.9        
Net hedging losses, net of income tax expense (0.9) [3]       (0.9)    
Reclassification of deferred hedging losses, net of income tax 0.7 [3],[4]       0.7    
Foreign currency translation adjustments (7.9)       (7.9)    
Exercise of stock options 3.2   3.2        
Net purchases of treasury shares - NQSP (0.1)         (0.1)  
Ending balance at Dec. 31, 2022 [1] 1,443.0 0.1 1,160.4 334.4 (51.0) (0.9) 0.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 330.1 [2]     330.1      
Share compensation plans 9.5   9.5        
Shares withheld for taxes - ordinary share issuances (1.1)   (1.1)        
Issuance of ordinary shares 1.6   1.6        
Net hedging losses, net of income tax expense (0.5) [3]       (0.5)    
Reclassification of deferred hedging losses, net of income tax 0.5 [3],[4]       0.5    
Foreign currency translation adjustments 1.2       1.2    
Net purchases of treasury shares - NQSP (0.1)         (0.1)  
Capital contribution from noncontrolling interest 499.6           499.6
Ending balance at Dec. 31, 2023 [1] 2,283.8 [5] 0.1 1,170.4 664.5 (49.8) (1.0) 499.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 131.7     103.2     28.5
Share compensation plans 27.9   27.9        
Shares withheld for taxes - ordinary share issuances (3.7)   (3.7)        
Net hedging losses, net of income tax expense (0.6)       (0.6)    
Reclassification of deferred hedging losses, net of income tax 0.6 [4]       0.6    
Foreign currency translation adjustments (53.8)       (40.6)   (13.2)
Exercise of stock options 0.4   0.4        
Capital contribution from noncontrolling interest 83.0           83.0
Net sales of treasury shares - NQSP 0.1         0.1  
Allkem Livent Merger 4,711.4   4,390.4       321.0
Ending balance at Dec. 31, 2024 $ 7,180.8 $ 0.1 $ 5,585.4 $ 767.7 $ (90.4) $ (0.9) $ 918.9
[1] Represents the financial position of predecessor Livent as of December 31, 2023, 2022 and 2021 which does not include the financial position of Allkem.
[2] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
[3] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
[4] For more detail on the components of these reclassifications and the affected line item in the consolidated statements of operations, see Note 19 within these consolidated financial statements.
[5] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
v3.25.0.1
CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares
Dec. 31, 2024
Jan. 04, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Stockholders' Equity [Abstract]          
Common stock, par value (in dollars per share) $ 1.00 $ 1.00 $ 1.00 $ 1.00 $ 1.00
v3.25.0.1
Description of the Business
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of the Business Description of the Business
Background and Nature of Operations
Arcadium Lithium plc ("Arcadium", "Arcadium Lithium", "we", "us", "Company" or "our") is a public limited company incorporated under the laws of the Bailiwick of Jersey. On January 4, 2024, Arcadium Lithium completed the previously announced Allkem Livent Merger by which Livent Corporation, a Delaware corporation ("Livent"), and Allkem Limited, an Australian company limited by shares ("Allkem"), became wholly owned subsidiaries of Arcadium Lithium. On January 4, 2024, the Company's shares started trading on the New York Stock Exchange under the trading symbol ALTM. See Note 4, Allkem Livent Merger for further details.
While Arcadium Lithium is a newly formed company from the merger of Allkem and Livent, our company has a rich heritage of innovation and a long, proven history of producing performance lithium compounds in a safe and sustainable manner. We are vertically integrated, with a global footprint and industry-leading end-to-end capabilities across lithium production including hard-rock mining, conventional pond-based brine extraction, direct lithium brine extraction and lithium chemicals manufacturing.
Our lithium asset portfolio, consisting of both operating assets and development projects, provides us with global reach, scale, and product flexibility. Today we have operating resources in Argentina and Australia and downstream conversion assets in the U.S., China, Japan, and the U.K. We also have multiple development stage projects in Argentina (greenfield and brownfield) and Canada (greenfield) that will in time allow us to increase production capabilities and meet the future needs of customers around the world. In the U.S., we operate the only integrated mine-to-metal production facility in the Western Hemisphere for high purity lithium metal, a core component of next generation battery technologies.
We manufacture a wide range of lithium products, including battery-grade lithium hydroxide, battery-grade lithium carbonate, spodumene, and other specialty chemicals such as butyllithium and high purity lithium metal. Our products are used in various performance applications, including lithium-based batteries, specialty polymers and pharmaceutical products and chemical synthesis applications.
Pending Rio Tinto Transaction
On October 9, 2024, Arcadium Lithium entered into the Transaction Agreement (the "Rio Tinto Transaction Agreement") with Rio Tinto Western Holdings Limited, a private limited company incorporated under the laws of England & Wales ("Parent"), and Rio Tinto BM Subsidiary Limited, a private limited company incorporated under the laws of England & Wales ("Buyer").
The Rio Tinto Transaction Agreement provides that pursuant to a scheme of arrangement (the "Scheme") under the Companies (Jersey) Law 1991, at the effective time of the Scheme, all of the ordinary shares, par value $1.00 per share, of the Company (the "Company Shares"), including the Company Shares represented by CHESS depositary interests issued by the Company and listed on the securities exchange operated by ASX Limited, then outstanding will be transferred from the shareholders of the Company to Buyer (or an affiliate of Buyer) in exchange for the right to receive an amount in cash, without interest, equal to $5.85 per Company Share (the "Rio Tinto Transaction").
If the Rio Tinto Transaction is consummated, the Company’s ordinary shares will be delisted from the New York Stock Exchange and the Company’s registration under the Exchange Act of 1934, as amended, will be terminated as promptly as practicable after the effective time of the Rio Tinto Transaction, and the quotation on the Australian Securities Exchange Ltd of the CHESS depositary interests issued by the Company will be suspended immediately prior to the effective time of the Rio Tinto Transaction.
The closing of the Rio Tinto Transaction is subject to customary closing conditions under the Rio Tinto Transaction Agreement, including, among others: the approval of the Scheme by the Company’s shareholders (which has been obtained); all applicable governmental consents under specified antitrust and investment screening laws having been obtained and remaining in full force and effect and all applicable waiting periods having expired, lapsed or been terminated (as applicable) (which consents have been obtained and applicable waiting periods expired); no governmental entity of a competent jurisdiction having issued any order that is in effect and restrains, enjoins or otherwise prohibits the consummation of the Rio Tinto Transaction and no governmental entity having jurisdiction over any party having adopted any law that is in effect and makes consummation of the Rio Tinto Transaction illegal or otherwise prohibited; the representations and warranties of each of the Company and Parent being true and correct to the extent required by, and subject to the applicable materiality standards set
forth in, the Rio Tinto Transaction Agreement; each of the Company, Parent and Buyer having in all material respects performed the obligations and complied with the covenants required to be performed or complied with by it under the Rio Tinto Transaction Agreement; and there having been no material adverse effect (as defined in the Rio Tinto Transaction Agreement). The timing surrounding whether these conditions will be satisfied or waived, if at all, is uncertain. Additionally, other events could intervene to delay or result in the failure to close the Rio Tinto Transaction. The Rio Tinto Transaction is currently expected to close shortly after the sanction hearing for the Royal Court of Jersey set on March 5, 2025, subject to satisfaction of the closing conditions.
If the Rio Tinto Transaction has not closed by October 9, 2025 (subject to extension until April 9, 2026 in order to obtain antitrust or investment screening law or other regulatory approvals), either the Company or Parent may choose to terminate the Rio Tinto Transaction Agreement. The Rio Tinto Transaction Agreement provides that, if the Rio Tinto Transaction Agreement is terminated, the Company will pay a $200 million termination fee to Rio Tinto in the case of certain events described in the Rio Tinto Transaction Agreement, including if the Rio Tinto Transaction Agreement is terminated in certain circumstances and the Company enters into an agreement for an alternative transaction within twelve months of such termination. However, this right to terminate the Rio Tinto Transaction Agreement will not be available to the Company or Parent if such party has materially breached the Rio Tinto Transaction Agreement and the breach is the principal cause of the failure of the closing to have occurred prior to such date. The Company or Parent may elect to terminate the Rio Tinto Transaction Agreement in certain other circumstances, including if the Company’s shareholders fail to approve the Rio Tinto Transaction at the shareholder meetings, and the Company and Parent can mutually decide to terminate the Rio Tinto Transaction Agreement at any time prior to the closing.
The Company expects to incur total transaction costs of approximately $129 million if the Rio Tinto Transaction closes, $23.2 million of which have been expensed and accrued in the Company's consolidated statement of operations and balance sheet for the year ended and as of December 31, 2024, respectively.
The foregoing summary of the Rio Tinto Transaction Agreement and the Rio Tinto Transaction contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the terms and conditions of the Rio Tinto Transaction Agreement, a copy of which is filed as Exhibit 2.5 to this Form 10-K.
v3.25.0.1
Principal Accounting Policies and Related Financial Information
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Principal Accounting Policies and Related Financial Information Principal Accounting Policies and Related Financial Information
Basis of presentation and principles of consolidation. In this Annual Report on Form 10-K the results of the Company as of December 31, 2024 and for the year ended December 31, 2024 include the operations and financial positions of Allkem. Because Arcadium Lithium plc is the successor company to Livent in the Allkem Livent Merger, which closed on January 4, 2024, we are presenting the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022, which do not include the financial positions or operations of Allkem. Refer to Note 4 for further information related to the Allkem Livent Merger.
The accompanying consolidated financial statements are presented on a consolidated basis and include all of the accounts and operations of Livent and its majority-owned subsidiaries. For entities that we control, but own less than 100%, we record the minority ownership as noncontrolling interest. The financial statements reflect the financial position, results of operations and cash flows of Arcadium Lithium in accordance with U.S. GAAP. All significant intercompany accounts and transactions are eliminated in consolidation.
Going Concern
These consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America applicable to a going concern, which contemplate the realization of assets and settlement of liabilities in the normal course of business as they come due. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but not limited to, twelve months from the date of issuance of these consolidated financial statements.
Pursuant to the Rio Tinto Transaction Agreement, while the Rio Tinto Transaction is pending, we are restricted or prohibited from certain non-ordinary course capital expenditures without the consent of Rio Tinto and are required to use commercially reasonable efforts to continue our existing expansion plans. Additionally, during that same time, we are subject to various restrictions under the Rio Tinto Transaction Agreement on raising additional capital, issuing additional equity or debt, and pursuing certain activities that could use significant amounts of our liquidity, including assuming or incurring additional debt, repurchasing equity, and entering into certain acquisition and disposition transactions, among other restrictions without the consent of Rio Tinto, which is not to be unreasonably withheld. We are permitted to continue to borrow under our Revolving
Credit Facility, under existing project financing arrangements, and in connection with letters of credit entered into in the ordinary course of business. Rio Tinto has agreed to cooperate with the Company to facilitate any necessary or appropriate actions and arrangements with respect to the Company's indebtedness in anticipation of the Rio Tinto Transaction.
The Company meets its liquidity needs, including those related to the consummation of the Rio Tinto Transaction, through available cash, cash generated from operations, borrowings under the committed Revolving Credit Facility, and other potential financing strategies available to us. As of December 31, 2024, we had cash and cash equivalents of $93.2 million and the remaining borrowing capacity under our Revolving Credit Facility, subject to meeting our debt covenants, was $139.2 million, including letters of credit utilization. Our net leverage ratio is determined, in large part, by our ability to manage the timing and amount of our capital expenditures, which due to certain provisions in the Rio Tinto Transaction Agreement, is less certain and outside of our control. Our net leverage ratio is also determined by our ability to achieve forecasted operating results and to pursue other working capital financing strategies that may be available to us, which is less certain and outside our control. The Company has incurred negative cash flow from operating and investing activities of $176.0 million and $445.3 million, respectively, for the year ended December 31, 2024 and projects insufficient liquidity in its future cash flows due to various standard restrictions under the Rio Tinto Transaction Agreement that raise substantial doubt about its ability to continue as a going concern.
On January 22, 2025, the Company entered into a commitment letter with Rio Tinto plc, whereby Rio Tinto plc (or an affiliate thereof) has committed to provide Arcadium Lithium Financing IRL Designated Activity Company a first lien secured term loan facility of $200 million (the "Pari Passu Term Loan") and a second lien secured term loan facility of $300 million (the "Junior Term Loan"), together the "Rio Tinto Term Loans." The Pari Passu Term Loan will be secured by first-priority liens on the same assets that secure the existing Revolving Credit Facility and the Junior Term Loan will be secured by second-priority liens on the same assets that secure the existing Revolving Credit Facility. The obligations under the Rio Tinto Loans will be guaranteed by the same entities that guarantee the obligations under the existing Revolving Credit Facility. The proceeds of the Rio Tinto Term Loans may be used for certain capital expenditures payments of the Company and its subsidiaries. The principal amount of the Rio Tinto Term Loans, together with accrued and unpaid interest thereon, will be due and payable on September 1, 2027, consistent with the existing Revolving Credit Facility. The Rio Tinto Term Loans will be subject to the same financial covenants as the existing Revolving Credit Facility which will require the maintenance of a maximum leverage ratio and a minimum interest coverage ratio. On January 30, 2025, pursuant to the Pari Passu Term Loan, we received $199.5 million cash proceeds, net of financing fees of $0.5 million. See Note 17 for details.
Management continuously monitors the Company’s cash resources against its short-term cash commitments to ensure there is sufficient liquidity to fund its obligations for at least twelve months from the financial statement issuance date. Management evaluates the Company’s liquidity to determine if there is substantial doubt about its ability to continue as a going concern. In preparing this going concern assessment, management applies significant judgment in estimating future cash flow requirements of the Company based on budgets and forecasts, which includes developing assumptions related to the estimation of amount and timing of future cash outflows and inflows. As noted above, the Rio Tinto Transaction Agreement prohibits the Company’s ability to pursue working capital financing strategies that otherwise may be available to us before the closing of the Rio Tinto Transaction, and the Pari Passu Term Loan limits our ability to manage the timing and amount of certain capital expenditures. Based on its assessment, including near term expected cash flows and limitations under the Rio Tinto Transaction Agreement to seek additional capital resources or curtail certain spending since October 2024, management estimates that current available liquidity and forecasted net cash flows will not be sufficient to meet the Company’s obligations, commitments and budgeted expenditures for the next twelve months from the consolidated financial statements issuance date and therefore substantial doubt exists about the Company’s ability to continue as a going concern.
Shareholder and all regulatory approvals have been received for the Rio Tinto Transaction as of February 13, 2025 and the transaction is expected to close shortly after the sanction hearing for the Royal Court of Jersey set on March 5, 2025. If the transaction does not close, contractual limitations would cease on the Company’s ability to manage its working capital strategies in October 2025. In that case, the Company’s ability to continue developing its portfolio of expansion projects is dependent on, among other factors, whether the Company can obtain the necessary financing through a combination of, but not limited to, the issuance of debt financing, equity, government funding, and financing and/or prepayments from existing or future customers. However, there is no assurance that the Company will be successful in attracting additional funding. Even if additional financing is available, it may not be available on terms favorable to the Company. Failure to secure additional financing on favorable terms when it becomes required would have an adverse effect on the Company’s financial position and on its ability to execute its business plan.
These consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and balance sheet classifications that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material.
Earnings per share. The weighted average ordinary shares outstanding for both basic and diluted earnings per share for all periods presented was calculated in accordance with ASC 260, Earnings Per Share.
Estimates and assumptions. In preparing the financial statements in conformity with U.S. GAAP we are required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these estimates under different assumptions or conditions, but we do not believe such differences will materially affect our financial position, results of operations or cash flows.
Cash equivalents. We consider investments in all liquid debt instruments with original maturities of three months or less to be cash equivalents.
Restricted cash. As of December 31, 2024, Arcadium had restricted cash of $18.1 million on deposit with Mizuho as collateral for the Project Loan Facility and $5.3 million on deposit as cash backing for a letter of credit. The restricted cash is classified within Other non-current assets in the Company's consolidated balance sheets.
The following tables provide a reconciliation of Cash and cash equivalents and restricted cash reported within Arcadium's consolidated balance sheets:
Year ended December 31,
(in Millions)2024
2023 (1)
Cash and cash equivalents$93.2 $237.6 
Restricted cash - Other non-current assets
23.4 — 
Total Cash and cash equivalents and restricted cash
$116.6 $237.6 
_________________________
1.Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
Trade receivables, net of allowance, and other receivables. Trade receivables consist of amounts owed to us from customer sales and are recorded when revenue is recognized. The allowance for trade receivables represents our best estimate of the probable losses associated with potential customer defaults. In developing our allowance for trade receivables, we use a two stage process which includes calculating a formula to develop an allowance to appropriately address the uncertainty surrounding collection risk of our entire portfolio and specific allowances for customers where the risk of collection has been reasonably identified either due to liquidity constraints or disputes over contractual terms and conditions.
Our method of calculating the formula consists of estimating the recoverability of trade receivables based on historical experience, current collection trends, and external business factors such as economic factors, including regional bankruptcy rates, and political factors. Our analysis of trade receivable collection risk is performed quarterly, and the allowance is adjusted accordingly.
One of our subsidiaries that conducts business within Argentina has outstanding receivables due from the Argentina government, which primarily represent export tax and export rebate receivables. As with all outstanding receivable balances, we continually review recoverability by analyzing historical experience, current collection trends and regional business and political factors among other factors.
Inventories. Inventories are stated at the lower of cost or net realizable value. Inventory costs include those costs directly attributable to products before sale, including all manufacturing overhead but excluding distribution costs. All inventories are determined on a first-in, first-out ("FIFO") basis.
Property, plant and equipment. We record property, plant and equipment, including capitalized interest, at cost. We recognize acquired property, plant and equipment, from acquisitions at its estimated fair value. Depreciation is calculated principally on a straight-line basis over the estimated useful lives of the assets. The major classifications of property, equipment and software, including their respective expected useful lives, consisted of the following:
Asset type Useful Life
Land —
Land improvements 20 years
Buildings
20-40 years
Mining rights33 years
Machinery and Equipment
3-18 years
Software
3-10 years
Gains and losses are reflected in income upon sale or retirement of assets. Expenditures that extend the useful lives of property, plant and equipment or increase productivity are capitalized. Ordinary repairs and maintenance are expensed as incurred through operating expense.
Capitalized interest. For the years ended December 31, 2024, 2023 and 2022 we capitalized interest expense of $24.9 million, $16.8 million and $15.8 million, respectively. These costs were associated with the construction of certain long-lived assets and have been capitalized as part of the cost of those assets. We amortize capitalized interest over the estimated useful lives of the assets.
Impairments of long-lived assets. We review the recoverability of the net book value of long-lived assets whenever events and circumstances indicate ("triggering events") that the net book value of an asset may not be recoverable from the estimated undiscounted future cash flows expected to result from its use and eventual disposition. In cases where a triggering event occurs and undiscounted expected future cash flows are less than the net book value, we recognize an impairment loss equal to the amount by which the net book value exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. We recorded a non-cash impairment charge of $51.7 million for the year ended December 31, 2024, related to our Mt Cattlin spodumene operation in Western Australia. See Note 11 for details.
Deferred compensation plan. We have established a trust fund administered by a third party to provide funding for benefits payable under the Arcadium Non-qualified Saving Plan ("NQSP") to which highly compensated Arcadium employees can elect to defer part of their compensation. The assets held in the trust consist of money market investments, a managed portfolio of equity securities and Arcadium ordinary shares. For each reporting period, the Company records a net mark-to-market adjustment to Selling, general and administrative expense in our consolidated statements of operations for the investments in the trust fund and the corresponding obligation to participants in the NQSP. The money market investments and equity securities assets are included in Other assets in the accompanying consolidated balance sheets. The investments in Arcadium ordinary shares under the NQSP are included in Treasury shares on our consolidated balance sheets. The deferred compensation obligation to participants is included in Other long-term liabilities on our consolidated balance sheets. See Note 21 and Note 23 for additional details on the NQSP deferred compensation plan.
4.125% Convertible Senior Notes due 2025 (the "2025 Notes"). We account for our 2025 Notes under Accounting Standards Update ("ASU") No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06").
Financial instruments. Our financial instruments include cash and cash equivalents, trade receivables, other current assets, investments held in trust fund, trade payables, debt, derivatives and amounts included in accruals meeting the definition of financial instruments. Trade receivables and trade payables are recorded at carrying value, which approximates fair value due to the short-term nature of the instruments. Investments held in trust are for the NQSP as discussed in "Deferred compensation plan" subsection above. The Company enters into derivative contracts to hedge exposures and the associated assets or liabilities are recorded in our consolidated balance sheets and the gains or losses associated with these transactions are included in the consolidated statements of operations.
Equity method investments. We stop applying the equity method when we have reduced the value of our equity method investment, commitments and additional investments (i.e., loans or advances) in the investee to zero. If the investee subsequently reports net income, we resume applying the equity method when our share of that net income is equal to the suspended losses (i.e., our share of the investee's net losses not previously recognized).
If facts and circumstances indicate that a decrease in value of the investment has occurred that is other than temporary, we recognize an impairment loss equal to an amount by which the carrying amount exceeds the fair value of the equity method investment. There were no impairments during the three years ended December 31, 2024.
Leases. The Company determines if an arrangement is a lease at the inception of the contract. Our operating leases are included in Operating lease right-of-use ("ROU") assets, Operating lease liabilities - current, and Operating lease liabilities - long term in the consolidated balance sheets. The operating lease ROU assets and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit interest rate, we utilize an estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. In determining the discount rate used in the present value calculation, the Company has elected to apply the portfolio approach for leases provided the leases commenced at or around the same time. This election allows the Company to account for leases at a portfolio level provided that the resulting accounting at this level would not differ materially from the accounting at the individual lease level. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
The Company has elected not to separate lease and non-lease components and accounts for each separate lease component and non-lease component associated with that lease component as a single lease component. Operating lease ROU assets include all contractual lease payments and initial direct costs incurred less any lease incentives. Facility leases generally only contain lease expense and non-component items such as taxes and pass-through charges. Additionally, we have elected not to apply the recognition requirements of ASC 842 to leases which have a lease term of less than one year at the commencement date.
Most of the Company's leases for corporate facilities contain terms for renewal and extension of the lease agreement. The exercise of lease renewal options is generally at the Company’s sole discretion. The Company includes the lease extensions when it is reasonably certain we will exercise the extension. The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or any material restrictive covenants. We currently do not have any finance leases. See Note 22 for information on related disclosures regarding leases.
Restructuring and other charges. We continually perform strategic reviews and assess the return on our businesses. This sometimes results in a plan to restructure the operations of our business. We record an accrual for severance and other exit costs under the provisions of the relevant accounting guidance.
Additionally, as part of these restructuring plans, write-downs of long-lived assets may occur. Two types of assets are impacted: assets to be disposed of by sale and assets to be abandoned. Assets to be disposed of by sale are measured at the lower of carrying amount or estimated net proceeds from the sale. Assets to be abandoned with no remaining future service potential are written down to amounts expected to be recovered. The useful life of assets to be abandoned that have a remaining future service potential are adjusted and depreciation is recorded over the adjusted useful life.
Restructuring and other charges also includes transaction costs related to the Allkem Livent Merger and the Rio Tinto Transaction.
Finite-lived intangible assets. Finite-lived intangible assets consist of patents, which are amortized over a period of approximately 15 years.
We evaluate the recovery of our finite-lived intangible assets by comparing the net carrying value of the asset group to the undiscounted net cash flows expected to be generated from the use and eventual disposition of that asset group when events or changes in circumstances indicate that its carrying amount may not be recoverable. If the carrying amount of the asset group is not recoverable, the fair value of the asset group is measured and if the carrying amount exceeds the fair value, an impairment loss is recognized.
Goodwill. We account for goodwill and other intangibles acquired in a business combination in conformity with current accounting guidance, which requires goodwill and indefinite-lived intangible assets to not be amortized.
The Company performs its annual goodwill impairment test in the fourth quarter of each year as of October 31 or upon the occurrence of events or changes in circumstances that would more likely than not reduce the fair value of its reporting units below their carrying amounts.
We test goodwill for impairment by comparing the estimated fair value of our reporting units to the related carrying value. Our reporting units are either our operating business segment or one level below our operating business segment for which discrete financial information is available and for which operating results are regularly reviewed by the business management. In applying the goodwill impairment test, the Company initially performs a qualitative test ("Step 0"), where it first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting units is less than its carrying
value. Qualitative factors may include, but are not limited to, economic conditions, industry and market considerations, cost factors, overall financial performance of the reporting units and other entity and reporting unit specific events. If after assessing these qualitative factors, the Company determines it is "more-likely-than-not" that the fair value of the reporting unit is less than the carrying value, the Company performs a quantitative test ("Step 1"). During Step 1, the Company estimates the fair value using a discounted cash flow model.
Impairment evaluations of goodwill could result in a reduction in our recorded asset values which could have a material adverse effect on our financial position and results of operations. We perform reviews of goodwill on an annual basis, or more frequently if triggering events indicate a possible impairment. We test goodwill at the reporting unit level by comparing the carrying value of the net assets of the reporting unit, including goodwill, to the reporting unit's fair value. If the carrying values of goodwill exceed their fair value, the goodwill would be considered impaired. If any impairment or related charge is warranted, our financial position and results of operations could be materially affected. Any such impairment or related charge could be a result of, for example, sustained declines in the Company’s share price; the deterioration of the cost of equity or debt capital increases due to valuations for comparable companies or comparable acquisitions valuations; or the deterioration of the outlook for future cash flows for the reporting unit due to but not limited to, increased competition, changes to discount rate, downward forecast revisions, restricted plans or changes in applicable regulations affecting our business.
The Company performed a qualitative Step 0 test for its goodwill balance in the fourth quarters of 2024 and 2023 and concluded that no impairment existed as of December 31, 2024 and 2023 because it was not more likely than not that the fair value of the reporting unit was less than its carrying value.
Revenue recognition. Revenue from product sales is recognized when we satisfy a performance obligation by transferring the promised goods to a customer, that is, when control of the good transfers to the customer. The customer is then invoiced at the agreed-upon price with payment terms generally ranging from 30 to 180 days. See Note 7 for further details regarding revenue recognition.
In determining when the control of goods is transferred, we typically assess, among other things, the transfer of title and risk of loss and the shipping terms of the contract.
We record amounts billed for shipping and handling fees as revenue. Costs incurred for shipping and handling are recorded in Cost of sales. When we perform shipping and handling activities after the transfer of control to the customer (e.g., when control transfers prior to delivery), they are considered fulfillment activities, and accordingly, the costs are accrued to Cost of sales when the related revenue is recognized.
Amounts billed for sales and use taxes, VAT, and certain excise and other specific transactional taxes imposed on revenue-producing transactions are presented on a net basis and excluded from revenue in the consolidated statements of operations. We record a liability until remitted to the respective taxing authority.
We satisfy our obligations by transferring goods and services in exchange for consideration from customers. The timing of performance sometimes differs from the timing of when the associated consideration is received from the customer, thus resulting in the recognition of a contract asset or liability. These may arise from provisional pricing within certain of our customer contracts, or if the customer’s payment of consideration is received prior to completion of our related performance obligation. Provisional pricing results in variable consideration which we estimate by using an expected value method taking into account all information that is reasonably available including publicly available pricing forecasts. We only include variable consideration within the transaction price to the extent that it is probable that a significant reversal in the amount of revenue recognized will not occur.
Research and Development. Research and development costs are expensed as incurred.
Income and other taxes. We provide current income taxes on income reported for financial statement purposes adjusted for transactions that do not enter into the computation of income taxes payable and recognize deferred tax liabilities and assets for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. Prior to the Separation, pursuant to the tax matters agreement with FMC, in jurisdictions where we file consolidated returns with FMC, we have recorded our allocated share of the consolidated liability as part of the income tax payable in our consolidated balance sheets. In taxing jurisdictions where we file as a standalone entity we have recorded the tax liability/benefit to income tax payable/receivable. We do not provide income taxes on the equity in undistributed earnings of consolidated foreign subsidiaries as it is our intention that such earnings will remain invested in those companies.
Segment information. In January 2024, Arcadium Lithium completed the Allkem Livent Merger. See Note 4, Allkem Livent Merger for further details. Following the closing of the Allkem Livent Merger, we currently operate as one reportable segment based on the commonalities among our products and services. See Note 6, Segment Reporting for further details.
Share-based compensation. Share-based compensation expense for the three years ended December 31, 2024 has been recognized for all share options and other equity-based arrangements. Share-based compensation cost is measured at the date of grant, based on the fair value of the award, and is recognized over the employee’s requisite service period. We made a policy election to recognize forfeitures in share-based compensation expense as they occur. See Note 18 for more information.
Environmental obligations. We provide for environmental-related obligations when they are probable and amounts can be reasonably estimated.
Included in our Environmental liabilities are costs for the operation, maintenance and monitoring of site remediation plans ("OM&M"). Such reserves are based on our best estimates for these OM&M plans. Over time we may incur OM&M costs in excess of these reserves which could be significant.
Environmental remediation charges represent the costs for the continuing charges associated with environmental remediation at operating sites from previous years and from products that are no longer manufactured. Arcadium Lithium has two environmental remediation sites located in North Carolina, United States and Québec, Canada. The charge associated with the cost of remediation for the years ended December 31, 2024, 2023 and 2022 are $4.3 million, $0.8 million and $1.2 million, respectively. These amounts are recorded as a component within "Restructuring and other charges" on the consolidated statements of operations. The total environmental remediation liability as of December 31, 2024 and 2023 was $7.8 million and $7.5 million, respectively.
Foreign currency. We translate the assets and liabilities of our foreign operations at exchange rates in effect at the balance sheet date. For foreign operations for which the functional currency is not the U.S. dollar, we record translation gains and losses as a component of accumulated other comprehensive loss in equity. The foreign operations’ statements of operations are translated at the monthly exchange rates for the period. Transactions denominated in foreign currency other than our functional currency of the operation are recorded upon initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are remeasured at each reporting date into the functional currency at the exchange rate at that date. Exchange rate differences are recognized as foreign currency transaction gain or loss recorded as a component of Cost of sales in our consolidated statements of operations. We recorded transaction and remeasurement (gains)/losses of $(185.6) million, $68.9 million and $7.0 million for the years ended December 31, 2024, 2023 and 2022, respectively.
Mine development costs. Mine development costs include expenditures incurred during the search for mineral resources as well as the determination of the technical feasibility and commercial viability of extracting the mineral resource, and stripping costs of removing overburden and waste materials to access the mineral body at an open pit mine.
The Company capitalizes exploration and evaluation ("E&E") expenditures to Property, Plant and Equipment ("PP&E") under a successful efforts basis when proven and probable reserves are established for the sites where E&E activities are being performed. E&E assets recognized as part of business combinations are also capitalized. All other E&E expenditures are expensed.
Stripping costs incurred prior to the production phase are capitalized to PP&E during the development of an open pit mine. When multiple open pits exist at a mining complex utilizing common processing facilities, such pre-production stripping costs are capitalized at each pit. The removal, production, and sale of de minimis saleable materials may occur during the development phase of an open pit mine and are assigned incremental mining costs related to the removal of that material. The production phase of an open pit mine commences when saleable minerals, beyond a de minimis amount, are produced. Stripping costs incurred during the production phase of a mine are variable production costs that are included as a component of inventory to be recognized in Cost of sales in the same period as the revenue from sale of that inventory.
Capitalized mine development costs are amortized using the units-of-production method based on estimated recoverable minerals in proven and probable reserves, and are amortized over the estimated life of the mineral body.
Mineral interests. Mineral interests include acquired interests in production, development and exploration stage properties. Mineral interests are capitalized at their fair value at the acquisition date, either as an individual asset purchase or as part of a business combination. Mineral interests in the development and exploration stage are not amortized until the underlying property is converted to the production stage, at which point the mineral interests are amortized over the estimated recoverable proven and probable reserves using a units-of-production method.
Asset retirement obligations. The Company accounts for asset retirement obligations ("AROs") in accordance with ASC 410-20, Asset Retirement Obligations. We record AROs at present value at the time the liability is incurred if we can reasonably estimate the settlement date. The associated AROs are capitalized as part of the carrying amount of related long-lived assets. In future periods, the liability is accreted to its present value and the capitalized cost is depreciated over the useful
life of the related asset. We also adjust the liability for changes resulting from the passage of time and/or revisions to the timing or the amount of the original estimate. Upon retirement of the long-lived asset, we settle the obligation for its recorded amount. See Note 16, for details.
The carrying amounts of the AROs as of December 31, 2024 and December 31, 2023 was $14.2 million and $3.7 million, respectively. These amounts are included in Accrued and other current liabilities and Other long-term liabilities in our consolidated balance sheets.
Blue Chip Swap. Our wholly owned subsidiary in Argentina uses the U.S. dollar as their functional currency. Argentine peso-denominated monetary assets and liabilities are remeasured at each balance sheet date to the official currency exchange rate then in effect which represents the exchange rate available for external commerce (import payments and export collections) and financial payments, with currency remeasurement and other transaction gains and losses recognized in earnings. In September 2019, the President of Argentina reinstituted exchange controls restricting foreign currency purchases in an attempt to stabilize Argentina’s financial markets. As a result, a legal trading mechanism known as the Blue Chip Swap emerged in Argentina for all individuals or entities to transfer U.S. dollars out of and into Argentina. The Blue Chip Swap rate is the implicit exchange rate resulting from the Blue Chip Swap transaction. Recently, the Blue Chip Swap rate has diverged significantly from Argentina’s official rate due to the economic environment. In 2023, through the Blue Chip Swap method, we realized a gain from the purchase in U.S. dollars and sale in Argentina pesos of Argentina Sovereign U.S. dollar-denominated bonds. The gain of U.S. $67.8 million and $68.5 million for the years ended December 31, 2024 and 2023, respectively, were recorded to Other gain in our consolidated statement of operations.
Reclassifications. Certain prior period balances have been reclassified to conform to the current period presentation in the consolidated financial statements and the accompanying notes.
Effective April 1, 2024, we began presenting gains and losses from foreign currency remeasurements as a component of Other (gains)/losses. Prior to April 1, 2024, we included gains and losses resulting from foreign currency remeasurements as a component of Cost of sales and Restructuring and other charges in the consolidated statement of operations. The following tables summarize the accounts that were recast for the year ended December 31, 2023 and 2022 to conform to the current period presentation.
Year Ended December 31
Year Ended December 31
20232022
(in Millions)Prior PresentationLoss/(gain) Reclassified Recast PresentationPrior PresentationLoss/(gain) ReclassifiedRecast Presentation
Cost of sales$413.2 $69.1 $344.1 $417.5 $6.8 $410.7 
Restructuring and other charges56.7 (0.2)56.9 7.5 0.2 7.3 
Other (gains)/losses(68.5)68.9 0.4 (22.2)7.0 (15.2)
v3.25.0.1
Recently Issued and Adopted Accounting Pronouncements and Regulatory Items
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Recently Issued and Adopted Accounting Pronouncements and Regulatory Items Recently Issued and Adopted Accounting Pronouncements and Regulatory Items
New accounting guidance and regulatory items
In December 2023, the Financial Accounting Standard Board ("FASB") issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU enhances existing income tax disclosures to better assess how an entity's operation and related tax risks, tax planning, and operational opportunities affect its tax rate and prospects for future cash flows. The ASU is effective for annual periods beginning after December 15, 2024. We are currently evaluating the effect the guidance will have on our consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280). This ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures related to significant segment expenses. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The ASU was adopted by the Company as of December 31, 2024, refer to Note 6, Segment Reporting, for additional disclosures required by the ASU.
v3.25.0.1
Allkem Livent Merger
 12 Months Ended
Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Allkem Livent Merger Allkem Livent Merger
On January 4, 2024 (the "Acquisition Date") Arcadium completed the previously announced Allkem Livent Merger by and among Livent Corporation, a Delaware corporation ("Livent"), Allkem Limited, an Australian public company ("Allkem"),
Arcadium Lithium plc, a public limited company incorporated under the laws of the Bailiwick of Jersey ("Arcadium"), Lightning-A Merger Sub, Inc. ("Merger Sub"), and Arcadium Lithium Intermediate IRL Limited, a private company limited by shares and incorporated and registered in Ireland ("Irish IntermediateCo").
The transaction was consummated by way of (a) a scheme of arrangement under Australian law, pursuant to which each issued, fully paid ordinary share of Allkem held by Allkem shareholders was exchanged for either one Arcadium Lithium CHESS Depositary Instrument (a "CDI") quoted on the Australian Stock Exchange (each CDI representing a beneficial ownership interest in one Arcadium ordinary share), or one Arcadium ordinary share (par value $1.00 per share) and (b) a merger, whereby Merger Sub, a wholly owned subsidiary of Irish IntermediateCo (a direct wholly owned subsidiary of Arcadium) merged with and into Livent, with Livent as the surviving entity. Each share of Livent common stock, par value $0.001 per share (each, a "Livent Share"), was converted into the right to receive 2.406 Arcadium ordinary shares.
Pursuant to the Allkem Livent Merger, 433,156,855 Arcadium ordinary shares (including 96,909 related to accelerated PRSU awards) were issued to former Livent stockholders and 641,337,840 Arcadium ordinary shares (comprising 98,725,616 Arcadium ordinary shares and 542,612,224 CDIs in respect of Arcadium ordinary shares) were issued to former Allkem shareholders. The Acquisition Date fair value of consideration transferred consisted of the following:

(in millions)Amount
Consideration:
Fair value of Arcadium ordinary shares issued to Allkem shareholders$4,385.6 
Fair value of converted Allkem performance rights attributable to pre-combination service4.8 
Total consideration$4,390.4 

The Allkem Livent Merger meets the criteria to be accounted for as a business combination and is accounted for using the acquisition method of accounting with Livent being treated as the accounting acquirer. Under the acquisition method of accounting, the assets and liabilities of Allkem and its subsidiaries are recorded at their respective fair values as of the date of completion of the Allkem Livent Merger and the difference between the fair value of the consideration paid for the acquired entity and fair value of the net assets acquired is recorded as goodwill.
Determining the fair value of the assets and liabilities of Allkem requires judgment and certain assumptions to be made, the most significant of these being related to the valuation of Allkem's mining properties and rights.
During the year ended December 31, 2024, adjustments were made within the permitted measurement period for the following: a decrease to property, plant and equipment of $46.6 million, increase to deferred income tax assets of $4.6 million, increase to accounts payable trade and other of $1.8 million, decrease to income taxes of $0.3 million, decrease to environmental liabilities of $7.0 million, decrease to deferred income tax liabilities of $49.3 million, increase to other long term liabilities of $8.7 million, and a net increase in goodwill of $54.5 million. The measurement period adjustments have been reflected as current period adjustments in the year ended December 31, 2024, in accordance with the guidance in ASU 2015-16 "Business Combinations." The measurement period adjustments had no effect on earnings or cash in the current period.
Transaction and related costs directly attributable to the acquisition of Allkem, consisting primarily of advisor fees, legal fees, accounting fees, and certain deal related bonuses were $103.9 million for the year ended December 31, 2024. The costs were expensed as incurred and are included in restructuring and other charges.
The following table summarizes the purchase price allocation for the Allkem Livent Merger as of January 4, 2024:

(in Millions, except per share amounts)Amount
Total consideration$4,390.4 
Assets acquired:
Cash and cash equivalents$681.4 
Trade receivables64.2 
Inventories127.6 
Prepaid and other current assets87.2 
Property, plant and equipment4,278.9 
Right of use assets - operating leases, net53.4 
Deferred income tax assets30.9 
Other assets (1)
174.0 
Total assets acquired$5,497.6 
Liabilities assumed:
Accounts payable, trade and other$223.7 
Accrued and other current liabilities35.1 
Income taxes78.5 
Long-term debt including current portion301.7 
Operating lease liabilities
53.4 
Environmental liabilities11.9 
Deferred income tax liabilities1,267.4 
Other long-term liabilities58.2 
Total liabilities assumed$2,029.9 
Fair value of net assets acquired$3,467.7 
Add: Fair value of noncontrolling interests acquired 321.0 
Fair value of net assets acquired less noncontrolling interests acquired$3,146.7 
Goodwill$1,243.7 
___________________
1.Includes long-term semi-finished goods inventory.

Trade receivables
The $64.2 million of acquired trade receivables represents the fair value of the gross amount due under the contracts.
Property, Plant and Equipment
Property, plant and equipment is inclusive of the fair value of mineral rights totaling $2,675.0 million and non-mineral rights property, plant and equipment totaling $1,603.9 million. The fair value of the mineral rights was estimated using the multi-period excess earnings method. The excess earnings methodology is an income approach methodology that estimates the projected cash flows of the business attributable to the asset, net of charges for the use of other identifiable assets of the business including working capital, fixed assets, and other intangible assets. Mineral rights are depreciated using a units-of-production method while all other property, plant and equipment is depreciated using the straight-line method.
Goodwill
Goodwill from acquisitions represents the excess of the purchase price over the fair value of net assets acquired. The amount disclosed within the table is attributable to the value of growth opportunities and expected synergies created by incorporating Allkem's business and operations into the Company's operations and the value of the assembled workforce. The goodwill has no amortizable basis for income tax purposes.
Allkem revenues and earnings
The following table represents Allkem's revenues and net earnings included in Arcadium's consolidated statements of operations from the Acquisition Date through December 31, 2024.
(in Millions)
Twelve Months Ended December 31, 2024
Revenue$337.5 
Income from operations before income taxes
$115.3 
Pro Forma Financial Information
Due to the Allkem Livent Merger closing on January 4, 2024, all activity in the first quarter of 2024 except for the first three days of January, which management deemed not material, is included in Arcadium’s consolidated statements of operations. The following unaudited pro forma financial information for the twelve months ended December 31, 2023 is based on our historical consolidated financial statements adjusted to reflect the Allkem Livent Merger as if it occurred on January 1, 2023. The unaudited pro forma financial information is not necessarily indicative of what would have occurred if the Allkem Livent Merger had been completed as of the beginning of the periods presented, nor is it indicative of future results. The unaudited pro forma information is not necessarily indicative of operating results that would have been achieved had the acquisition been completed as of January 1, 2023 and does not intend to project the future financial results of the Company after the acquisition. The unaudited pro forma information is based on certain assumptions, which management believes are reasonable, and does not reflect the cost of any integration activities or synergies that may be derived from any integration activities. The unaudited pro forma financial results are as follows:

(in Millions)
Twelve Months Ended December 31, 2023
(Unaudited)
Revenue$2,001.7 
Net income$374.0 
v3.25.0.1
Goodwill
 12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill Goodwill
The following table summarizes the changes in goodwill for the twelve months ended December 31, 2024.

(in Millions)
Total
Balance as of December 31, 2023 (1)
$120.7 
Acquisitions - Allkem Livent Merger1,243.7 
Purchase price adjustments - Nemaska Lithium
(1.5)
Balance as of December 31, 2024$1,362.9 
___________________
1.Balance as of December 31, 2023 related to October 18, 2023 consolidation of Nemaska Lithium.
v3.25.0.1
Segment Reporting
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
Arcadium Lithium earns revenue and incurs expenses from extracting and producing lithium compounds that are sold across global markets. The activity focuses on specialty products that require a high level of manufacturing and technical know-how to meet customer requirements. The products offered vary across the chemical, energy, polymer and specialty application customer base, but variations of processed lithium are the key common component.
We manage business activities on a consolidated basis with one reportable segment based on the commonalities among our products and services, and the way our chief operating decision maker, the chief executive officer, reviews and evaluates performance. The chief operating decision maker assess performance and allocates resources based on net income that is reported on the consolidated statement of operations. Net income, along with other measures such as Adjusted EBITDA, are used to monitor actual results against budgets and forecasts. The chief operating decision maker also uses net income, along with other measures, to benchmark performance against industry forecasts and other participants. The analysis along with the monitoring of results against budget and forecasts are used in assessing the performance of the segment. The accounting policies of the reportable segment are the same as those described in the Principal Accounting Policies within Note 2.

Year ended December 31,
(in Millions)
2024
2023 (1)
2022 (1)
Revenue
$1,007.8 $882.5 $813.2 
Less:
Cost of sales - as reviewed by chief operating decision maker
670.3344.1410.1
Selling, administration and research costs (2)
133.269.059.1
Depreciation and amortization
113.729.627.7
Other segment items
(41.1)109.7 42.8 
Net income
$131.7 $330.1 $273.5 
__________________
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.Primarily includes people costs and professional fees.

Other segment items includes interest, income taxes, foreign exchange remeasurement gains/losses, results of unconsolidated affiliates accounted for under the equity method, impairment charges and other expenses.
The measure of segment assets is reported on the consolidated balance sheets as total assets. The chief operating decision maker uses net income and other measures such as Adjusted EBITDA to evaluate income generated from the segment’s assets in capital management decisions.
v3.25.0.1
Revenue Recognition
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
Disaggregation of revenue
We disaggregate revenue from contracts with customers by geographical areas (based on product destination) and by product categories. The following table provides information about disaggregated revenue by major geographical region:
 Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
Asia Pacific (2)
$860.1 $649.7 $566.5 
North America (2)
84.4 143.8 145.7 
Europe, Middle East & Africa61.2 87.2 98.1 
Latin America 2.1 1.8 2.9 
Total Revenue$1,007.8 $882.5 $813.2 
____________________
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.In 2024, countries with sales in excess of 10% of combined revenue consisted of China, Japan and South Korea. Sales for the year ended December 31, 2024 for China, Japan and South Korea totaled $564.8 million, $142.1 million, and $138.5 million, respectively. In 2023, countries with sales in excess of 10% of combined revenue consisted of China, the U.S., Japan and South Korea. Sales for the year ended December 31, 2023 for China, the U.S., Japan and South Korea totaled $364.8 million, $138.7 million, $136.9 million, and $123.0 million, respectively. In 2022, countries with sales in excess of 10% of combined revenue consisted of China, Japan, and the U.S. Sales for the year ended December 31, 2022 for China, Japan, and the U.S. totaled $304.9 million, $167.6 million, and $139.1 million, respectively.

For the year ended December 31, 2024, two customers accounted for approximately 25% and 22% of total revenue, and our 10 largest customers accounted in aggregate for approximately 74% of our revenue. For the year ended 2023 two customers accounted for approximately 28% and 22% of total revenue, and our 10 largest customers accounted in aggregate for approximately 72% of our revenue. For the year end 2022 one customer accounted for approximately 24% of total revenue and our 10 largest customer accounted in aggregate for approximately 63% of our revenue. A loss of any material customer could have a material adverse effect on our business, financial condition and results of operations.
The following table provides information about disaggregated revenue by major product category:
 Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
Lithium Hydroxide$437.2 $564.4 $415.5 
Lithium Carbonate (2)
291.7 44.8 68.7 
Butyllithium and Other Lithium Specialties169.2 273.3 329.0 
Spodumene Concentrate (3)
109.7 — — 
Total Revenue$1,007.8 $882.5 $813.2 
______________________
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.Includes lithium carbonate by-product revenue.
3.Includes low-grade spodumene sales and minimal other products.

Our lithium products are developed and sold to global and regional customers in the EV, electronics, agrochemicals, pharmaceuticals, polymer and specialty alloy metals market among others. Lithium hydroxide and lithium carbonate products are used in advanced batteries for all-electric vehicles as well as other products that require portable energy storage such as power tools and military devices. Lithium hydroxide is also sold into grease applications for use in automobiles, aircraft, railcars, agricultural and other types of equipment. Butyllithium products are primarily used as polymer initiators, and in the synthesis of agrochemicals and pharmaceuticals. High purity lithium metal and other specialty compounds include lithium phosphate, pharmaceutical-grade lithium carbonate and specialty organics. We sell whatever lithium carbonate we do not use internally as feedstock for lithium hydroxide production to our customers for various applications.
Sale of Goods
Revenue from product sales is recognized when we satisfy a performance obligation by transferring the promised goods to a customer, that is, when control of the good transfers to the customer. The customer is then invoiced at the agreed-upon price with payment terms generally ranging from 30 to 180 days.
In determining when the control of goods is transferred, we typically assess, among other things, the transfer of title and risk of loss and the shipping terms of the contract.
We record amounts billed for shipping and handling fees as revenue. Costs incurred for shipping and handling are recorded in cost of sales. When we perform shipping and handling activities after the transfer of control to the customer (e.g., when control transfers prior to delivery), they are considered fulfillment activities, and accordingly, the costs are accrued to cost of sales when the related revenue is recognized.
Amounts billed for sales and use taxes, VAT, and certain excise and other specific transactional taxes imposed on revenue-producing transactions are presented on a net basis and excluded from revenue in the consolidated statements of operations. We record a liability until remitted to the respective taxing authority.
Right of Return
We warrant to our customers that our products conform to mutually agreed product specifications. We accrue for expected returns as they occur.
Contract asset and contract liability balances
We satisfy our obligations by transferring goods and services in exchange for consideration from customers. The timing of performance sometimes differs from the timing the associated consideration is received from the customer, thus resulting in the recognition of a contract liability. We recognize a contract liability if the customer’s payment of consideration is received prior to completion of our related performance obligation.
On July 25, 2022 we entered into a long-term supply agreement with a customer to deliver battery-grade lithium hydroxide over six years between 2025 and 2030. The contract included an advance payment from the customer of $198 million, which we received in the third quarter of 2022. Revenue will be recognized as volumes are delivered. Any unrecognized deferred revenue is refundable if the agreement is terminated for any reason specified in the agreement.
The following table presents the opening and closing balances of our contract liabilities and current trade receivables (including buy/sell arrangements), net of allowances from contracts with customers.
 Balance as of
(in Millions)December 31, 2024December 31, 2023
Increase
Receivables from contracts with customers, net of allowances$130.3 $106.7 $23.6 
Contract liability - short-term 42.3 4.4 37.9 
Contract liability - long-term238.1 217.8 20.3 
Performance obligations
Revenue is recognized when the performance obligation is satisfied, which is when the customer obtains control of the good or service. Occasionally, we may enter into multi-year take or pay supply agreements with customers. The aggregate amount of revenue expected to be recognized related to these contracts' performance obligations that are unsatisfied or partially unsatisfied is approximately $1.4 billion in the next four years. These approximate revenues do not include amounts of variable consideration attributable to contract renewals or contract contingencies. Based on our past experience with the customers under these arrangements, we expect to continue recognizing revenue in accordance with the contracts as we transfer control of the product to the customer (refer to the sales of goods section for our determination of transfer of control). However, in the case a shortfall of volume purchases occurs, we will recognize the amount payable by the customer over the remaining performance obligations in the contract.
v3.25.0.1
Inventories, Net
 12 Months Ended
Dec. 31, 2024
Inventory Disclosure [Abstract]  
Inventories, Net Inventories, Net
Inventories consisted of the following:
 December 31,
 (in Millions)20242023
Finished goods$99.8 $59.1 
Semi-finished goods202.5 108.8 
Raw materials, supplies, and other115.3 49.6 
FIFO inventory, net$417.6 $217.5 
v3.25.0.1
Partially-Owned Subsidiaries and Noncontrolling Interests
 12 Months Ended
Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]  
Partially-Owned Subsidiaries and Noncontrolling Interests Partially-Owned Subsidiaries and Noncontrolling Interests    
Nemaska Lithium Inc. ("Nemaska Lithium", or "NLI")
Nemaska Lithium, domiciled in Canada and headquartered in Montreal, Québec, is a non-public mining company not yet in the production stage. It is a development company aiming to vertically integrate, from extracting, processing and concentrating spodumene to conversion of spodumene into battery grade lithium hydroxide, primarily intended for energy storage applications. Its primary assets are construction in progress and intangibles principally related to intellectual property. Nemaska Lithium intends to develop the Whabouchi spodumene mine and concentrator in the James Bay region of Québec and a lithium hydroxide conversion plant in Bécancour, Québec (collectively, the "Nemaska Lithium Project"). As a developing company and to fund the Nemaska Lithium Project, Nemaska Lithium is reliant on securing financing from its shareholders through share subscriptions.
In December 2019, Nemaska Lithium and certain affiliates filed for creditor protection in Canada under the Companies’ Creditors Arrangement Act (the "CCAA") in the Superior Court of Québec (the "CCAA Court"). In October 2020, the CCAA Court approved a sale of Nemaska Lithium structured as a credit bid under the CCAA to a group made up of Orion Mine Finance ("Orion"), Investissement Québec ("IQ", a company established by the Government of Québec to favor investment in Québec by Québec-based and international companies) and The Pallinghurst Group ("Pallinghurst", acting through a new entity named Québec Lithium Partners (UK) Limited ("QLP")). After a series of amalgamations and restructurings, the sale transactions were completed on December 1, 2020, pursuant to which IQ and QLP each acquired a 50% equity interest in Nemaska Lithium.
In the fourth quarter of 2020, the Company entered into an agreement with Pallinghurst for a 50% equity interest in QLP. Through this investment, we obtained indirect ownership of a 25% equity interest in Nemaska Lithium.
On June 6, 2022, Livent issued 17,500,000 shares of its common stock to acquire the remaining 50% share of QLP previously owned by Pallinghurst and certain of its investors (the "QLP Merger"). Upon consummation of the QLP Merger, Livent recorded an Investment of $387.1 million, QLP's cash and cash equivalents of $0.3 million and short-term debt of $13.5 million; and an increase to additional paid in capital of $373.9 million. The Company now owns a 50% economic interest in NLI through its ownership of QLP. The Québec provincial government, through IQ, continues to own the remaining 50% interest in Nemaska Lithium. At present, we do not have off-take rights on the production to come out of the Nemaska Lithium Project.
On October 18, 2023, we entered into an amendment to our shareholders agreement with Nemaska Lithium, and also amendments to certain related service agreements. The amendments to these agreements provide QLP with control of certain substantive participating rights, and as such, the Company began to consolidate Nemaska Lithium as of October 18, 2023. Nemaska Lithium is a development company which, as of the October 18, 2023 consolidation date, met the U.S. GAAP definition of a business and, as such, the Company remeasured its equity interest in Nemaska, including the noncontrolling interest of IQ, at fair value as of the consolidation date. We estimated the fair value of IQ's noncontrolling interest by multiplying the total fair value of Nemaska Lithium equity by IQ's equity ownership interest and also considered any discounts for lack of control and marketability.
The allocation of the fair value of the assets and liabilities of Nemaska Lithium assumed under business combination accounting guidance for the Nemaska Lithium consolidation, including the impact of income taxes, is completed as of December 31, 2024 with no significant measurement period adjustments. Nemaska Lithium is consolidated on a one-quarter lag basis. The table below represents Nemaska Lithium's balance sheet at fair value consolidated by the Company as of October 18, 2023:
Nemaska Lithium Inc.
October 18,
(in Millions)Note
2023 (a)
ASSETS
Cash and cash equivalents$133.5 
Sales tax receivable9.2 
Prepaid expenses3.4 
Total current assets146.1 
In-trust depositsb9.9 
Property, plant and equipmentc932.2 
Goodwilld119.2 
Intangible assetse45.0 
Other non-current assets0.5 
Total non-current assets1,106.8 
Total assets$1,252.9 
LIABILITIES AND EQUITY
Current portion of long-term debtf$2.4 
Accounts payable and accrued liabilities59.8 
Total current liabilities62.2 
Long-term debtg56.1 
Contract liability - long-termg19.8 
Asset retirement obligationsh3.4 
Deferred income taxes111.9 
Other non-current liabilities0.3 
Total non-current liabilities191.5 
Total current and long-term liabilities253.7 
Arcadium shareholders’ equity
499.6 
Noncontrolling interest499.6 
Total equity999.2 
Total liabilities and equity$1,252.9 
______________________________
a.Represents the Nemaska Lithium balance sheet as of the October 18, 2023 consolidation date.
b.Represents a deposit held in trust for estimated restoration costs relating to the Whabouchi site asset retirement obligation.
c.Primarily represents mining property, mining rights and construction in progress for the Whabouchi and Bécancour sites related to project engineering, equipment and site preparation and capitalized financing costs.
d.Primarily related to potential synergies arising from the proximity of Nemaska Lithium to other resources in the region.
e.Primarily represents intellectual property in relation to patents and development costs with a weighted average amortization period of 15 years.
f.Represents current portion of the unsecured obligation governing the working relationship between the Nemaska Lithium Project and the Cree Nation of Nemaska.
g.Primarily represents $75.0 million for the prepayment received for a customer supply agreement entered on October 18, 2023, recorded net of imputed discount of $19.8 million.
h.Represents the asset retirement obligation for estimated inflation-adjusted and discounted future costs associated with mine reclamation and closure activities at the Whabouchi site, and assuming that the disbursements would be made in 2056.
Arcadium's cash and cash equivalents balance in its consolidated balance sheet as of December 31, 2024 includes Nemaska Lithium's cash of $11.4 million at September 30, 2024 as Nemaska Lithium is consolidated on a one-quarter lag. All cash at Nemaska Lithium will be used for capital expenditures and operating expenses of the Nemaska Lithium Project.
As of December 31, 2024, Nemaska Lithium received cash of $225.0 million related to advance payments in connection with a customer supply agreement repayable in equal quarterly installments beginning in January 2027 and ending in October 2031. The related liability, consolidated on a one-quarter lag basis, is $152.1 million debt and $72.9 million contract liability as of December 31, 2024, see Note 17 for details. Prepayments from the customer under the arrangement total $350.0 million, with final prepayment of $125 million received on January 3, 2025.
In the fourth quarter of 2024, the Company contributed cash of $96.7 million to Nemaska Lithium which, due to one-quarter lag reporting, is not yet recorded in our consolidation of Nemaska. The balance is recorded to Other assets - noncurrent because the cash is expected to be used by Nemaska primarily for capital expenditures. IQ contemporaneously made an equal contribution in the fourth quarter of 2024 which, due to one-quarter lag reporting, is not recorded in our consolidation of Nemaska.
Before October 18, 2023, the Company accounted for its interest in Nemaska Lithium as an equity method investment on a one-quarter lag basis and it was included in Investments in our consolidated balance sheets. The carrying amount of our interest in Nemaska Lithium was $437.1 million as of December 31, 2022 under equity method investment accounting. For the years ended December 31, 2023, and 2022 we recorded a $23.1 million, and $15.1 million loss, respectively, related to our interest in Nemaska Lithium to Equity in net loss of unconsolidated affiliate in our consolidated statements of operations.
Sales de Jujuy Pte Ltd and Sales de Jujuy S.A.
The Company has an interest of 72.68% in Sales de Jujuy Pte Ltd ("SDJ Pte"), 66.5% in Sales de Jujuy S.A. ("SDJ"), the legal entities which operate the Olaroz Lithium Facility (the "Olaroz Plant").
Located in the Jujuy Province of northern Argentina, the Olaroz Plant produces lithium carbonate chemicals for the battery, technical and chemical markets. The Olaroz Plant is operated through SDJ, which is a 91.5% owned subsidiary of SDJ Pte, a Singaporean company owned by Arcadium (72.68%) and Toyotsu Lithium Pte Ltd. (27.32%), an affiliated company of TTC. Jujuy Energia y Minera Sociedad del Estado ("JEMSE") owns the remaining 8.5% of SDJ. Consequently, the effective equity ownership of the Olaroz Plant is 66.5% by Arcadium, 25% by TTC, and 8.5% by JEMSE.
As of December 31, 2024, Arcadium had restricted cash of $18.1 million on deposit with Mizuho Bank ("Mizuho") as collateral for the Project Loan Facility and classified within Other non-current assets in its consolidated balance sheets. See Note 17 for details.
Arcadium's cash and cash equivalents balance in its consolidated balance sheet as of December 31, 2024 includes $21.1 million held by the entities discussed above.
Arcadium funded JEMSE’s equity contributions in SDJ with an interest-free loan (the "JEMSE Receivable") to be repaid by JEMSE out of 33% of the dividends it receives from SDJ. The fair value of the non-current receivable is $5.0 million as of December 31, 2024.
Investments
Investments consisted of the following:
 (in Millions)December 31, 2024December 31, 2023
ESM ILiAD, LLC$30.1 $30.1 
Arcadium NQSP6.3 4.7 
Other0.5 — 
Investments$36.9 $34.8 
ESM ILiAD, LLC ("ESM")
In the fourth quarter of 2023, the Company entered into an agreement with EnergySource Minerals, LLC ("EnergySource"), a developer of lithium projects in the Salton Sea Known Geothermal Resource Area in California, for a minority equity interest in ESM, a subsidiary of EnergySource and the parent company of ILiAD Technologies, LLC ("ILiAD Technologies"). In connection with its investment in ESM, Arcadium Lithium will have the right to license ILiAD Technologies' Integrated Lithium Adsorption Desorption ("ILiAD") technology for potential deployment at its lithium brine resources in Argentina.
Arcadium Lithium accounts for its interest in ESM under ASC Topic 321, Investments – Equity Securities ("ASC 321"). Since our investment in ESM does not have a readily determinable fair value, we use the measurement alternative under ASC 321. Our investment is measured at cost less impairments, adjusted for observable price changes in orderly transactions for the identical or similar investment of the same issuer. If the Company determines that an indicator of impairment or upward adjustment is present, an adjustment is recorded, which is measured as the difference between carrying value and estimated fair value. Estimated fair value is generally determined using an income approach on discounted cash flows or negotiated transaction values. As of December 31, 2024 and 2023, the carrying amount of our investment in ESM was $30.1 million.
Toyotsu Lithium Corporation ("TLC")
The Company owns 49% of the Class A voting shares and 100% of the Class B non-voting shares in TLC. Toyota Tsusho Corporation ("TTC") owns 51% of the Class A voting shares. As a result, the Company has a 75% economic interest and a 49% ownership interest in TLC and TTC has the remaining 25% economic interest and 51% ownership interest in TLC. TLC constructed and now operates the Naraha Lithium Hydroxide Plant (the "Naraha Plant"), located in Japan. The technical grade lithium carbonate feedstock for the plant is sourced from the Company’s Olaroz Plant.
The Company accounts for its interest in TLC as an equity method investment because it does not have control but has significant influence. This is evidenced by the Company having 2 of the 5 board members while decisions are made by a majority. In addition to capital contributions made through its investment in TLC, Allkem has also provided past funding through loans. At the Acquisition Date, the carrying values of the investment in TLC and a fully reserved loan receivable were zero and fair value was deemed to be equal to carrying value.
For the year ended December 31, 2024, we recorded a $7.5 million loss related to our interest in TLC to Equity in net loss of unconsolidated affiliates in our consolidated statements of operations. At December 31, 2024, the carrying value of our interest in TLC was zero and the the loan receivable with TLC was zero.
v3.25.0.1
Investments
 12 Months Ended
Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]  
Investments Partially-Owned Subsidiaries and Noncontrolling Interests    
Nemaska Lithium Inc. ("Nemaska Lithium", or "NLI")
Nemaska Lithium, domiciled in Canada and headquartered in Montreal, Québec, is a non-public mining company not yet in the production stage. It is a development company aiming to vertically integrate, from extracting, processing and concentrating spodumene to conversion of spodumene into battery grade lithium hydroxide, primarily intended for energy storage applications. Its primary assets are construction in progress and intangibles principally related to intellectual property. Nemaska Lithium intends to develop the Whabouchi spodumene mine and concentrator in the James Bay region of Québec and a lithium hydroxide conversion plant in Bécancour, Québec (collectively, the "Nemaska Lithium Project"). As a developing company and to fund the Nemaska Lithium Project, Nemaska Lithium is reliant on securing financing from its shareholders through share subscriptions.
In December 2019, Nemaska Lithium and certain affiliates filed for creditor protection in Canada under the Companies’ Creditors Arrangement Act (the "CCAA") in the Superior Court of Québec (the "CCAA Court"). In October 2020, the CCAA Court approved a sale of Nemaska Lithium structured as a credit bid under the CCAA to a group made up of Orion Mine Finance ("Orion"), Investissement Québec ("IQ", a company established by the Government of Québec to favor investment in Québec by Québec-based and international companies) and The Pallinghurst Group ("Pallinghurst", acting through a new entity named Québec Lithium Partners (UK) Limited ("QLP")). After a series of amalgamations and restructurings, the sale transactions were completed on December 1, 2020, pursuant to which IQ and QLP each acquired a 50% equity interest in Nemaska Lithium.
In the fourth quarter of 2020, the Company entered into an agreement with Pallinghurst for a 50% equity interest in QLP. Through this investment, we obtained indirect ownership of a 25% equity interest in Nemaska Lithium.
On June 6, 2022, Livent issued 17,500,000 shares of its common stock to acquire the remaining 50% share of QLP previously owned by Pallinghurst and certain of its investors (the "QLP Merger"). Upon consummation of the QLP Merger, Livent recorded an Investment of $387.1 million, QLP's cash and cash equivalents of $0.3 million and short-term debt of $13.5 million; and an increase to additional paid in capital of $373.9 million. The Company now owns a 50% economic interest in NLI through its ownership of QLP. The Québec provincial government, through IQ, continues to own the remaining 50% interest in Nemaska Lithium. At present, we do not have off-take rights on the production to come out of the Nemaska Lithium Project.
On October 18, 2023, we entered into an amendment to our shareholders agreement with Nemaska Lithium, and also amendments to certain related service agreements. The amendments to these agreements provide QLP with control of certain substantive participating rights, and as such, the Company began to consolidate Nemaska Lithium as of October 18, 2023. Nemaska Lithium is a development company which, as of the October 18, 2023 consolidation date, met the U.S. GAAP definition of a business and, as such, the Company remeasured its equity interest in Nemaska, including the noncontrolling interest of IQ, at fair value as of the consolidation date. We estimated the fair value of IQ's noncontrolling interest by multiplying the total fair value of Nemaska Lithium equity by IQ's equity ownership interest and also considered any discounts for lack of control and marketability.
The allocation of the fair value of the assets and liabilities of Nemaska Lithium assumed under business combination accounting guidance for the Nemaska Lithium consolidation, including the impact of income taxes, is completed as of December 31, 2024 with no significant measurement period adjustments. Nemaska Lithium is consolidated on a one-quarter lag basis. The table below represents Nemaska Lithium's balance sheet at fair value consolidated by the Company as of October 18, 2023:
Nemaska Lithium Inc.
October 18,
(in Millions)Note
2023 (a)
ASSETS
Cash and cash equivalents$133.5 
Sales tax receivable9.2 
Prepaid expenses3.4 
Total current assets146.1 
In-trust depositsb9.9 
Property, plant and equipmentc932.2 
Goodwilld119.2 
Intangible assetse45.0 
Other non-current assets0.5 
Total non-current assets1,106.8 
Total assets$1,252.9 
LIABILITIES AND EQUITY
Current portion of long-term debtf$2.4 
Accounts payable and accrued liabilities59.8 
Total current liabilities62.2 
Long-term debtg56.1 
Contract liability - long-termg19.8 
Asset retirement obligationsh3.4 
Deferred income taxes111.9 
Other non-current liabilities0.3 
Total non-current liabilities191.5 
Total current and long-term liabilities253.7 
Arcadium shareholders’ equity
499.6 
Noncontrolling interest499.6 
Total equity999.2 
Total liabilities and equity$1,252.9 
______________________________
a.Represents the Nemaska Lithium balance sheet as of the October 18, 2023 consolidation date.
b.Represents a deposit held in trust for estimated restoration costs relating to the Whabouchi site asset retirement obligation.
c.Primarily represents mining property, mining rights and construction in progress for the Whabouchi and Bécancour sites related to project engineering, equipment and site preparation and capitalized financing costs.
d.Primarily related to potential synergies arising from the proximity of Nemaska Lithium to other resources in the region.
e.Primarily represents intellectual property in relation to patents and development costs with a weighted average amortization period of 15 years.
f.Represents current portion of the unsecured obligation governing the working relationship between the Nemaska Lithium Project and the Cree Nation of Nemaska.
g.Primarily represents $75.0 million for the prepayment received for a customer supply agreement entered on October 18, 2023, recorded net of imputed discount of $19.8 million.
h.Represents the asset retirement obligation for estimated inflation-adjusted and discounted future costs associated with mine reclamation and closure activities at the Whabouchi site, and assuming that the disbursements would be made in 2056.
Arcadium's cash and cash equivalents balance in its consolidated balance sheet as of December 31, 2024 includes Nemaska Lithium's cash of $11.4 million at September 30, 2024 as Nemaska Lithium is consolidated on a one-quarter lag. All cash at Nemaska Lithium will be used for capital expenditures and operating expenses of the Nemaska Lithium Project.
As of December 31, 2024, Nemaska Lithium received cash of $225.0 million related to advance payments in connection with a customer supply agreement repayable in equal quarterly installments beginning in January 2027 and ending in October 2031. The related liability, consolidated on a one-quarter lag basis, is $152.1 million debt and $72.9 million contract liability as of December 31, 2024, see Note 17 for details. Prepayments from the customer under the arrangement total $350.0 million, with final prepayment of $125 million received on January 3, 2025.
In the fourth quarter of 2024, the Company contributed cash of $96.7 million to Nemaska Lithium which, due to one-quarter lag reporting, is not yet recorded in our consolidation of Nemaska. The balance is recorded to Other assets - noncurrent because the cash is expected to be used by Nemaska primarily for capital expenditures. IQ contemporaneously made an equal contribution in the fourth quarter of 2024 which, due to one-quarter lag reporting, is not recorded in our consolidation of Nemaska.
Before October 18, 2023, the Company accounted for its interest in Nemaska Lithium as an equity method investment on a one-quarter lag basis and it was included in Investments in our consolidated balance sheets. The carrying amount of our interest in Nemaska Lithium was $437.1 million as of December 31, 2022 under equity method investment accounting. For the years ended December 31, 2023, and 2022 we recorded a $23.1 million, and $15.1 million loss, respectively, related to our interest in Nemaska Lithium to Equity in net loss of unconsolidated affiliate in our consolidated statements of operations.
Sales de Jujuy Pte Ltd and Sales de Jujuy S.A.
The Company has an interest of 72.68% in Sales de Jujuy Pte Ltd ("SDJ Pte"), 66.5% in Sales de Jujuy S.A. ("SDJ"), the legal entities which operate the Olaroz Lithium Facility (the "Olaroz Plant").
Located in the Jujuy Province of northern Argentina, the Olaroz Plant produces lithium carbonate chemicals for the battery, technical and chemical markets. The Olaroz Plant is operated through SDJ, which is a 91.5% owned subsidiary of SDJ Pte, a Singaporean company owned by Arcadium (72.68%) and Toyotsu Lithium Pte Ltd. (27.32%), an affiliated company of TTC. Jujuy Energia y Minera Sociedad del Estado ("JEMSE") owns the remaining 8.5% of SDJ. Consequently, the effective equity ownership of the Olaroz Plant is 66.5% by Arcadium, 25% by TTC, and 8.5% by JEMSE.
As of December 31, 2024, Arcadium had restricted cash of $18.1 million on deposit with Mizuho Bank ("Mizuho") as collateral for the Project Loan Facility and classified within Other non-current assets in its consolidated balance sheets. See Note 17 for details.
Arcadium's cash and cash equivalents balance in its consolidated balance sheet as of December 31, 2024 includes $21.1 million held by the entities discussed above.
Arcadium funded JEMSE’s equity contributions in SDJ with an interest-free loan (the "JEMSE Receivable") to be repaid by JEMSE out of 33% of the dividends it receives from SDJ. The fair value of the non-current receivable is $5.0 million as of December 31, 2024.
Investments
Investments consisted of the following:
 (in Millions)December 31, 2024December 31, 2023
ESM ILiAD, LLC$30.1 $30.1 
Arcadium NQSP6.3 4.7 
Other0.5 — 
Investments$36.9 $34.8 
ESM ILiAD, LLC ("ESM")
In the fourth quarter of 2023, the Company entered into an agreement with EnergySource Minerals, LLC ("EnergySource"), a developer of lithium projects in the Salton Sea Known Geothermal Resource Area in California, for a minority equity interest in ESM, a subsidiary of EnergySource and the parent company of ILiAD Technologies, LLC ("ILiAD Technologies"). In connection with its investment in ESM, Arcadium Lithium will have the right to license ILiAD Technologies' Integrated Lithium Adsorption Desorption ("ILiAD") technology for potential deployment at its lithium brine resources in Argentina.
Arcadium Lithium accounts for its interest in ESM under ASC Topic 321, Investments – Equity Securities ("ASC 321"). Since our investment in ESM does not have a readily determinable fair value, we use the measurement alternative under ASC 321. Our investment is measured at cost less impairments, adjusted for observable price changes in orderly transactions for the identical or similar investment of the same issuer. If the Company determines that an indicator of impairment or upward adjustment is present, an adjustment is recorded, which is measured as the difference between carrying value and estimated fair value. Estimated fair value is generally determined using an income approach on discounted cash flows or negotiated transaction values. As of December 31, 2024 and 2023, the carrying amount of our investment in ESM was $30.1 million.
Toyotsu Lithium Corporation ("TLC")
The Company owns 49% of the Class A voting shares and 100% of the Class B non-voting shares in TLC. Toyota Tsusho Corporation ("TTC") owns 51% of the Class A voting shares. As a result, the Company has a 75% economic interest and a 49% ownership interest in TLC and TTC has the remaining 25% economic interest and 51% ownership interest in TLC. TLC constructed and now operates the Naraha Lithium Hydroxide Plant (the "Naraha Plant"), located in Japan. The technical grade lithium carbonate feedstock for the plant is sourced from the Company’s Olaroz Plant.
The Company accounts for its interest in TLC as an equity method investment because it does not have control but has significant influence. This is evidenced by the Company having 2 of the 5 board members while decisions are made by a majority. In addition to capital contributions made through its investment in TLC, Allkem has also provided past funding through loans. At the Acquisition Date, the carrying values of the investment in TLC and a fully reserved loan receivable were zero and fair value was deemed to be equal to carrying value.
For the year ended December 31, 2024, we recorded a $7.5 million loss related to our interest in TLC to Equity in net loss of unconsolidated affiliates in our consolidated statements of operations. At December 31, 2024, the carrying value of our interest in TLC was zero and the the loan receivable with TLC was zero.
v3.25.0.1
Property, Plant and Equipment, Net
 12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment, Net Property, Plant and Equipment, Net
Property, plant and equipment consisted of the following:
 December 31,
(in Millions)20242023
Land and land improvements$337.0 $106.2 
Buildings1,006.8 134.9 
Machinery and equipment1,011.8 420.7 
Mineral rights
3,184.9 560.0 
Construction in progress2,181.9 1,284.4 
Total cost7,722.4 2,506.2 
Accumulated depreciation(351.2)(269.1)
Property, plant and equipment, net$7,371.2 $2,237.1 

At December 31, 2024 and 2023, the majority of our Property, plant and equipment, net balance is domiciled in Argentina and Canada. Depreciation is calculated principally on a straight-line basis over the estimated useful lives of the assets or a units-of-production basis based on the rate of depletion of reserves. Land is not depreciated. The major classifications of property, equipment and software, including their respective principal depreciation and amortization method and expected useful lives, consisted of the following:
Asset type Depreciation and amortization methodUseful Life
Land N/A—
Land improvements Straight-line20 years
Buildings Straight-line
20-40 years
Mineral rightsUnits-of-productionBased on rate of depletion of reserves
Mining extraction equipmentUnits-of-productionBased on rate of depletion of reserves
Leased plant and equipmentStraight-line
Lease period (1-10.5 years)
Other machinery and equipment Straight-line
3-18 years
SoftwareStraight-line
3-10 years
Depreciation expense was $120.2 million, $26.6 million, and $25.1 million in 2024, 2023 and 2022, respectively.
Long-Lived Asset Impairment
On September 4, 2024, Arcadium Lithium announced that it will suspend Stage 4A waste stripping, and any expansionary investment beyond Stage 3, at its Mt Cattlin spodumene operation in Western Australia given the decline in spodumene prices. As a result, the Company plans to place the Mt Cattlin site into care and maintenance by the end of the first half of 2025 after it completes Stage 3 mining and ore processing. The Company does not intend to close its Mt Cattlin site. Care and maintenance will keep the mine and processing facilities in a position to potentially resume operations when market conditions become more favorable. The Company will also continue to explore the viability of underground mining at the Mt Cattlin site, which could potentially extend the remaining mine life.
In the third quarter of 2024, as a result of the plan to place Mt Cattlin into care and maintenance, the Company determined that there were indicators of impairment and therefore performed long-lived assets impairment testing for the Mt Cattlin asset group. As a result of the evaluation using the income approach, the Company determined the undiscounted cash flows of Mt Cattlin's assets were not greater than their carrying value, resulting in a non-cash charge of $51.7 million for the year ended December 31, 2024, recorded to Impairment charges in the consolidated statement of operations. Management will continue to monitor events and circumstances that would require a future test of recoverability on the remaining Mt Cattlin long-lived assets.
v3.25.0.1
Restructuring and Other Charges
 12 Months Ended
Dec. 31, 2024
Restructuring and Related Activities [Abstract]  
Restructuring and Other Charges Restructuring and Other Charges
The following table shows total restructuring and other charges included in the consolidated statements of operations:
 Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
Restructuring charges:
Severance-related and exit costs $19.0 $2.4 $1.8 
Other charges:
Costs related to the Rio Tinto Transaction
23.2 — — 
Cost related to the Allkem Livent Merger103.9 54.1 2.9 
Loss on asset replacement (2)
6.9 — — 
Other
4.2 0.4 2.6 
Total restructuring and other charges $157.2 $56.9 $7.3 
_____________________
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.Represents one-time write off of construction in process for structural redesign at the Bécancour development project.
v3.25.0.1
Environmental Obligations
 12 Months Ended
Dec. 31, 2024
Environmental Remediation Obligations [Abstract]  
Environmental Obligations Environmental Obligations
We are subject to various federal, state, local and foreign environmental laws and regulations that govern emissions of air pollutants, discharges of water pollutants, and the manufacturing, storage, handling and disposal of hazardous substances, hazardous wastes and other toxic materials and remediation of contaminated sites. We are also subject to liabilities arising under the Comprehensive Environmental Response, Compensation and Liability Act ("CERCLA") and similar state laws that impose responsibility on persons who arranged for the disposal of hazardous substances, and on current and previous owners and operators of a facility for the clean-up of hazardous substances released from the facility into the environment. We are also subject to liabilities under the Resource Conservation and Recovery Act ("RCRA") and analogous state laws that require owners and operators of facilities that have treated, stored or disposed of hazardous waste pursuant to a RCRA permit to follow certain waste management practices and to clean up releases of hazardous substances into the environment associated with past or present practices. In addition, when deemed appropriate, we enter certain sites with potential liability into voluntary remediation compliance programs, which are also subject to guidelines that require owners and operators, current and previous, to clean up releases of hazardous substances into the environment associated with past or present practices.
Environmental liabilities consist of obligations relating to waste handling and the remediation and/or study of sites at which we are alleged to have released or disposed of hazardous substances. As of the periods presented, the Bessemer City and the former Allkem Lithium One, Inc. sites located in North Carolina, United States and Québec, Canada, respectively, are the only sites for which we have a reserve. We have provided reserves for potential environmental obligations that we consider probable and for which a reasonable estimate of the obligation can be made. Accordingly, total reserves of $7.8 million and $7.5 million existed for the years ended December 31, 2024 and 2023, respectively.
The estimated reasonably possible environmental loss contingencies exceed amount accrued by approximately $1.3 million at December 31, 2024. This reasonably possible estimate is based upon information available as of the date of the filing and the actual future losses may be higher given the uncertainties regarding the status of laws, regulations, enforcement policies, the impact of potentially responsible parties, technology and information related to the site.
Although potential environmental remediation expenditures in excess of the reserves and estimated loss contingencies could be significant, the impact on our future consolidated financial results is not subject to reasonable estimation due to numerous uncertainties concerning the nature and scope of possible contamination, identification of remediation alternatives under constantly changing requirements, selection of new and diverse clean-up technologies to meet compliance standards, and the timing of potential expenditures. The liabilities arising from potential environmental obligations that have not been reserved for at this time may be material to results of operations in the future.
The table below is a roll forward of our total environmental reserves.
(in Millions)Environmental Reserves Total
Balance as of December 31, 2022$7.0 
Change in reserves 0.8 
Cash payments(0.3)
Balance as of December 31, 2023$7.5 
Change in reserves 4.3 
Acquisitions - Allkem Livent Merger
2.8 
Cash payments(6.8)
Balance as of December 31, 2024$7.8 

The table below provides detail of current and long-term environmental reserves.
 December 31,
(in Millions)20242023
Environmental reserves, current (1)
$0.9 $0.5 
Environmental reserves, long-term (2)
6.9 7.0 
Total environmental reserves$7.8 $7.5 
______________
1.These amounts are included within "Accrued and other liabilities" on the consolidated balance sheets.
2.These amounts are included in "Environmental liabilities" on the consolidated balance sheets.
v3.25.0.1
Other (Gains)/Losses
 12 Months Ended
Dec. 31, 2024
Other Income and Expenses [Abstract]  
Other (Gains)/Losses Other (Gains)/Losses
The following table shows amounts included in Other (Gains)/Losses in the consolidated statements of operations:
Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
Blue Chip Swap gains: (2)
Non-recurring - SDV and MdA Holdings LLC (3)
$(45.2)$(61.6)$(22.2)
Recurring - SDJ and MdA(22.6)(6.9)— 
Total Blue Chip Swap gains(67.8)(68.5)(22.2)
Foreign currency remeasurement (gains)/losses:
Foreign currency remeasurement (gains)/losses (4)
(171.3)68.9 7.0 
Remeasurement gains on U.S. dollar denominated cash held by foreign currency functional subsidiary(14.3)— — 
Total Foreign currency remeasurement (gains)/losses
(185.6)68.9 7.0 
Loss on trading securities and other
1.0 — — 
Total Other (gains)/losses
$(252.4)$0.4 $(15.2)
___________________________
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.See Note 2 for details.
3.Represents the non-recurring gain from the sale in Argentina pesos of Argentina Sovereign U.S. dollar-denominated bonds due to the divergence of Argentina's Blue Chip Swap market exchange rate from the official rate.
4.The twelve months ended December 31, 2024 primarily includes impact of currency fluctuations on deferred income tax assets and liabilities related to the Allkem Livent Merger.
v3.25.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
Domestic and foreign components of income from operations before income taxes are shown below:
 Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
Domestic$(21.5)$34.8 $133.2 
Foreign232.1 354.2 202.2 
Total$210.6 $389.0 $335.4 
The provision for income taxes attributable to income from operations consisted of: 
 Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
Current:
Federal $9.5 $31.7 $43.7 
Foreign89.7 27.6 5.6 
State(0.4)0.6 1.3 
Total current$98.8 $59.9 $50.6 
Deferred:
Federal $6.5 $4.5 $(1.9)
Foreign(26.7)(5.9)13.3 
State0.3 0.4 (0.1)
Total deferred(19.9)(1.0)11.3 
Total$78.9 $58.9 $61.9 
____________________
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.

The effective income tax rate applicable to income from operations before income taxes was different from the statutory U.S. federal income tax rate due to the factors listed in the following table: 
 Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
U.S. Federal statutory rate$44.2 $81.7 $70.4 
Foreign earnings subject to different tax rates(9.6)(78.9)(30.0)
Foreign derived intangible income — (0.9)(2.1)
State and local income taxes, less federal income tax benefit(0.1)0.9 0.9 
Tax on intercompany dividends and deemed dividends for tax purposes 3.5 27.7 19.8 
Changes to unrecognized tax benefits6.8 0.4 (0.5)
Other non-deductible expenses (2)
23.5 6.2 0.1 
Other non-taxable income
(2.8)(4.9)(2.9)
Change in valuation allowance (3)
(44.6)66.0 (1.7)
Exchange gains and losses (4)
40.1 (43.0)6.9 
Withholding taxes net of credits7.3 4.7 0.6 
Tax on global activities (5)
5.4 — — 
Other 5.2 (1.0)0.4 
Total tax provision$78.9 $58.9 $61.9 
____________________ 
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.The year ended December 31, 2024 primarily includes the impact of management fees and transaction costs incurred by our parent company that are non-deductible.
3.For the year ended December 31, 2024, the Company released a valuation allowance of $(77.2) million to the statement of operations on the net deferred tax assets in Argentina. For the year ended December 31, 2023, the Company recorded a valuation allowance of $60.3 million to the statement of operations on the net deferred tax assets in Argentina. These adjustments were primarily due to the significant fluctuations in foreign currency impacts that occurred during both periods.
4.Includes the impact of foreign currency exchange gains or losses in Argentina on net monetary assets for which no corresponding tax expense or benefit is realized and the tax provision for statutory taxable gains or losses in foreign jurisdictions for which there is no corresponding amount in income before taxes. Additionally, the years ended December 31, 2024, 2023 and 2022 include an adjustment relating to inflation.
5.Represents additional expense for global minimum taxes at our parent company in accordance with the newly implemented Pillar Two rules.
Significant components of our deferred tax assets and liabilities were attributable to:
 Year Ended December 31,
(in Millions)2024
2023 (1)
Net operating loss carry-forwards and credits (2)
$203.9 $239.2 
Exploration and development expenses
11.2 12.0 
Disallowed interest expense (3)
88.9 8.8 
Other assets and reserves12.4 20.7 
Deferred tax assets$316.4 $280.7 
Valuation allowance, net (4)
(46.9)(83.1)
Deferred tax assets, net of valuation allowance$269.5 $197.6 
Property, plant and equipment, net (3)
(1,322.6)(281.8)
Intangibles(6.3)(11.8)
Deferred inflationary gain(49.0)(28.4)
Other liabilities(4.7)(0.6)
Deferred tax liabilities(1,382.6)(322.6)
Net deferred tax liabilities$(1,113.1)$(125.0)
___________________
1.Represents the results of predecessor Livent’s operations for the year ended December 31, 2023 which do not include the operations of Allkem.
2.The year ended December 31, 2024 primarily relates to net operating losses generated in Canada. The year ended December 31, 2023 primarily relates to net operating losses generated in Argentina and Canada. The net operating losses in Canada primarily relate to Nemaska Lithium, see Note 9 for details.
3.As part of the Allkem Livent Merger, the Company recorded deferred tax assets of $47.8 million related primarily to accrued interest, and deferred tax liabilities of $1,311.7 million related to property, plant and equipment, within the purchase price allocation for the year ended December 31, 2024. See Note 4 for details
4.For the year ended December 31, 2023, the Company recorded a valuation allowance in 2023 on the net deferred tax assets in Argentina, primarily relating to the net operating loss as a result of the significant fluctuations in foreign currency. These significant fluctuations in foreign currency impacts primarily occurred in December 2023. The balance at the end of the year was $80.2 million.
We evaluate our deferred income taxes quarterly to determine if valuation allowances are required or should be adjusted. U.S. GAAP requires companies to assess whether valuation allowances should be established against deferred tax assets based on all available evidence, both positive and negative, using a "more likely than not" standard. In assessing the need for a valuation allowance, appropriate consideration is given to all positive and negative evidence related to the realization of deferred tax assets. This assessment considers, among other matters, the nature and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, and tax planning alternatives. The Company recorded a valuation allowance of $28.9 million to the balance sheet in 2024 on the net deferred tax assets in Ireland, primarily relating to the future utilization of foreign tax credits against foreign source income taxed by the Irish tax authorities. In addition, we also recorded a valuation allowance of $3.4 million on deferred tax assets generated from net operating losses in Argentina.
As of December 31, 2024, we had total foreign net operating loss carry-forwards of $153.3 million (tax effected) primarily related to Canada and expiring within 20 years. The net operating losses in Canada primarily relate to Nemaska Lithium, see Note 9 for details. As of December 31, 2023, we had total foreign net operating loss carry-forwards of $233.1 million (tax effected) primarily related to Argentina and Canada and expiring within 5 years and within 20 years, respectively.
Income taxes are not provided for any additional outside basis differences inherent in our investments in subsidiaries because the investments and related unremitted earnings are essentially permanent in duration or we have concluded that no additional tax liability will arise upon disposal. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings is not practicable due to the complexity of the hypothetical calculation.
Uncertain Income Tax Positions
U.S. GAAP accounting guidance for uncertainty in income taxes prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition.
As of December 31, 2024, we had total unrecognized tax benefits of $14.7 million, of which $11.9 million would favorably impact the effective tax rate from operations if recognized. As of December 31, 2023, we had total unrecognized tax benefits of $4.7 million. As of December 31, 2022, we had total unrecognized tax benefits of $4.5 million. Interest and penalties related to unrecognized tax benefits are reported as a component of income tax expense. For the years ended December 31, 2024, 2023 and 2022, we recognized interest and penalties of $9.2 million, $0.3 million, and $0.2 million, respectively, in the consolidated statement of operations. As of December 31, 2024 and 2023, we have accrued interest and penalties in the consolidated balance sheets of $7.1 million and $1.1 million, respectively.
Due to the potential for resolution of federal, state, or foreign examinations, and the expiration of various jurisdictional statutes of limitation, it is reasonably possible that our liability for unrecognized tax benefits will increase within the next 12 months by a range of zero to $0.4 million.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: 
Year Ended December 31,
(in Millions)202420232022
Balance at beginning of year
$4.7 $4.5 $2.9 
Increases related to positions taken in the current year4.5 0.4 3.3 
Decreases related to positions taken in prior years(3.7)— — 
Increases related to positions taken in prior years14.2 — — 
Decreases related to lapse of statutes of limitations(0.8)(0.2)(0.1)
Settlement of uncertain tax positions(4.2)— (1.6)
Balance at end of year$14.7 $4.7 $4.5 
v3.25.0.1
Asset Retirement Obligations
 12 Months Ended
Dec. 31, 2024
Asset Retirement Obligation Disclosure [Abstract]  
Asset Retirement Obligations Asset Retirement Obligations
Legacy Allkem asset retirement obligations acquired in the Allkem Livent Merger were recorded at fair value on the Acquisition Date and consist of $9.4 million, $1.5 million and $1.0 million related to the Mt Cattlin spodumene mine in Western Australia, the Olaroz lithium brine extraction facility in Jujuy, Argentina and the Sal de Vida lithium brine extraction facility (currently under development) in Catamarca, Argentina, respectively.
v3.25.0.1
Debt
 12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Debt Debt
Long-term debt
Long-term debt consists of the following:
Interest Rate
Percentage
Maturity
Date		December 31, 2024December 31, 2023
(in Millions)SOFR borrowingsBase rate borrowings
Revolving Credit Facility (1)
6.18%8.25%2027$344.0 $— 
4.125% Convertible Senior Notes due 2025
4.125%2025245.8 245.8 
Transaction costs - 2025 Notes(0.9)(2.4)
Nemaska - Prepayment agreement (2)
8.9%75.0 75.0 
Discount - Prepayment agreement(20.1)(19.8)
Nemaska - Prepayment agreement - tranche 2 (2)
9.4%150.0 — 
Discount - Prepayment agreement(52.8)— 
Nemaska - Other0.6 3.4 
Debt assumed in Allkem Livent Merger (3)
Project Loan Facility - Stage 2 of Olaroz Plant2.61%2029135.0 — 
Affiliate Loans with TTC14.30%203081.5 — 
Affiliate Loan with TLP10.03%20262.5 — 
Total debt assumed in Allkem Livent Merger219.0 — 
Subtotal long-term debt (including current maturities)960.6 302.0 
Less current maturities(288.9)(2.4)
Total long-term debt $671.7 $299.6 
______________________________
1.As of December 31, 2024 and December 31, 2023, there were $16.8 million and $15.5 million, respectively, in letters of credit outstanding under our Revolving Credit Facility and $139.2 million and $484.5 million available funds as of December 31, 2024 and December 31, 2023, respectively. Fund availability is subject to the Company meeting its debt covenants.
2.Represents advance payments in connection with customer supply agreement which do not have a contractual interest rate or bear any actual interest and are repayable in equal quarterly installments beginning in January 2027 and ending in October 2031. Represents U.S. GAAP imputed interest rate.
3.On March 7, 2024 SDJ paid $18.1 million to repay a portion of the outstanding balance of the Stage 1 and Stage 2 Olaroz Plan Project Loan Facility. On September 10, 2024, SDJ paid $9.1 million to repay the outstanding balance of the Stage 1 Olaroz Plan Project Loan Facility in its entirety, as well as $9.0 million to repay a portion of the outstanding of the Stage 2 Olaroz Plan Project Loan Facility. On May 30, 2024, SDV paid the outstanding principal balance of $47.0 million, a prepayment fee of $0.9 million and accrued interest and commitment fees of $1.3 million to repay the Sal de Vida Project Financing Facility in its entirety.


Rio Tinto Term Loans
On January 22, 2025, the Company entered into a commitment letter with Rio Tinto plc, whereby Rio Tinto plc (or an affiliate thereof) has committed to provide Arcadium Lithium Financing IRL Designated Activity Company (the "Borrower") a first lien secured term loan facility of $200 million (the "Pari Passu Term Loan") and a second lien secured term loan facility of $300 million (the "Junior Term Loan"), together the "Rio Tinto Term Loans." The Pari Passu Term Loan will be secured by first-priority liens on the same assets that secure the existing Revolving Credit Facility and the Junior Term Loan will be secured by second-priority liens on the same assets that secure the existing Revolving Credit Facility. The obligations under the Rio Tinto Loans will be guaranteed by the same entities that guarantee the obligations under the existing Revolving Credit Facility. The proceeds of the Rio Tinto Term Loans may be used for certain capital expenditure payments of the Borrower and its subsidiaries. The principal amount of the Rio Tinto Term Loans, together with accrued and unpaid interest thereon, will be due and payable on September 1, 2027, consistent with the existing Revolving Credit Facility. The Rio Tinto Term Loans will be subject to the same financial covenants as the existing Revolving Credit Facility which will require the maintenance of a maximum leverage ratio and a minimum interest coverage ratio.
The Rio Tinto Term Loans will bear interest at adjusted term SOFR (defined as the forward-looking SOFR term rate published by CME Group Benchmark Administration Limited plus 0.10% per annum subject to a floor of zero) plus, an applicable margin, as determined in accordance with the provisions of the Pari Passu Term Loan and the Junior Term Loan agreements. Interest will be payable on the last day of an interest period. On January 30, 2025, pursuant to the Pari Passu Term Loan, we received $199.5 million cash proceeds, net of financing fees of $0.5 million.

4.125% Convertible Senior Notes due 2025
In 2020, the Company issued $245.8 million in aggregate principal amount of 4.125% Convertible Senior Notes due in July 2025 (the "2025 Notes"). The 2025 Notes are our general unsecured senior obligations. Total net cash proceeds received were $238.2 million net of $7.6 million of third-party transaction costs, including initial purchasers' discounts and commissions.
Each $1,000 of principal of the 2025 Notes was initially convertible into 114.4885 shares of common stock of Livent Corporation, which was equivalent to an initial conversion price of $8.73 per share, subject to adjustment upon the occurrence of specified events. Following the effectiveness of that certain First Supplemental Indenture, dated as of January 4, 2024, by and among the Company, Livent Corporation and U.S. Bank Trust Company, National Association (the "First Supplemental Indenture"), each $1,000 of principal of the 2025 Notes was convertible into 275.459331 ordinary shares of the Company, which is equivalent to a conversion price of $3.63 per share, subject to adjustment upon the occurrence of specified events. We may redeem for cash all or any portion of the 2025 Notes, at our option, if the last reported sale price of our ordinary shares has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the 2025 Notes to be redeemed, plus accrued and unpaid interest. On and after January 15, 2025, holders of the 2025 Notes are entitled to convert all or any portion of their 2025 Notes at any time prior to the close of business on the business day immediately preceding July 15, 2025, which is the maturity date of the 2025 Notes. Following the effectiveness of that certain Second Supplemental Indenture, dated as of January 1, 2025, by and among the Company, Livent Corporation and U.S. Bank Trust Company, National Association (the "Second Supplemental Indenture"), we guaranteed Livent Corporation’s obligations under that certain Indenture, dated as of June 25, 2020, by and among the Company, Livent Corporation and U.S. Bank Trust Company, National Association (as amended and supplemented by the First Supplemental Indenture and the Second Supplemental Indenture, the "Indenture") and Livent Corporation irrevocably elected to settle all future conversions of 2025 Notes by issuing Ordinary Shares (in addition to cash in lieu of delivery of any fractional Ordinary Share) to holders of 2025 Notes that elect to convert all or any portion of their 2025 Notes.
If a fundamental change occurs prior to the maturity date, holders of the 2025 Notes may require us to repurchase all or a portion of their 2025 Notes for cash at a repurchase price equal to 100% of the principal amount plus any accrued and unpaid interest. In addition, if a fundamental change occurs prior to the maturity date or if we deliver a notice of redemption, we will increase the conversion rate for a holder who elects to convert its 2025 Notes in connection with such fundamental change or notice of redemption in certain circumstances.
On February 13, 2025, in connection with the Rio Tinto Transaction and pursuant to the Indenture, the Company delivered to the trustee and the holders of the 2025 Notes a Notice of Merger Event (the "Merger Event Notice"), which provided that the Rio Tinto Transaction is expected to become effective on March 6, 2025, on which date the holders of record of the Company's ordinary shares shall be entitled to exchange the ordinary shares for the Per Share Consideration Price, as defined in the Merger Event Notice.
In the first quarter of 2025, the holders of the 2025 Notes were notified that the last reported sale price of Arcadium Lithium's ordinary shares for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, December 31, 2024 was greater than or equal to 130% of the conversion price then in effect on each trading day, and as a result, the holders have the option to convert all or any portion of their 2025 Notes through March 31, 2025.
The conversion rate for the 2025 Notes is 275.4593 ordinary shares of Arcadium Lithium per $1,000 principal amount of 2025 Notes. The 2025 Notes mature on July 15, 2025 and were reclassified to current portion of long-term debt in the third quarter of 2024.
On the July 15, 2025 maturity date, we are required to deposit with the trustee under the Indenture cash sufficient to pay all of the outstanding 2025 Notes and all other sums due and payable by Livent Corporation under the Indenture.
The Company recorded interest expense related to the amortization of transaction costs of $1.5 million for each of the years ended December 31, 2024 and 2023, all of which was capitalized. The Company recorded $10.1 million of accrued interest expense related to the principal amount for each of the years ended December 31, 2024 and 2023, all of which was capitalized.
Amended and Restated Credit Agreement, (the "Revolving Credit Facility")
On January 4, 2024, Livent Corporation, Livent USA Corp., the Company, Arcadium Lithium Financing IRL Limited ("FinCo") and Irish IntermediateCo (collectively, the "Borrowers" and, each, a "Borrower"), the guarantors party thereto from time to time (the "Guarantors"), the lenders party thereto (the "Lenders") and issuing banks party thereto and Citibank, N.A., as administrative agent (the "Administrative Agent") for the Lenders, entered into a Joinder and First Amendment (the "Credit Agreement Amendment") to that certain Amended and Restated Credit Agreement, dated as of September 1, 2022, among Livent, Livent USA Corp., the guarantors party thereto from time to time, the lenders party thereto from time to time and the Administrative Agent (the "Credit Agreement" and as amended by the Credit Agreement Amendment, the
Amended Credit Agreement").
The Credit Agreement Amendment provided for, among other things, (i) the addition of Arcadium, Irish IntermediateCo and FinCo as borrowers and obligors under the Amended Credit Agreement and (ii) the assignment of certain of Livent Corporation's rights and obligations (including information reporting obligations) under the Amended Credit Agreement to Arcadium.
The Revolving Credit Facility provides for a $500 million senior secured revolving credit facility, $50 million of which is available for the issuance of letters of credit for the account of the Borrowers, with an option to request, and subject to each Lender’s sole discretion, that the aggregate revolving credit commitments be increased to up to $700 million. The issuance of letters of credit and the proceeds of revolving credit loans made pursuant to the Revolving Credit Facility may be used for general corporate purposes, including capital expenditures and permitted acquisitions.
Revolving loans under the Revolving Credit Facility will bear interest at a floating rate, which will be (i) a base rate, (ii) Adjusted Term Secured Overnight Financing Rate ("SOFR") (defined as the forward-looking SOFR term rate published by CME Group Benchmark Administration Limited plus 0.10% per annum subject to a floor of zero) or (iii) Euro Interbank Offered Rate ("EURIBOR"), plus, in each case, an applicable margin, as determined in accordance with the provisions of the Revolving Credit Facility. The Revolving Credit Facility includes a quarterly commitment fee on the average daily unused amount of each Lender’s revolving credit commitment at a rate equal to an applicable percentage based on the Company’s first lien leverage ratio. The initial commitment fee is 0.25% per annum. Amounts under the Revolving Credit Facility may be borrowed, repaid and re-borrowed from time to time until the final maturity date on September 1, 2027. Voluntary prepayments and commitment reductions are permitted at any time without payment of any prepayment fee upon proper notice and subject to minimum dollar amounts. Certain of the Borrowers’ domestic subsidiaries (the "Guarantors") guarantee the obligations of the Borrowers under the Revolving Credit Facility. The obligations of the Borrower and the Guarantors are secured by all of the assets of the Borrowers and the Guarantors, including the Borrowers’ facility and real estate in Bessemer City, North Carolina, subject to certain exceptions and exclusions.
We recorded $0.8 million of incremental deferred financing costs in the consolidated balance sheets for the Revolving Credit Facility commitment and legal fees and a $0.2 million loss on debt extinguishment in the consolidated statements of operations for the year ended December 31, 2024 for the write-off of existing deferred financing costs to recognize a partial change in syndication related to the Revolving Credit Facility. The carrying value of our deferred financing costs was $2.1 million as of December 31, 2024 and is recorded to Other assets in our consolidated balance sheet.
Covenants
The Credit Agreement contains certain affirmative and negative covenants that are binding on the Borrowers and their subsidiaries, including, among others, restrictions (subject to exceptions and qualifications) on the ability of the Borrowers and their subsidiaries to create liens, to undertake fundamental changes, to incur debt, to sell or dispose of assets, to make investments, to make restricted payments such as dividends, distributions or equity repurchases, to change the nature of their businesses, to enter into transactions with affiliates and to enter into certain burdensome agreements. Furthermore, the Borrowers are subject to financial covenants regarding leverage (measured as the ratio of debt to adjusted earnings) and interest coverage (measured as the ratio of adjusted earnings to interest expense). Our financial covenants have not changed with the Credit Agreement Amendment. Our maximum allowable first lien leverage ratio is 3.5 as of December 31, 2024. Our minimum allowable interest coverage ratio is 3.5. We were in compliance with all requirements of the covenants as of December 31, 2024.
Debt assumed as a result of Allkem Livent Merger
The following is a summary of Allkem's indebtedness that Arcadium Lithium assumed as a result of the Allkem Livent Merger.
Project Financing Facility
Galaxy Lithium (SAL DE VIDA) S.A. ("SDV"), which is owned 100% by Arcadium, entered into a project financing facility with the International Finance Corporation related to the Sal de Vida development project ("Sal de Vida") in Argentina (the "Project Financing Facility"). The Project Financing Facility originally provided for a total of $180.0 million in limited recourse, sustainability-linked green project financing maturing in March 2033. On May 30, 2024, SDV paid the lender the outstanding principal balance of $47.0 million, a prepayment fee of $0.9 million and accrued interest and commitment fees of $1.3 million to repay the Project Financing Facility in its entirety.
Project Loan Facility
SDJ has a project loan facility with Mizuho Bank related to the Olaroz Plant (the "Project Loan Facility"):
•On September 10, 2024, SDJ paid the lender the outstanding principal balance of $9.1 million, to repay the Project Loan Facility for Stage 1 of the Olaroz Plant in its entirety.
•The Project Loan Facility for Stage 2 of the Olaroz project had an outstanding balance of $135.0 million as of December 31, 2024. The interest rate for the Stage 2 loan is a fixed rate of 2.6119% per annum until expiry in March 2029.
As of December 31, 2024, Arcadium had restricted cash of $18.1 million on deposit with Mizuho as collateral for the Project Loan Facility and classified within Other non-current assets in its consolidated balance sheet.
As of December 31, 2024, Arcadium is also required to reserve $101.3 million of its cash and cash equivalents in support of a guarantee to TTC associated with the Stage 2 Project Loan Facility for the Olaroz Plant. Arcadium would incur a 2.5% fee for permitted reductions to this reserve.
Affiliate Loans With TTC
SDJ has eleven loans with TTC related to the Olaroz Plant originally providing for a total of $93.0 million in principal. As of December 31, 2024, the loans have an outstanding principal balance of $81.5 million and are payable ranging from July 2024 until March 2030.
v3.25.0.1
Share-Based Compensation
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
Arcadium Lithium plc Omnibus Incentive Plan (the "Arcadium Plan")
As of December 31, 2024, there were 64,548,000 Arcadium ordinary shares authorized for issuance under the Arcadium Plan. The Arcadium Plan provides for the grant of a variety of cash and equity awards to officers, directors, employees and consultants, including share options, restricted shares, restricted share units (including performance units), share appreciation rights, and management incentive awards. The Compensation Committee of the Arcadium Board of Directors (the "Arcadium Committee") has the authority to amend the Arcadium Plan at any time, approve financial targets, award grants, establish performance objectives and conditions and the times and conditions for payment of awards.
Share options granted under the Arcadium Plan may be incentive or non-qualified share options. The exercise price for share options may not be less than the fair market value of the share at the date of grant. Awards granted under the Arcadium Plan vest or become exercisable or payable at the time designated by the Arcadium Committee. The options granted in 2024 will vest on the first, second and third anniversaries of the date of grant, subject generally to continued employment, and the cost is recognized over the vesting period. Incentive and non-qualified options granted under the Arcadium Plan expire not later than 10 years from the grant date.
Under the Arcadium Plan, awards of restricted share units ("RSUs") vest over periods designated by the Arcadium Committee. The RSUs granted in 2024 to employees will vest equally on the first, second and third anniversaries of the grant date, subject generally to continued employment, and cost is recognized over the vesting period. The RSUs granted to non-employee directors in 2024 vest at the Company's next annual meeting of shareholders following the grant date. Compensation cost is recognized over the vesting periods based on the market value of Arcadium ordinary shares on the grant date of the award.
Allkem Replacement Awards
Pursuant to the Allkem Transaction Agreement, the equity awards of Allkem (including performance rights) outstanding as of immediately prior to the closing of the Allkem Livent Merger were converted into equity awards denominated in shares of Arcadium ordinary shares. The Company issued time-based vesting restricted shares in connection with the conversion of such awards. The estimated fair value of the portion of the Allkem equity awards for which the required service period had been
completed at the time of the closing of the Allkem Livent Merger was treated as purchase consideration. The remaining estimated fair value is recorded as compensation expense over the remainder of the service period associated with the awards. The Allkem Replacement Awards are authorized for issuance under the Arcadium Plan.
Treatment of Equity Awards in the Rio Tinto Transaction
At the completion of the Rio Tinto Transaction, the Company’s outstanding equity awards will be treated as follows:
•Restricted Stock Units: Each outstanding RSU that is held by a non-employee director will be cancelled and converted into the right to receive an amount in cash, without interest, equal to $5.85 per Company share. Each other outstanding RSU will be cancelled and exchanged for an award of restricted stock units with respect to a number of ordinary shares of either Rio Tinto plc or Rio Tinto Limited (each, a "Listed Share"), determined by multiplying the number of Company shares subject to such RSU by the Equity Award Conversion Ratio (as defined in the Rio Tinto Transaction Agreement).
•Restricted Share Rights (or "Allkem Replacement Awards" per the Allkem Transaction Agreement): Each outstanding restricted share right with respect to Company shares, whether vested or unvested (each, a "Restricted Share Right"), will be cancelled and exchanged for an award of restricted share rights with respect to a number of Listed Shares, determined by multiplying the number of Company shares subject to such Restricted Share Right by the Equity Award Conversion Ratio.
•Stock Options: Each outstanding stock option with respect to the Company’s shares, whether vested or unvested (each, a "Company Stock Option"), will be cancelled and exchanged for an option to purchase a number of applicable Listed Shares determined by multiplying (i) the number of Company shares subject to such Company Stock Option by (ii) the Equity Award Conversion Ratio, rounded down to the nearest whole share. Such stock option will have a per-share exercise price determined by dividing (i) the exercise price per Company share at which such Company Stock Option was exercisable immediately prior to the closing by (ii) the Equity Award Conversion Ratio, rounded up to the nearest whole cent.
Legacy Livent Awards
As of December 31, 2024, there were 6,579,305 Arcadium ordinary shares authorized for issuance upon the exercise or settlement of the Legacy Livent Awards.
Share Compensation
We recognized the following share compensation expense for Legacy Livent Awards and awards under the Arcadium Plan:
Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
Share Option Expense, net of taxes of $0.4, $0.3 and $0.3
$3.0 $1.7 $1.8 
Restricted Share Expense, net of taxes of $(0.7), $0.9 and $0.7
24.7 4.5 3.6 
Performance-Based Restricted Share Expense, net of taxes of $0.1, $0.3, and $0.1
0.4 1.8 0.4 
Total Share Compensation Expense, net of taxes of $(0.2), $1.5 and $1.1 (2)
$28.1 $8.0 $5.8 
____________________ 
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.Gross share compensation charges of $12.2 million and $15.7 million were recorded to "Selling, general and administrative expenses" and "Restructuring and other charges", respectively, in our consolidated statement of operations for the year ended December 31, 2024. Gross share compensation charges of $8.4 million and $1.1 million were recorded to "Selling, general and administrative expenses" and "Restructuring and other charges", respectively, in our consolidated statement of operations for the year ended and December 31, 2023. Gross share compensation charges of $6.8 million and $0.1 million were recorded to "Selling, general and administrative expenses" and "Restructuring and other charges", respectively, in our consolidated statement of operations for the year ended December 31, 2022.
Share Options
The grant date fair values of the share options granted in the year ended December 31, 2024, were estimated using the Black-Scholes option valuation model, the key assumptions for which are listed in the table below. The expected volatility assumption is based on the historical volatility of a group of ten of our publicly traded peers that operate in the specialty chemical sector. The expected life represents the period of time that options granted are expected to be outstanding. The risk-free interest rate is based on U.S. Treasury securities with terms equal to the expected timing of share option exercises as of the grant date. The dividend yield assumption reflects anticipated dividends on Arcadium's ordinary shares. Arcadium share options granted in 2024 will vest equally on the first, second and third anniversaries of the grant date and expire ten years from the date of grant.
The following table contains Black Scholes valuation assumptions for share options granted for the years ended December 31, 2024, 2023 and 2022: 
202420232022
Grant date
3/6/20245/14/20246/28/20247/30/20249/1/20242/22/20232/23/2022
Expected dividend yield—%—%—%—%—%—%—%
Expected volatility31.18%31.97%33.00%33.22%35.06%30.19%28.89%
Expected life (in years)6.06.06.06.06.06.5
6.5
Risk-free interest rate4.08%4.41%4.28%4.00%3.72%4.04%1.95%
The weighted-average grant date fair value of options granted during the years ended December 31, 2024, 2023 and 2022 was $1.89 per share, $9.22 and $7.01 per share, respectively.
The following summary shows share option activity for the Allkem Livent Merger and the Arcadium Plan for the year ended December 31, 2024:
Number of Options Granted But Not ExercisedWeighted-Average Remaining Contractual Life
(in Years)		Weighted-Average Exercise Price Per ShareAggregate Intrinsic Value (in Millions)
Outstanding as of December 31, 2023
5,060,687 5.6$6.73 $6.5 
Granted4,055,748 $4.82 
Exercised(171,819)$3.58 $0.3 
Forfeited(275,656)$5.22 
Outstanding as of December 31, 2024
8,668,960 6.6$5.95 $2.9 
Exercisable as of December 31, 2024 (1)
4,069,419 4.1$6.30 $1.7 
_________________________
1.In December 2024, 706,975 share options of certain Arcadium executive officers vested on an accelerated basis.
As of December 31, 2024 and December 31, 2023, we had total remaining unrecognized compensation cost related to unvested share options of $5.7 million and $1.8 million, which will be amortized over the weighted-average remaining requisite service period of approximately 2.2 years. The aggregate intrinsic value of share options exercised for the year ended December 31, 2023 and 2022 was $1.4 million and $4.9 million, respectively.
Restricted Share Unit Awards
The grant date fair value of RSUs under the Arcadium Plan is based on the market price per share of Arcadium's ordinary shares on the date of grant, and the related compensation cost is amortized to expense on a straight-line basis over the vesting period during which the employees perform related services, which for the RSUs granted during the year ended December 31, 2024, will vest equally on the first, second and third anniversaries of the grant date.
Pursuant to the Allkem Transaction Agreement, on the Acquisition Date, 927,510 employee RSUs vested on an accelerated pro rata basis. The following table shows RSU activity for the Allkem Livent Merger and the Arcadium Plan for the year ended December 31, 2024:
Restricted Share Units
Number of
awards		Weighted-Average Grant Date Fair ValueAggregate Intrinsic Value (in Millions)
Nonvested December 31, 2023
2,287,088 $7.83 $17.1 
Granted (1)
5,217,604 $4.89 
Vested (2)
(2,634,791)$6.82 
Forfeited(290,380)$5.52 
Nonvested December 31, 2024 (3)
4,579,521 $5.21 $23.5 
___________________
1.The Company granted 1,080,825 Allkem Replacement Awards on January 12, 2024 pursuant to the Allkem Transaction Agreement.
2.Immediately prior to the Acquisition Date, 768,440 non-employee Director RSUs vested and were paid out in cash of $5.3 million pursuant to the Allkem Transaction Agreement. In December 2024, 347,361 RSUs of certain Arcadium executive officers vested on an accelerated basis.
The weighted-average grant date fair value of RSUs granted during the years ended December 31, 2023 and 2022 was $9.51 per share and $9.44 per share, respectively. The intrinsic value of RSUs vested during the years ended December 31, 2024, 2023, and 2022 was $10.4 million, $1.8 million, and $4.7 million, respectively. The total fair value of RSUs vested during the years ended December 31, 2024, 2023 and 2022 was $14.1 million, $0.8 million, and $2.5 million, respectively.
As of December 31, 2024, the Arcadium Plan had total remaining unrecognized compensation cost related to unvested RSUs of $15.4 million which will be amortized over the weighted-average remaining requisite service period of approximately 2.1 years.

Performance-Based Restricted Share Unit ("PRSU") Awards
Pursuant to the Allkem Transaction Agreement, on the Acquisition Date, 96,885 employee PRSUs vested on an accelerated basis at the higher of the PRSU payout on the accelerated vest date, which was —%, or 100%. The following table shows PRSU activity for the twelve months ended December 31, 2024.
Performance-Based Restricted Share Units
Number of
awards		Weighted-Average Grant Date Fair ValueAggregate Intrinsic Value (in Millions)
Nonvested as of December 31, 202396,885 $9.42 $0.7 
Vested(96,885)$9.42 
Nonvested as of December 31, 2024
— $— $— 
v3.25.0.1
Equity
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Equity Equity
After the closing of the Allkem Livent Merger on January 4, 2024 and as of December 31, 2024, we had 5 billion ordinary shares of $1.00 par value each and 125 million preferred shares of $1.00 par value each authorized. The following is a summary of Arcadium's ordinary shares issued and outstanding:
IssuedTreasuryOutstanding
Balance as of December 31, 2022 (1)
432,243,013 (249,202)431,993,811 
RSU awards324,577 — 324,577 
PRSU awards126,421 — 126,421 
Share option awards
365,661 — 365,661 
Net purchases of treasury shares - NQSP
— (14,467)(14.467)
Issuance of ordinary shares - conversion of 2025 Notes
274 — 274 
Balance as of December 31, 2023 (1)
433,059,946 (263,669)432,796,277 
Issued to Allkem shareholders - Allkem Livent Merger641,337,840 — 641,337,840 
PRSU and RSU awards accelerated - Allkem Livent Merger648,969 — 648,969 
Arcadium RSU awards1,345,007 — 1,345,007 
Arcadium share option awards127,260 — 127,260 
Net sales of treasury shares - NQSP
— 3,525 3,525 
Balance as of December 31, 2024
1,076,519,022 (260,144)1,076,258,878 
_____________________
1.Balances outstanding as of December 31, 2023 and 2022, representing predecessor Livent, have been adjusted to reflect the 2.406 Exchange Ratio.

Accumulated other comprehensive loss
Summarized below is the roll forward of accumulated other comprehensive loss, net of tax.
(in Millions)Foreign currency adjustments
Derivative Instruments (1)
Total
Accumulated other comprehensive loss, net of tax as of December 31, 2022
$(51.0)$— $(51.0)
Other comprehensive income before reclassifications1.2 (0.5)$0.7 
Amounts reclassified from accumulated other comprehensive loss— 0.5 0.5 
Accumulated other comprehensive loss, net of tax as of December 31, 2023
$(49.8)$— $(49.8)
Other comprehensive income before reclassifications
(40.6)(0.6)(41.2)
Amounts reclassified from accumulated other comprehensive loss— 0.6 0.6 
Accumulated other comprehensive loss, net of tax as of December 31, 2024
$(90.4)$— $(90.4)
______________
1.See Note 21 for more information.
Reclassifications of accumulated other comprehensive loss

The table below provides details about the reclassifications from accumulated other comprehensive loss and the affected line items in the consolidated statement of operations for each of the periods presented.
Details about Accumulated Other Comprehensive Loss ComponentsAmounts Reclassified from Accumulated Other Comprehensive LossAffected Line Item in the Consolidated Statements of Income
(in Millions)Year ended December 31, 2024Year ended December 31, 2023Year ended December 31, 2022
Derivative instruments
Foreign currency contracts$0.6 $0.5 $0.9 Costs of sales
Total before tax0.6 0.5 0.9 
— — (0.2)Provision for income taxes
Amount included in net income$0.6 $0.5 $0.7 
Total reclassifications for the period$0.6 $0.5 $0.7 Amount included in net income

Dividends
For the years ended December 31, 2024, 2023 and 2022, we paid no dividends. We do not expect to pay any dividends in the foreseeable future.
v3.25.0.1
Earnings Per Share
 12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
Earnings per ordinary share ("EPS") is computed by dividing net income attributable to Arcadium Lithium plc by the weighted average number of ordinary shares outstanding during the period on a basic and diluted basis.
Our potentially dilutive securities include potential ordinary shares related to our share options, restricted share units, performance-based restricted share units and 2025 Notes. Diluted earnings per share ("Diluted EPS") considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential ordinary shares would have an anti-dilutive effect. Diluted EPS excludes the impact of potential ordinary shares related to our share options in periods in which the option exercise price is greater than the average market price of our ordinary shares for the period. We use the if-converted method when calculating the potential dilutive effect of our 2025 Notes.
Earnings applicable to ordinary shares and ordinary shares used in the calculation of basic and diluted earnings per share are as follows:
(in Millions, Except Per Share Data)Year Ended December 31,
2024
2023 (1)
2022 (1)
Numerator:
Net income attributable to Arcadium Lithium plc$103.2 $330.1 $273.5 
Denominator:
Weighted average ordinary shares outstanding - basic
1,069.8 432.4 413.4 
Dilutive share equivalents from share-based plans 1.2 3.3 4.1 
Dilutive share equivalents from 2025 Notes67.7 67.7 67.7 
Weighted average ordinary shares outstanding - diluted
1,138.7 503.4 485.2 
Basic earnings per ordinary share
$0.10 $0.76 $0.66 
Diluted earnings per ordinary share
$0.09 $0.66 $0.56 
_______________________________
1.For the years ended December 31, 2023 and 2022 weighted average ordinary shares outstanding - basic and diluted, dilutive share equivalents and basic and diluted earnings per ordinary share amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio.
Anti-dilutive share options
For the year ended December 31, 2024, options to purchase 8,162,842 shares of our ordinary shares, at an average exercise price of $6.25 per share were anti-dilutive and not included in the computation of diluted earnings per share because the exercise price of the options was greater than the average market price of the ordinary shares for the period. For the year ended December 31, 2023, options to purchase 373,901 shares of our ordinary shares, at an average exercise price of $9.70 per share were anti-dilutive and not included in the computation of diluted earnings per share because the exercise price of the options was greater than the average market price of the ordinary shares for the period. For the year ended 2022, none of the outstanding options to purchase shares of our ordinary shares were anti-dilutive.
v3.25.0.1
Financial Instruments, Risk Management and Fair Value Measurements
 12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Financial Instrument, Risk Management and Fair Value Measurements Financial Instruments, Risk Management and Fair Value Measurements
Our financial instruments include cash and cash equivalents, trade receivables, other current assets, investments held in trust fund, trade payables, debt, derivatives and amounts included in accruals meeting the definition of financial instruments. Investments in the NQSP deferred compensation plan trust fund are considered Level 1 investments based on readily available quoted prices in active markets for identical assets. The carrying value of cash and cash equivalents, trade receivables, other current assets, and accounts payable approximates their fair value and are considered Level 1 investments. Our other financial instruments include the following:
Financial InstrumentValuation Method
Foreign exchange forward contractsEstimated amounts that would be received or paid to terminate the contracts at the reporting date based on current market prices for applicable currencies.
The estimated fair value of our foreign exchange forward contracts have been determined using standard pricing models which take into account the present value of expected future cash flows discounted to the balance sheet date. These standard pricing models utilize inputs derived from, or corroborated by, observable market data such as interest rate yield curves and currency and commodity spot and forward rates.
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The inputs used to measure fair value are classified into the following hierarchy:
Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2 - Unadjusted quoted prices in active markets for similar assets or liabilities, or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability.
Level 3 - Unobservable inputs for the asset or liability.
The estimated fair value and the carrying amount of debt was $1,146.2 million and $671.7 million, respectively, as of December 31, 2024. Our 2025 Notes are classified as Level 2 in the fair value hierarchy.
Use of Derivative Financial Instruments to Manage Risk
We mitigate certain financial exposures connected to currency risk through a program of risk management that includes the use of derivative financial instruments. We enter into foreign exchange forward contracts to reduce the effects of fluctuating foreign currency exchange rates.
We formally document all relationships between hedging instruments and hedged items, as well as the risk management objective and strategy for undertaking various hedge transactions. This process includes relating derivatives that are designated as fair value or cash flow hedges to specific assets and liabilities on the balance sheet or to specific firm commitments or forecasted transactions. We also assess both at the inception of the hedge and on an ongoing basis, whether each derivative is highly effective in offsetting changes in fair values or cash flows of the hedged item. If we determine that a derivative is not highly effective as a hedge, or if a derivative ceases to be a highly effective hedge, we discontinue hedge accounting with respect to that derivative prospectively.
Foreign Currency Exchange Risk Management
We conduct business in many foreign countries, exposing earnings, cash flows, and our financial position to foreign currency risks. The majority of these risks arise as a result of foreign currency transactions. The primary currencies for which we have exchange rate exposure are the Euro, the British pound, the Chinese yuan, the Argentine peso, and the Japanese yen. We
currently do not hedge foreign currency risks associated with the Argentine peso due to the limited availability and the high cost of suitable derivative instruments. Our policy is to minimize exposure to adverse changes in currency exchange rates. This is accomplished through a controlled program of risk management that could include the use of foreign currency debt and forward foreign exchange contracts. We also use forward foreign exchange contracts to hedge firm and highly anticipated foreign currency cash flows, with an objective of balancing currency risk to provide adequate protection from significant fluctuations in the currency markets.
Concentration of Credit Risk
Our counterparties to derivative contracts are primarily major financial institutions. We limit the dollar amount of contracts entered into with any one financial institution and monitor counterparties’ credit ratings. We also enter into master netting agreements with each financial institution, where possible, which helps mitigate the credit risk associated with our financial instruments. While we may be exposed to credit losses due to the nonperformance of counterparties, we consider this risk remote.

Accounting for Derivative Instruments and Hedging Activities
Cash Flow Hedges
We recognize all derivatives on the balance sheet at fair value. On the date we enter into the derivative instrument, we designate the derivative as a hedge of the variability of cash flows to be received or paid related to a forecasted transaction (cash flow hedge). We record in Accumulated Other Comprehensive Loss ("AOCL") changes in the fair value of derivatives that are designated as and meet all the required criteria for, a cash flow hedge. We then reclassify these amounts into earnings as the underlying hedged item affects earnings. In contrast we immediately record in earnings changes in the fair value of derivatives that are not designated as cash flow hedges. As of December 31, 2024, we had no open foreign currency forward contracts in AOCL designated as cash flow hedges of underlying forecasted sales and purchases.
Derivatives Not Designated As Cash Flow Hedging Instruments
We hold certain forward contracts that have not been designated as cash flow hedging instruments for accounting purposes. Contracts used to hedge the exposure to foreign currency fluctuations associated with certain monetary assets and liabilities are not designated as cash flow hedging instruments and changes in the fair value of these items are recorded in earnings.
We had open forward contracts not designated as cash flow hedging instruments for accounting purposes with various expiration dates to buy, sell or exchange foreign currencies with a U.S. dollar equivalent of approximately $145.6 million as of December 31, 2024.
Fair Value of Derivative Instruments
The Company had no open derivative cash flow hedge contracts as of December 31, 2024 and 2023.
The following tables summarize the gains or losses related to our cash flow hedges and derivatives not designated as cash flow hedging instruments.

Derivatives in Cash Flow Hedging Relationships
(in Millions)Total Foreign Exchange Contracts
Accumulated other comprehensive loss, net of tax at December 31, 2022$— 
Unrealized hedging losses, net of tax(0.5)
Reclassification of deferred hedging losses, net of tax (1)
0.5 
Total derivative instrument impact on comprehensive income, net of tax— 
Accumulated other comprehensive loss, net of tax at December 31, 2023$— 
Unrealized hedging losses, net of tax
(0.6)
Reclassification of deferred hedging losses, net of tax (1)
0.6 
Total derivative instrument impact on comprehensive loss, net of tax— 
Accumulated other comprehensive loss, net of tax at December 31, 2024$— 
____________________
1.Amounts are included in "Cost of sales" on the consolidated statement of operations.
Derivatives Not Designated as Cash Flow Hedging Instruments
Location of Loss
Recognized in Income on Derivatives
Amount of Pre-tax Loss
Recognized in Income on Derivatives (1)
Year Ended December 31,
(in Millions) 202420232022
Foreign Exchange contractsCost of sales $18.9 $(2.8)$(5.2)
Total$18.9 $(2.8)$(5.2)
____________________
1.Amounts in the columns represent the gain or loss on the derivative instrument offset by the gain or loss on the hedged item.


Fair-Value Measurements
Fair-Value Hierarchy
We have categorized our assets and liabilities that are recorded at fair value, based on the priority of the inputs to the valuation technique, into a three-level fair-value hierarchy. The fair-value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure the assets and liabilities fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair-value measurement of the instrument.

Recurring Fair Value Measurements
The following tables present our fair-value hierarchy for those assets and liabilities measured at fair-value on a recurring basis in our consolidated balance sheets as of December 31, 2024 and 2023.  
(in Millions)December 31, 2024Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets
Investments in deferred compensation plan (1)
$6.3 $6.3 $— $— 
JEMSE Receivable5.0 — — 5.0 
Equity securities (2)
0.30.3 — — 
Total Assets
$11.6 $6.6 $— $5.0 
Liabilities
Deferred compensation plan obligation (3)
$7.6 $7.6 $— $— 
Total Liabilities
$7.6 $7.6 $— $— 

(in Millions)December 31, 2023Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets
Investments in deferred compensation plan (1)
$4.1 $4.1 $— — 
Total Assets$4.1 $4.1 $— $— 
Liabilities
Deferred compensation plan obligation (3)
$6.7 $6.7 $— $— 
Total Liabilities (4)
$6.7 $6.7 $— $— 
____________________
1.Balance is included in "Other assets" in the consolidated balance sheets. Arcadium NQSP investments in Arcadium ordinary shares are recorded as Treasury shares in the consolidated balance sheets and carried at historical cost. A mark-to-market gain of $0.6 million and a
mark-to-market gain of $0.2 million related to the Arcadium ordinary shares was recorded in "Selling, general and administrative expense" in the consolidated statements of operations for the years ended December 31, 2024 and December 31, 2023, respectively, with a corresponding offset to the deferred compensation plan obligation in the consolidated balance sheets.
2.Mark-to-market gains and losses are recorded to Other gain/loss in the consolidated statement of operations.
3.Balance is included in "Other long-term liabilities" in the consolidated balance sheets.
4.The Company had no open cash flow hedge contracts as of December 31, 2023.
v3.25.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Commitments
Leases
All of our leases are operating leases as of December 31, 2024. We have operating leases for corporate offices, manufacturing facilities, and land. Our leases have remaining lease terms of less than 2 years to 26 years.
The Company assumed an ROU asset and corresponding lease liability of $53.4 million in the Allkem Livent Merger, all of which are accounted for as operating leases.
Disclosures about our leases under ASC 842 are summarized in the table below.
Year ended December 31,
(in Millions)
2024
2023 (1)
2022 (1)
Lease Cost
Operating lease cost (2)
$15.5 $1.4 $1.3 
Short-term lease cost0.5 0.4 0.4 
Total lease cost (2)
$16.0 $1.8 $1.7 
Other information
Cash paid for amounts included in the measurement of lease liabilities:
Cash paid for operating leases $14.9 $1.4 $1.3 
____________________________
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.Lease expense is classified as "Selling, general and administrative expenses" in our consolidated statements of operations.

As of December 31, 2024, our operating leases had a weighted average remaining lease term of 8.4 years and a weighted average discount rate of 8.7%.
The table below presents a maturity analysis of our operating lease liabilities for each of the next five years and a total of the amounts for the remaining years.
(in Millions)Undiscounted cash flows
2025$10.2 
20269.4 
20278.7 
20288.5 
2029
9.0 
Thereafter26.0 
       Total future minimum lease payments71.8 
Less: Imputed interest(25.0)
       Total$46.8 
Contingencies
We are a party to various legal proceedings, including those noted in this section. Arcadium records reserves for estimated losses from contingencies when information available indicates that a loss is probable and the amount of the loss, or range of loss, can be reasonably estimated. As additional information becomes available, management adjusts its assessments and estimates. Legal costs are expensed as incurred.
In addition to the legal proceedings noted below, we have certain contingent liabilities arising in the ordinary course of business. Some of these contingencies are known but are so preliminary that the merits cannot be determined, or if more advanced, are not deemed material based on current knowledge; and some are unknown - for example, claims with respect to which we have no notice or claims which may arise in the future from products sold, guarantees or warranties made, or indemnities provided. Therefore, we are unable to develop a reasonable estimate of our potential exposure of loss for these contingencies, either individually or in the aggregate, at this time. There can be no assurance that the outcome of these contingencies will be favorable, and adverse results in certain of these contingencies could have a material adverse effect on the consolidated financial position, results of operations in any one reporting period, or liquidity.
Argentine Customs & Tax Authority Matters
Minera del Altiplano SA, our subsidiary in Argentina ("MdA"), has received notices from the Argentine Customs Authorities that they are conducting customs audits in Salta (for 2015 to 2019, 2021, 2022 and 2023), Rosario (for 2016 and 2017), Buenos Aires, Ezeiza (for 2018, 2019, 2021 and 2022) and Campana (2022) regarding the export of lithium carbonate by MdA from each of those locations. See Note 23 for more information about the payment the Company made in June 2023 for export duties and interest claimed by the Customs Authorities of Buenos Aires, Ezeiza and Salta related to exports made between the years 2018 – 2022.
Sales de Jujuy S.A., our subsidiary in Argentina ("SDJ") has received a notice from the Argentine Customs Authority regarding custom duties for the export of lithium carbonate by SDJ from January 2022 through August 2023.
SDJ also received notification from Jujuy provincial tax authority regarding a royalty adjustment in favor of the Province for the periods 2021 and 2022.
A range of reasonably possible liabilities, if any, cannot be currently estimated by the Company.
MdA was also notified from the Argentine Tax Authority of the start of an ex officio determination process regarding transfer pricing for the period 2017 and of a transfer pricing audit for the period 2018. SDJ was also notified by the Argentine Tax Authority of the start of an ex officio determination process regarding transfer pricing for the period of 2018.
In January, 2023, the Argentina Ministry of Economy issued a resolution to cancel an export rebate regime relating to lithium products, which was followed by Presidential Decree No. 57/2023 in February, 2023. The Presidential Decree prospectively cancels all export rebates for lithium products. Prior to the Presidential Decree, MdA and SDJ had the right to collect 4% of the FOB value for exported products (which consisted of the "La Puna" rebate which was 2.5% and the "Export" rebate which was 1.5%). In October 2023 by Presidential Decree No. 557/2023 the Export rebate of 1.5% was reinstated. Subsequent to the Presidential Decree entering into force on October 26, 2023 MdA and SDJ are entitled to the 1.5% rebate/refund on FOB value
of its exported products. As of December 31, 2024, MdA and SDJ have a receivable of approximately $5.4 million USD and $1.7 million USD, respectively, which is still valid and remains in force after the Presidential Decrees.
A range of possible liabilities, if any, cannot be currently estimated by the Company.
Australia Tax Matters
We were informed on April 16, 2024 that the Australian Taxation Office will be performing a combined assurance review of Allkem Pty Ltd and its Australian subsidiaries for the period of July 1, 2019 to June 30, 2023.
Canada Tax Matters
We were notified that Nemaska Lithium has received certain audit queries from the Canada Revenue Agency ("CRA") related to the Approval and Vesting Order (the "RVO") issued under the Companies' Creditors Arrangement Act ("CCAA") on October 15, 2020, by the Superior Court of Québec. Nemaska Lithium has been responding to those queries.
Securities Class Action Lawsuits
On September 6, 2024, two separate securities class action lawsuits were filed against the Company in the Court of Common Pleas of Philadelphia County, Pennsylvania (City of Pontiac Reestablished General Employees’ Retirement System, on behalf of itself and all others similarly situated vs. Arcadium Lithium plc et. al., and Satish Chalasani and Kelly Johnson, individually and on behalf of all others similarly situated vs. Arcadium Lithium plc et. al.). Each lawsuit is alleging securities law claims arising from the Allkem Livent Merger and is seeking unspecified monetary damages. A range of possible liabilities, if any, cannot be currently estimated by the Company.
Galaxy (formerly "James Bay") Royalty Claim
On January 16, 2025, Galaxy Lithium (Canada) Inc., Galaxy Lithium (Ontario) Inc. and Arcadium Lithium plc were notified that the former holder of a royalty (net smelter return) has filed a lawsuit in the Québec Superior Court against the Company relating to the repurchase of his royalty relating to the Galaxy Lithium Project. The individual is seeking monetary damages of approximately $30 million CAD. A range of possible liabilities, if any, cannot be currently estimated by the Company.
v3.25.0.1
Supplemental Information
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental Information Supplemental Information
The following tables present details of prepaid and other current assets, other assets, accrued and other liabilities and other long-term liabilities as presented on the consolidated balance sheets:
(in Millions) December 31,
20242023
Prepaid and other current assets
Income tax receivable - refunds and prepayments$82.2 $29.5 
Argentina government receivable (1)
40.6 7.9 
Prepaid expenses42.8 16.9 
Other receivables47.8 28.2 
Bank Acceptance Drafts (2)
1.1 — 
Other current assets4.2 3.9 
Total$218.7 $86.4 
(in Millions) December 31,
20242023
Other assets
Argentina government receivable (1)(3)
$131.8 $71.3 
Advance to contract manufacturers (4)
27.9 27.6 
Long-term semi-finished goods inventory105.0 1.0 
Tax related items4.3 4.0 
Capitalized software, net2.3 1.1 
Investment in transit - Nemaska Lithium (5)
96.7 — 
Deposits
23.4 — 
Other long-term assets20.9 22.7 
Total$412.3 $127.7 
____________________
1.We have various subsidiaries that conduct business within Argentina. At December 31, 2024 and 2023, $42.0 million and $38.8 million of outstanding receivables due from the Argentina government, which primarily represent export tax and export rebate receivables, were denominated in U.S. dollars. A judicial decision relating to the U.S. dollar-denominated export tax receivable portion $34.8 million permits the Argentina government to reimburse us in Argentine pesos at the historical foreign exchange rate applicable at each past payment date, adjusted by a bank deposit interest rate. While the Company filed an appeal on November 6, 2023 and believes it has valid defenses on the technical merits, the ultimate resolution of this matter could result in a possible loss of up to $34.4 million. We continually review the recoverability of all outstanding receivables by analyzing historical experience, current collection trends and regional business and political factors among other factors.
2.Bank Acceptance Drafts are a common Chinese finance note used to settle trade transactions. The Company accepts these notes from Chinese customers based on criteria intended to ensure collectability and limit working capital usage.
3.In June 2023, the Company decided to pay $21.7 million for the export duties and interest claimed by the Customs Authorities of Buenos Aires, Ezeiza and Salta related to exports made between the years 2018 – 2022 registered in those locations. This payment stops the accrual of any further interest. It was a deposit made under protest, and was not an admission of any of the claims made by the Customs Authorities or a waiver of any of the Company's defenses, including recovery of the deposit plus interest. The cases remain in discussion. See Note 22 for more information.
4.We record deferred charges related to certain contract manufacturing agreements which we amortize over the term of the underlying contract.
5.Represents the Company's cash contributed to Nemaska Lithium in the fourth quarter of 2024 which, due to one-quarter lag reporting, are not yet recorded in our consolidation of Nemaska. The balance is recorded to Other assets - noncurrent because the cash is expected to be used by Nemaska primarily for capital expenditures. IQ contemporaneously made an equal contribution in the fourth quarter of 2024 which, due to one-quarter lag reporting, is not recorded in our consolidation of Nemaska. See Note 9 for details.
(in Millions) December 31,
20242023
Accrued and other current liabilities
Accrued payroll$46.2 $20.3 
Restructuring reserves1.4 1.7 
Retirement liability - 401k3.5 3.2 
Environmental reserves, current0.9 0.5 
Accrued investment in unconsolidated affiliates— 27.0 
Accrued capital expenditures137.8 84.1 
Total$189.8 $136.8 

(in Millions) December 31,
20242023
Other long-term liabilities
Deferred compensation plan obligation$7.6 $6.7 
Contingencies related to uncertain tax positions (1)
22.2 6.2 
Self insurance reserves1.1 1.1 
Asset retirement obligations14.2 3.7 
Affiliate Loans with TTC - accrued interest
53.4 — 
Other long-term liabilities13.2 3.6 
Total$111.7 $21.3 
____________________
1.As of December 31, 2024, we have recorded a liability for uncertain tax positions of $21.8 million and a $0.4 million indemnification liability to FMC for assets where the offsetting uncertain tax position is with FMC.
v3.25.0.1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Pay vs Performance Disclosure      
Net income $ 103.2 $ 330.1 [1],[2] $ 273.5 [1],[2]
[1] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
[2] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.0.1
Insider Trading Policies and Procedures
 12 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
v3.25.0.1
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Cybersecurity Risk Management and Strategy
Arcadium Lithium is committed to protecting its information systems and data from unauthorized access, use, disruption, and destruction. Our cybersecurity risk management strategy is designed to detect, assess, and manage cybersecurity risks in an organized and effective manner with active involvement from the board of directors and management. We also endeavor to actively maintain and monitor our cybersecurity program to stay ahead of the emerging cybersecurity threat landscape.
Our cybersecurity program includes the following key elements:
•Enterprise Risk Management ("ERM") process to identify and prioritize cybersecurity risks.
•Strong cybersecurity program that conforms to the National Institute of Standards and Technology framework, including a zero-trust model, monitoring, and threat intelligence.
•Cybersecurity awareness training program to educate employees about risks and how to detect malicious attack attempts.
•Cybersecurity Incident Response plan that is tightly integrated with the Global Crisis Management Plan to effectively respond and recover from material incidents.
•Risk-based security architecture designed to protect our most critical assets from the most common threats.
•Maintenance of a cybersecurity insurance policy.
Our ERM program is maintained and overseen by a cross-functional team of business leaders from across the organization. The program incorporates regular sessions to review the Company's overall risk posture, identify new risks and develop mitigation strategies. ERM matters are reviewed with the Risk Council Review Committee and are ultimately overseen by the Audit Committee of the Board of Directors, which regularly meets with and receives guidance and support from the Board of Directors.
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block]
Our cybersecurity program includes the following key elements:
•Enterprise Risk Management ("ERM") process to identify and prioritize cybersecurity risks.
•Strong cybersecurity program that conforms to the National Institute of Standards and Technology framework, including a zero-trust model, monitoring, and threat intelligence.
•Cybersecurity awareness training program to educate employees about risks and how to detect malicious attack attempts.
•Cybersecurity Incident Response plan that is tightly integrated with the Global Crisis Management Plan to effectively respond and recover from material incidents.
•Risk-based security architecture designed to protect our most critical assets from the most common threats.
•Maintenance of a cybersecurity insurance policy.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Board of Directors Oversight [Text Block]
Board of Directors Oversight of Cybersecurity Risks
The Board of Directors is responsible for overseeing Arcadium Lithium's Enterprise Risk Management, which includes cybersecurity reporting.
The process includes:
•Receipt of regular updates from the Audit Committee of the Board of Directors on the latest cybersecurity risk posture and overall effectiveness of the Company's cybersecurity program.
•Independent reviews of the Company's cybersecurity program through the SOX audit process.
•Regular discussions about cybersecurity risks at meetings of the board of directors.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
The Board of Directors is responsible for overseeing Arcadium Lithium's Enterprise Risk Management, which includes cybersecurity reporting.
The process includes:
•Receipt of regular updates from the Audit Committee of the Board of Directors on the latest cybersecurity risk posture and overall effectiveness of the Company's cybersecurity program.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Receipt of regular updates from the Audit Committee of the Board of Directors on the latest cybersecurity risk posture and overall effectiveness of the Company's cybersecurity program.
•Independent reviews of the Company's cybersecurity program through the SOX audit process.
•Regular discussions about cybersecurity risks at meetings of the board of directors.
Cybersecurity Risk Role of Management [Text Block]
Management's Role in Assessing and Managing Material Risks from Cybersecurity Threats
Our management team has a comprehensive understanding of the Company's cybersecurity posture and associated risks. The team possesses significant expertise and experience to develop, implement and maintain appropriate cybersecurity controls to reduce risk and seek to keep the Company safe from malicious attacks.
Furthermore:
•Management regularly assesses company risk posture using internal reporting and monitoring tools.
•Management develops and implements mitigation strategies that are based on industry best practice.
•Management monitors and maintains the effectiveness of the cybersecurity program through penetration testing and regular assessments.

The management team also works with external advisors, partners, and auditors for expert guidance on all cybersecurity-related matters.
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
Our management team has a comprehensive understanding of the Company's cybersecurity posture and associated risks. The team possesses significant expertise and experience to develop, implement and maintain appropriate cybersecurity controls to reduce risk and seek to keep the Company safe from malicious attacks.
Furthermore:
•Management regularly assesses company risk posture using internal reporting and monitoring tools.
•Management develops and implements mitigation strategies that are based on industry best practice.
•Management monitors and maintains the effectiveness of the cybersecurity program through penetration testing and regular assessments.

The management team also works with external advisors, partners, and auditors for expert guidance on all cybersecurity-related matters.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]
Our management team has a comprehensive understanding of the Company's cybersecurity posture and associated risks. The team possesses significant expertise and experience to develop, implement and maintain appropriate cybersecurity controls to reduce risk and seek to keep the Company safe from malicious attacks.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Management regularly assesses company risk posture using internal reporting and monitoring tools.
•Management develops and implements mitigation strategies that are based on industry best practice.
•Management monitors and maintains the effectiveness of the cybersecurity program through penetration testing and regular assessments.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
v3.25.0.1
Principal Accounting Policies and Related Financial Information (Policies)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Basis of presentation and principles of consolidation
Basis of presentation and principles of consolidation. In this Annual Report on Form 10-K the results of the Company as of December 31, 2024 and for the year ended December 31, 2024 include the operations and financial positions of Allkem. Because Arcadium Lithium plc is the successor company to Livent in the Allkem Livent Merger, which closed on January 4, 2024, we are presenting the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022, which do not include the financial positions or operations of Allkem. Refer to Note 4 for further information related to the Allkem Livent Merger.
The accompanying consolidated financial statements are presented on a consolidated basis and include all of the accounts and operations of Livent and its majority-owned subsidiaries. For entities that we control, but own less than 100%, we record the minority ownership as noncontrolling interest. The financial statements reflect the financial position, results of operations and cash flows of Arcadium Lithium in accordance with U.S. GAAP. All significant intercompany accounts and transactions are eliminated in consolidation.
Earnings per share
Earnings per share. The weighted average ordinary shares outstanding for both basic and diluted earnings per share for all periods presented was calculated in accordance with ASC 260, Earnings Per Share.
Estimates and assumptions
Estimates and assumptions. In preparing the financial statements in conformity with U.S. GAAP we are required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these estimates under different assumptions or conditions, but we do not believe such differences will materially affect our financial position, results of operations or cash flows.
Cash equivalents
Cash equivalents. We consider investments in all liquid debt instruments with original maturities of three months or less to be cash equivalents.
Restricted cash. As of December 31, 2024, Arcadium had restricted cash of $18.1 million on deposit with Mizuho as collateral for the Project Loan Facility and $5.3 million on deposit as cash backing for a letter of credit. The restricted cash is classified within Other non-current assets in the Company's consolidated balance sheets.
Trade receivables, net of allowance and other receivables
Trade receivables, net of allowance, and other receivables. Trade receivables consist of amounts owed to us from customer sales and are recorded when revenue is recognized. The allowance for trade receivables represents our best estimate of the probable losses associated with potential customer defaults. In developing our allowance for trade receivables, we use a two stage process which includes calculating a formula to develop an allowance to appropriately address the uncertainty surrounding collection risk of our entire portfolio and specific allowances for customers where the risk of collection has been reasonably identified either due to liquidity constraints or disputes over contractual terms and conditions.
Our method of calculating the formula consists of estimating the recoverability of trade receivables based on historical experience, current collection trends, and external business factors such as economic factors, including regional bankruptcy rates, and political factors. Our analysis of trade receivable collection risk is performed quarterly, and the allowance is adjusted accordingly.
Inventories
Inventories. Inventories are stated at the lower of cost or net realizable value. Inventory costs include those costs directly attributable to products before sale, including all manufacturing overhead but excluding distribution costs. All inventories are determined on a first-in, first-out ("FIFO") basis.
Property, plant and equipment Property, plant and equipment. We record property, plant and equipment, including capitalized interest, at cost. We recognize acquired property, plant and equipment, from acquisitions at its estimated fair value. Depreciation is calculated principally on a straight-line basis over the estimated useful lives of the assets.Gains and losses are reflected in income upon sale or retirement of assets. Expenditures that extend the useful lives of property, plant and equipment or increase productivity are capitalized. Ordinary repairs and maintenance are expensed as incurred through operating expense.
Capitalized interest
Capitalized interest. For the years ended December 31, 2024, 2023 and 2022 we capitalized interest expense of $24.9 million, $16.8 million and $15.8 million, respectively. These costs were associated with the construction of certain long-lived assets and have been capitalized as part of the cost of those assets. We amortize capitalized interest over the estimated useful lives of the assets.
Impairments of long-lived assets
Impairments of long-lived assets. We review the recoverability of the net book value of long-lived assets whenever events and circumstances indicate ("triggering events") that the net book value of an asset may not be recoverable from the estimated undiscounted future cash flows expected to result from its use and eventual disposition. In cases where a triggering event occurs and undiscounted expected future cash flows are less than the net book value, we recognize an impairment loss equal to the amount by which the net book value exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. We recorded a non-cash impairment charge of $51.7 million for the year ended December 31, 2024, related to our Mt Cattlin spodumene operation in Western Australia. See Note 11 for details.
Deferred compensation plan Deferred compensation plan. We have established a trust fund administered by a third party to provide funding for benefits payable under the Arcadium Non-qualified Saving Plan ("NQSP") to which highly compensated Arcadium employees can elect to defer part of their compensation. The assets held in the trust consist of money market investments, a managed portfolio of equity securities and Arcadium ordinary shares. For each reporting period, the Company records a net mark-to-market adjustment to Selling, general and administrative expense in our consolidated statements of operations for the investments in the trust fund and the corresponding obligation to participants in the NQSP. The money market investments and equity securities assets are included in Other assets in the accompanying consolidated balance sheets. The investments in Arcadium ordinary shares under the NQSP are included in Treasury shares on our consolidated balance sheets. The deferred compensation obligation to participants is included in Other long-term liabilities on our consolidated balance sheets.
4.125% Convertible Senior Notes due 2025 (the "2025 Notes")
4.125% Convertible Senior Notes due 2025 (the "2025 Notes"). We account for our 2025 Notes under Accounting Standards Update ("ASU") No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06").
Financial instruments
Financial instruments. Our financial instruments include cash and cash equivalents, trade receivables, other current assets, investments held in trust fund, trade payables, debt, derivatives and amounts included in accruals meeting the definition of financial instruments. Trade receivables and trade payables are recorded at carrying value, which approximates fair value due to the short-term nature of the instruments. Investments held in trust are for the NQSP as discussed in "Deferred compensation plan" subsection above. The Company enters into derivative contracts to hedge exposures and the associated assets or liabilities are recorded in our consolidated balance sheets and the gains or losses associated with these transactions are included in the consolidated statements of operations.
Equity method investments
Equity method investments. We stop applying the equity method when we have reduced the value of our equity method investment, commitments and additional investments (i.e., loans or advances) in the investee to zero. If the investee subsequently reports net income, we resume applying the equity method when our share of that net income is equal to the suspended losses (i.e., our share of the investee's net losses not previously recognized).
If facts and circumstances indicate that a decrease in value of the investment has occurred that is other than temporary, we recognize an impairment loss equal to an amount by which the carrying amount exceeds the fair value of the equity method investment.
Leases
Leases. The Company determines if an arrangement is a lease at the inception of the contract. Our operating leases are included in Operating lease right-of-use ("ROU") assets, Operating lease liabilities - current, and Operating lease liabilities - long term in the consolidated balance sheets. The operating lease ROU assets and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit interest rate, we utilize an estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. In determining the discount rate used in the present value calculation, the Company has elected to apply the portfolio approach for leases provided the leases commenced at or around the same time. This election allows the Company to account for leases at a portfolio level provided that the resulting accounting at this level would not differ materially from the accounting at the individual lease level. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
The Company has elected not to separate lease and non-lease components and accounts for each separate lease component and non-lease component associated with that lease component as a single lease component. Operating lease ROU assets include all contractual lease payments and initial direct costs incurred less any lease incentives. Facility leases generally only contain lease expense and non-component items such as taxes and pass-through charges. Additionally, we have elected not to apply the recognition requirements of ASC 842 to leases which have a lease term of less than one year at the commencement date.
Most of the Company's leases for corporate facilities contain terms for renewal and extension of the lease agreement. The exercise of lease renewal options is generally at the Company’s sole discretion. The Company includes the lease extensions when it is reasonably certain we will exercise the extension. The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or any material restrictive covenants. We currently do not have any finance leases.
Restructuring and other charges
Restructuring and other charges. We continually perform strategic reviews and assess the return on our businesses. This sometimes results in a plan to restructure the operations of our business. We record an accrual for severance and other exit costs under the provisions of the relevant accounting guidance.
Additionally, as part of these restructuring plans, write-downs of long-lived assets may occur. Two types of assets are impacted: assets to be disposed of by sale and assets to be abandoned. Assets to be disposed of by sale are measured at the lower of carrying amount or estimated net proceeds from the sale. Assets to be abandoned with no remaining future service potential are written down to amounts expected to be recovered. The useful life of assets to be abandoned that have a remaining future service potential are adjusted and depreciation is recorded over the adjusted useful life.
Restructuring and other charges also includes transaction costs related to the Allkem Livent Merger and the Rio Tinto Transaction.
Finite-lived intangible assets and Goodwill
Finite-lived intangible assets. Finite-lived intangible assets consist of patents, which are amortized over a period of approximately 15 years.
We evaluate the recovery of our finite-lived intangible assets by comparing the net carrying value of the asset group to the undiscounted net cash flows expected to be generated from the use and eventual disposition of that asset group when events or changes in circumstances indicate that its carrying amount may not be recoverable. If the carrying amount of the asset group is not recoverable, the fair value of the asset group is measured and if the carrying amount exceeds the fair value, an impairment loss is recognized.
Goodwill. We account for goodwill and other intangibles acquired in a business combination in conformity with current accounting guidance, which requires goodwill and indefinite-lived intangible assets to not be amortized.
The Company performs its annual goodwill impairment test in the fourth quarter of each year as of October 31 or upon the occurrence of events or changes in circumstances that would more likely than not reduce the fair value of its reporting units below their carrying amounts.
We test goodwill for impairment by comparing the estimated fair value of our reporting units to the related carrying value. Our reporting units are either our operating business segment or one level below our operating business segment for which discrete financial information is available and for which operating results are regularly reviewed by the business management. In applying the goodwill impairment test, the Company initially performs a qualitative test ("Step 0"), where it first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting units is less than its carrying
value. Qualitative factors may include, but are not limited to, economic conditions, industry and market considerations, cost factors, overall financial performance of the reporting units and other entity and reporting unit specific events. If after assessing these qualitative factors, the Company determines it is "more-likely-than-not" that the fair value of the reporting unit is less than the carrying value, the Company performs a quantitative test ("Step 1"). During Step 1, the Company estimates the fair value using a discounted cash flow model.
Impairment evaluations of goodwill could result in a reduction in our recorded asset values which could have a material adverse effect on our financial position and results of operations. We perform reviews of goodwill on an annual basis, or more frequently if triggering events indicate a possible impairment. We test goodwill at the reporting unit level by comparing the carrying value of the net assets of the reporting unit, including goodwill, to the reporting unit's fair value. If the carrying values of goodwill exceed their fair value, the goodwill would be considered impaired. If any impairment or related charge is warranted, our financial position and results of operations could be materially affected. Any such impairment or related charge could be a result of, for example, sustained declines in the Company’s share price; the deterioration of the cost of equity or debt capital increases due to valuations for comparable companies or comparable acquisitions valuations; or the deterioration of the outlook for future cash flows for the reporting unit due to but not limited to, increased competition, changes to discount rate, downward forecast revisions, restricted plans or changes in applicable regulations affecting our business.
The Company performed a qualitative Step 0 test for its goodwill balance in the fourth quarters of 2024 and 2023 and concluded that no impairment existed as of December 31, 2024 and 2023 because it was not more likely than not that the fair value of the reporting unit was less than its carrying value.
Revenue recognition
Revenue recognition. Revenue from product sales is recognized when we satisfy a performance obligation by transferring the promised goods to a customer, that is, when control of the good transfers to the customer. The customer is then invoiced at the agreed-upon price with payment terms generally ranging from 30 to 180 days. See Note 7 for further details regarding revenue recognition.
In determining when the control of goods is transferred, we typically assess, among other things, the transfer of title and risk of loss and the shipping terms of the contract.
We record amounts billed for shipping and handling fees as revenue. Costs incurred for shipping and handling are recorded in Cost of sales. When we perform shipping and handling activities after the transfer of control to the customer (e.g., when control transfers prior to delivery), they are considered fulfillment activities, and accordingly, the costs are accrued to Cost of sales when the related revenue is recognized.
Amounts billed for sales and use taxes, VAT, and certain excise and other specific transactional taxes imposed on revenue-producing transactions are presented on a net basis and excluded from revenue in the consolidated statements of operations. We record a liability until remitted to the respective taxing authority.
We satisfy our obligations by transferring goods and services in exchange for consideration from customers. The timing of performance sometimes differs from the timing of when the associated consideration is received from the customer, thus resulting in the recognition of a contract asset or liability. These may arise from provisional pricing within certain of our customer contracts, or if the customer’s payment of consideration is received prior to completion of our related performance obligation. Provisional pricing results in variable consideration which we estimate by using an expected value method taking into account all information that is reasonably available including publicly available pricing forecasts. We only include variable consideration within the transaction price to the extent that it is probable that a significant reversal in the amount of revenue recognized will not occur.
Our lithium products are developed and sold to global and regional customers in the EV, electronics, agrochemicals, pharmaceuticals, polymer and specialty alloy metals market among others. Lithium hydroxide and lithium carbonate products are used in advanced batteries for all-electric vehicles as well as other products that require portable energy storage such as power tools and military devices. Lithium hydroxide is also sold into grease applications for use in automobiles, aircraft, railcars, agricultural and other types of equipment. Butyllithium products are primarily used as polymer initiators, and in the synthesis of agrochemicals and pharmaceuticals. High purity lithium metal and other specialty compounds include lithium phosphate, pharmaceutical-grade lithium carbonate and specialty organics. We sell whatever lithium carbonate we do not use internally as feedstock for lithium hydroxide production to our customers for various applications.
Sale of Goods
Revenue from product sales is recognized when we satisfy a performance obligation by transferring the promised goods to a customer, that is, when control of the good transfers to the customer. The customer is then invoiced at the agreed-upon price with payment terms generally ranging from 30 to 180 days.
In determining when the control of goods is transferred, we typically assess, among other things, the transfer of title and risk of loss and the shipping terms of the contract.
We record amounts billed for shipping and handling fees as revenue. Costs incurred for shipping and handling are recorded in cost of sales. When we perform shipping and handling activities after the transfer of control to the customer (e.g., when control transfers prior to delivery), they are considered fulfillment activities, and accordingly, the costs are accrued to cost of sales when the related revenue is recognized.
Amounts billed for sales and use taxes, VAT, and certain excise and other specific transactional taxes imposed on revenue-producing transactions are presented on a net basis and excluded from revenue in the consolidated statements of operations. We record a liability until remitted to the respective taxing authority.
Right of Return
We warrant to our customers that our products conform to mutually agreed product specifications. We accrue for expected returns as they occur.
Contract asset and contract liability balances
We satisfy our obligations by transferring goods and services in exchange for consideration from customers. The timing of performance sometimes differs from the timing the associated consideration is received from the customer, thus resulting in the recognition of a contract liability. We recognize a contract liability if the customer’s payment of consideration is received prior to completion of our related performance obligation.
On July 25, 2022 we entered into a long-term supply agreement with a customer to deliver battery-grade lithium hydroxide over six years between 2025 and 2030. The contract included an advance payment from the customer of $198 million, which we received in the third quarter of 2022. Revenue will be recognized as volumes are delivered. Any unrecognized deferred revenue is refundable if the agreement is terminated for any reason specified in the agreement.
Research and Development
Research and Development. Research and development costs are expensed as incurred.
Income and other taxes
Income and other taxes. We provide current income taxes on income reported for financial statement purposes adjusted for transactions that do not enter into the computation of income taxes payable and recognize deferred tax liabilities and assets for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. Prior to the Separation, pursuant to the tax matters agreement with FMC, in jurisdictions where we file consolidated returns with FMC, we have recorded our allocated share of the consolidated liability as part of the income tax payable in our consolidated balance sheets. In taxing jurisdictions where we file as a standalone entity we have recorded the tax liability/benefit to income tax payable/receivable. We do not provide income taxes on the equity in undistributed earnings of consolidated foreign subsidiaries as it is our intention that such earnings will remain invested in those companies.
Segment information Segment information. In January 2024, Arcadium Lithium completed the Allkem Livent Merger. See Note 4, Allkem Livent Merger for further details. Following the closing of the Allkem Livent Merger, we currently operate as one reportable segment based on the commonalities among our products and services.
Share-based compensation Share-based compensation. Share-based compensation expense for the three years ended December 31, 2024 has been recognized for all share options and other equity-based arrangements. Share-based compensation cost is measured at the date of grant, based on the fair value of the award, and is recognized over the employee’s requisite service period. We made a policy election to recognize forfeitures in share-based compensation expense as they occur.
Environmental obligations
Environmental obligations. We provide for environmental-related obligations when they are probable and amounts can be reasonably estimated.
Included in our Environmental liabilities are costs for the operation, maintenance and monitoring of site remediation plans ("OM&M"). Such reserves are based on our best estimates for these OM&M plans. Over time we may incur OM&M costs in excess of these reserves which could be significant.
Environmental remediation charges represent the costs for the continuing charges associated with environmental remediation at operating sites from previous years and from products that are no longer manufactured.
Foreign currency Foreign currency. We translate the assets and liabilities of our foreign operations at exchange rates in effect at the balance sheet date. For foreign operations for which the functional currency is not the U.S. dollar, we record translation gains and losses as a component of accumulated other comprehensive loss in equity. The foreign operations’ statements of operations are translated at the monthly exchange rates for the period. Transactions denominated in foreign currency other than our functional currency of the operation are recorded upon initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are remeasured at each reporting date into the functional currency at the exchange rate at that date. Exchange rate differences are recognized as foreign currency transaction gain or loss recorded as a component of Cost of sales in our consolidated statements of operations.
Mine development costs and Mineral interests
Mine development costs. Mine development costs include expenditures incurred during the search for mineral resources as well as the determination of the technical feasibility and commercial viability of extracting the mineral resource, and stripping costs of removing overburden and waste materials to access the mineral body at an open pit mine.
The Company capitalizes exploration and evaluation ("E&E") expenditures to Property, Plant and Equipment ("PP&E") under a successful efforts basis when proven and probable reserves are established for the sites where E&E activities are being performed. E&E assets recognized as part of business combinations are also capitalized. All other E&E expenditures are expensed.
Stripping costs incurred prior to the production phase are capitalized to PP&E during the development of an open pit mine. When multiple open pits exist at a mining complex utilizing common processing facilities, such pre-production stripping costs are capitalized at each pit. The removal, production, and sale of de minimis saleable materials may occur during the development phase of an open pit mine and are assigned incremental mining costs related to the removal of that material. The production phase of an open pit mine commences when saleable minerals, beyond a de minimis amount, are produced. Stripping costs incurred during the production phase of a mine are variable production costs that are included as a component of inventory to be recognized in Cost of sales in the same period as the revenue from sale of that inventory.
Capitalized mine development costs are amortized using the units-of-production method based on estimated recoverable minerals in proven and probable reserves, and are amortized over the estimated life of the mineral body.
Mineral interests. Mineral interests include acquired interests in production, development and exploration stage properties. Mineral interests are capitalized at their fair value at the acquisition date, either as an individual asset purchase or as part of a business combination. Mineral interests in the development and exploration stage are not amortized until the underlying property is converted to the production stage, at which point the mineral interests are amortized over the estimated recoverable proven and probable reserves using a units-of-production method.
Asset retirement obligations
Asset retirement obligations. The Company accounts for asset retirement obligations ("AROs") in accordance with ASC 410-20, Asset Retirement Obligations. We record AROs at present value at the time the liability is incurred if we can reasonably estimate the settlement date. The associated AROs are capitalized as part of the carrying amount of related long-lived assets. In future periods, the liability is accreted to its present value and the capitalized cost is depreciated over the useful
life of the related asset. We also adjust the liability for changes resulting from the passage of time and/or revisions to the timing or the amount of the original estimate. Upon retirement of the long-lived asset, we settle the obligation for its recorded amount.
Reclassifications
Reclassifications. Certain prior period balances have been reclassified to conform to the current period presentation in the consolidated financial statements and the accompanying notes.
Effective April 1, 2024, we began presenting gains and losses from foreign currency remeasurements as a component of Other (gains)/losses. Prior to April 1, 2024, we included gains and losses resulting from foreign currency remeasurements as a component of Cost of sales and Restructuring and other charges in the consolidated statement of operations.
New accounting guidance and regulatory items
New accounting guidance and regulatory items
In December 2023, the Financial Accounting Standard Board ("FASB") issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU enhances existing income tax disclosures to better assess how an entity's operation and related tax risks, tax planning, and operational opportunities affect its tax rate and prospects for future cash flows. The ASU is effective for annual periods beginning after December 15, 2024. We are currently evaluating the effect the guidance will have on our consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280). This ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures related to significant segment expenses. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The ASU was adopted by the Company as of December 31, 2024, refer to Note 6, Segment Reporting, for additional disclosures required by the ASU.
Derivatives
Use of Derivative Financial Instruments to Manage Risk
We mitigate certain financial exposures connected to currency risk through a program of risk management that includes the use of derivative financial instruments. We enter into foreign exchange forward contracts to reduce the effects of fluctuating foreign currency exchange rates.
We formally document all relationships between hedging instruments and hedged items, as well as the risk management objective and strategy for undertaking various hedge transactions. This process includes relating derivatives that are designated as fair value or cash flow hedges to specific assets and liabilities on the balance sheet or to specific firm commitments or forecasted transactions. We also assess both at the inception of the hedge and on an ongoing basis, whether each derivative is highly effective in offsetting changes in fair values or cash flows of the hedged item. If we determine that a derivative is not highly effective as a hedge, or if a derivative ceases to be a highly effective hedge, we discontinue hedge accounting with respect to that derivative prospectively.
Foreign Currency Exchange Risk Management
We conduct business in many foreign countries, exposing earnings, cash flows, and our financial position to foreign currency risks. The majority of these risks arise as a result of foreign currency transactions. The primary currencies for which we have exchange rate exposure are the Euro, the British pound, the Chinese yuan, the Argentine peso, and the Japanese yen. We
currently do not hedge foreign currency risks associated with the Argentine peso due to the limited availability and the high cost of suitable derivative instruments. Our policy is to minimize exposure to adverse changes in currency exchange rates. This is accomplished through a controlled program of risk management that could include the use of foreign currency debt and forward foreign exchange contracts. We also use forward foreign exchange contracts to hedge firm and highly anticipated foreign currency cash flows, with an objective of balancing currency risk to provide adequate protection from significant fluctuations in the currency markets.
Concentration of Credit Risk
Our counterparties to derivative contracts are primarily major financial institutions. We limit the dollar amount of contracts entered into with any one financial institution and monitor counterparties’ credit ratings. We also enter into master netting agreements with each financial institution, where possible, which helps mitigate the credit risk associated with our financial instruments. While we may be exposed to credit losses due to the nonperformance of counterparties, we consider this risk remote.

Accounting for Derivative Instruments and Hedging Activities
Cash Flow Hedges
We recognize all derivatives on the balance sheet at fair value. On the date we enter into the derivative instrument, we designate the derivative as a hedge of the variability of cash flows to be received or paid related to a forecasted transaction (cash flow hedge). We record in Accumulated Other Comprehensive Loss ("AOCL") changes in the fair value of derivatives that are designated as and meet all the required criteria for, a cash flow hedge. We then reclassify these amounts into earnings as the underlying hedged item affects earnings. In contrast we immediately record in earnings changes in the fair value of derivatives that are not designated as cash flow hedges.
v3.25.0.1
Principal Accounting Policies and Related Financial Information (Tables)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Schedule of Restrictions on Cash and Cash Equivalents
The following tables provide a reconciliation of Cash and cash equivalents and restricted cash reported within Arcadium's consolidated balance sheets:
Year ended December 31,
(in Millions)2024
2023 (1)
Cash and cash equivalents$93.2 $237.6 
Restricted cash - Other non-current assets
23.4 — 
Total Cash and cash equivalents and restricted cash
$116.6 $237.6 
_________________________
1.Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
Schedule of Property, Plant and Equipment The major classifications of property, equipment and software, including their respective expected useful lives, consisted of the following:
Asset type Useful Life
Land —
Land improvements 20 years
Buildings
20-40 years
Mining rights33 years
Machinery and Equipment
3-18 years
Software
3-10 years
Property, plant and equipment consisted of the following:
 December 31,
(in Millions)20242023
Land and land improvements$337.0 $106.2 
Buildings1,006.8 134.9 
Machinery and equipment1,011.8 420.7 
Mineral rights
3,184.9 560.0 
Construction in progress2,181.9 1,284.4 
Total cost7,722.4 2,506.2 
Accumulated depreciation(351.2)(269.1)
Property, plant and equipment, net$7,371.2 $2,237.1 
The major classifications of property, equipment and software, including their respective principal depreciation and amortization method and expected useful lives, consisted of the following:
Asset type Depreciation and amortization methodUseful Life
Land N/A—
Land improvements Straight-line20 years
Buildings Straight-line
20-40 years
Mineral rightsUnits-of-productionBased on rate of depletion of reserves
Mining extraction equipmentUnits-of-productionBased on rate of depletion of reserves
Leased plant and equipmentStraight-line
Lease period (1-10.5 years)
Other machinery and equipment Straight-line
3-18 years
SoftwareStraight-line
3-10 years
Schedule of Impact of Reclassifications The following tables summarize the accounts that were recast for the year ended December 31, 2023 and 2022 to conform to the current period presentation.
Year Ended December 31
Year Ended December 31
20232022
(in Millions)Prior PresentationLoss/(gain) Reclassified Recast PresentationPrior PresentationLoss/(gain) ReclassifiedRecast Presentation
Cost of sales$413.2 $69.1 $344.1 $417.5 $6.8 $410.7 
Restructuring and other charges56.7 (0.2)56.9 7.5 0.2 7.3 
Other (gains)/losses(68.5)68.9 0.4 (22.2)7.0 (15.2)
v3.25.0.1
Allkem Livent Merger (Tables)
 12 Months Ended
Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Schedule of Estimated fair Value of the Consideration Associated with the Allkem Livent Merger The Acquisition Date fair value of consideration transferred consisted of the following:
(in millions)Amount
Consideration:
Fair value of Arcadium ordinary shares issued to Allkem shareholders$4,385.6 
Fair value of converted Allkem performance rights attributable to pre-combination service4.8 
Total consideration$4,390.4 
Schedule of Purchase Price Allocation
The following table summarizes the purchase price allocation for the Allkem Livent Merger as of January 4, 2024:

(in Millions, except per share amounts)Amount
Total consideration$4,390.4 
Assets acquired:
Cash and cash equivalents$681.4 
Trade receivables64.2 
Inventories127.6 
Prepaid and other current assets87.2 
Property, plant and equipment4,278.9 
Right of use assets - operating leases, net53.4 
Deferred income tax assets30.9 
Other assets (1)
174.0 
Total assets acquired$5,497.6 
Liabilities assumed:
Accounts payable, trade and other$223.7 
Accrued and other current liabilities35.1 
Income taxes78.5 
Long-term debt including current portion301.7 
Operating lease liabilities
53.4 
Environmental liabilities11.9 
Deferred income tax liabilities1,267.4 
Other long-term liabilities58.2 
Total liabilities assumed$2,029.9 
Fair value of net assets acquired$3,467.7 
Add: Fair value of noncontrolling interests acquired 321.0 
Fair value of net assets acquired less noncontrolling interests acquired$3,146.7 
Goodwill$1,243.7 
___________________
1.Includes long-term semi-finished goods inventory.
Schedule of Pro Forma Information
The following table represents Allkem's revenues and net earnings included in Arcadium's consolidated statements of operations from the Acquisition Date through December 31, 2024.
(in Millions)
Twelve Months Ended December 31, 2024
Revenue$337.5 
Income from operations before income taxes
$115.3 
The unaudited pro forma financial results are as follows:
(in Millions)
Twelve Months Ended December 31, 2023
(Unaudited)
Revenue$2,001.7 
Net income$374.0 
v3.25.0.1
Goodwill (Tables)
 12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
The following table summarizes the changes in goodwill for the twelve months ended December 31, 2024.

(in Millions)
Total
Balance as of December 31, 2023 (1)
$120.7 
Acquisitions - Allkem Livent Merger1,243.7 
Purchase price adjustments - Nemaska Lithium
(1.5)
Balance as of December 31, 2024$1,362.9 
___________________
1.Balance as of December 31, 2023 related to October 18, 2023 consolidation of Nemaska Lithium.
v3.25.0.1
Segment Reporting (Tables)
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment The accounting policies of the reportable segment are the same as those described in the Principal Accounting Policies within Note 2.
Year ended December 31,
(in Millions)
2024
2023 (1)
2022 (1)
Revenue
$1,007.8 $882.5 $813.2 
Less:
Cost of sales - as reviewed by chief operating decision maker
670.3344.1410.1
Selling, administration and research costs (2)
133.269.059.1
Depreciation and amortization
113.729.627.7
Other segment items
(41.1)109.7 42.8 
Net income
$131.7 $330.1 $273.5 
__________________
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.Primarily includes people costs and professional fees.
v3.25.0.1
Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue The following table provides information about disaggregated revenue by major geographical region:
 Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
Asia Pacific (2)
$860.1 $649.7 $566.5 
North America (2)
84.4 143.8 145.7 
Europe, Middle East & Africa61.2 87.2 98.1 
Latin America 2.1 1.8 2.9 
Total Revenue$1,007.8 $882.5 $813.2 
____________________
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.In 2024, countries with sales in excess of 10% of combined revenue consisted of China, Japan and South Korea. Sales for the year ended December 31, 2024 for China, Japan and South Korea totaled $564.8 million, $142.1 million, and $138.5 million, respectively. In 2023, countries with sales in excess of 10% of combined revenue consisted of China, the U.S., Japan and South Korea. Sales for the year ended December 31, 2023 for China, the U.S., Japan and South Korea totaled $364.8 million, $138.7 million, $136.9 million, and $123.0 million, respectively. In 2022, countries with sales in excess of 10% of combined revenue consisted of China, Japan, and the U.S. Sales for the year ended December 31, 2022 for China, Japan, and the U.S. totaled $304.9 million, $167.6 million, and $139.1 million, respectively.
The following table provides information about disaggregated revenue by major product category:
 Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
Lithium Hydroxide$437.2 $564.4 $415.5 
Lithium Carbonate (2)
291.7 44.8 68.7 
Butyllithium and Other Lithium Specialties169.2 273.3 329.0 
Spodumene Concentrate (3)
109.7 — — 
Total Revenue$1,007.8 $882.5 $813.2 
______________________
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.Includes lithium carbonate by-product revenue.
3.Includes low-grade spodumene sales and minimal other products.
Receivables and Contract Liabilities
The following table presents the opening and closing balances of our contract liabilities and current trade receivables (including buy/sell arrangements), net of allowances from contracts with customers.
 Balance as of
(in Millions)December 31, 2024December 31, 2023
Increase
Receivables from contracts with customers, net of allowances$130.3 $106.7 $23.6 
Contract liability - short-term 42.3 4.4 37.9 
Contract liability - long-term238.1 217.8 20.3 
v3.25.0.1
Inventories, Net (Tables)
 12 Months Ended
Dec. 31, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories consisted of the following:
 December 31,
 (in Millions)20242023
Finished goods$99.8 $59.1 
Semi-finished goods202.5 108.8 
Raw materials, supplies, and other115.3 49.6 
FIFO inventory, net$417.6 $217.5 
v3.25.0.1
Partially-Owned Subsidiaries and Noncontrolling Interests (Tables)
 12 Months Ended
Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]  
Schedule of Equity Method Investment, Summarized Financial Information The table below represents Nemaska Lithium's balance sheet at fair value consolidated by the Company as of October 18, 2023:
Nemaska Lithium Inc.
October 18,
(in Millions)Note
2023 (a)
ASSETS
Cash and cash equivalents$133.5 
Sales tax receivable9.2 
Prepaid expenses3.4 
Total current assets146.1 
In-trust depositsb9.9 
Property, plant and equipmentc932.2 
Goodwilld119.2 
Intangible assetse45.0 
Other non-current assets0.5 
Total non-current assets1,106.8 
Total assets$1,252.9 
LIABILITIES AND EQUITY
Current portion of long-term debtf$2.4 
Accounts payable and accrued liabilities59.8 
Total current liabilities62.2 
Long-term debtg56.1 
Contract liability - long-termg19.8 
Asset retirement obligationsh3.4 
Deferred income taxes111.9 
Other non-current liabilities0.3 
Total non-current liabilities191.5 
Total current and long-term liabilities253.7 
Arcadium shareholders’ equity
499.6 
Noncontrolling interest499.6 
Total equity999.2 
Total liabilities and equity$1,252.9 
______________________________
a.Represents the Nemaska Lithium balance sheet as of the October 18, 2023 consolidation date.
b.Represents a deposit held in trust for estimated restoration costs relating to the Whabouchi site asset retirement obligation.
c.Primarily represents mining property, mining rights and construction in progress for the Whabouchi and Bécancour sites related to project engineering, equipment and site preparation and capitalized financing costs.
d.Primarily related to potential synergies arising from the proximity of Nemaska Lithium to other resources in the region.
e.Primarily represents intellectual property in relation to patents and development costs with a weighted average amortization period of 15 years.
f.Represents current portion of the unsecured obligation governing the working relationship between the Nemaska Lithium Project and the Cree Nation of Nemaska.
g.Primarily represents $75.0 million for the prepayment received for a customer supply agreement entered on October 18, 2023, recorded net of imputed discount of $19.8 million.
h.Represents the asset retirement obligation for estimated inflation-adjusted and discounted future costs associated with mine reclamation and closure activities at the Whabouchi site, and assuming that the disbursements would be made in 2056.
v3.25.0.1
Investments (Tables)
 12 Months Ended
Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]  
Schedule of Investments in and Advances to Affiliates, Schedule of Investments
Investments consisted of the following:
 (in Millions)December 31, 2024December 31, 2023
ESM ILiAD, LLC$30.1 $30.1 
Arcadium NQSP6.3 4.7 
Other0.5 — 
Investments$36.9 $34.8 
v3.25.0.1
Property, Plant and Equipment, Net (Tables)
 12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment The major classifications of property, equipment and software, including their respective expected useful lives, consisted of the following:
Asset type Useful Life
Land —
Land improvements 20 years
Buildings
20-40 years
Mining rights33 years
Machinery and Equipment
3-18 years
Software
3-10 years
Property, plant and equipment consisted of the following:
 December 31,
(in Millions)20242023
Land and land improvements$337.0 $106.2 
Buildings1,006.8 134.9 
Machinery and equipment1,011.8 420.7 
Mineral rights
3,184.9 560.0 
Construction in progress2,181.9 1,284.4 
Total cost7,722.4 2,506.2 
Accumulated depreciation(351.2)(269.1)
Property, plant and equipment, net$7,371.2 $2,237.1 
The major classifications of property, equipment and software, including their respective principal depreciation and amortization method and expected useful lives, consisted of the following:
Asset type Depreciation and amortization methodUseful Life
Land N/A—
Land improvements Straight-line20 years
Buildings Straight-line
20-40 years
Mineral rightsUnits-of-productionBased on rate of depletion of reserves
Mining extraction equipmentUnits-of-productionBased on rate of depletion of reserves
Leased plant and equipmentStraight-line
Lease period (1-10.5 years)
Other machinery and equipment Straight-line
3-18 years
SoftwareStraight-line
3-10 years
v3.25.0.1
Restructuring and Other Charges (Tables)
 12 Months Ended
Dec. 31, 2024
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring Charges and Asset Disposals
The following table shows total restructuring and other charges included in the consolidated statements of operations:
 Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
Restructuring charges:
Severance-related and exit costs $19.0 $2.4 $1.8 
Other charges:
Costs related to the Rio Tinto Transaction
23.2 — — 
Cost related to the Allkem Livent Merger103.9 54.1 2.9 
Loss on asset replacement (2)
6.9 — — 
Other
4.2 0.4 2.6 
Total restructuring and other charges $157.2 $56.9 $7.3 
_____________________
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.Represents one-time write off of construction in process for structural redesign at the Bécancour development project.
v3.25.0.1
Environmental Obligations (Tables)
 12 Months Ended
Dec. 31, 2024
Environmental Remediation Obligations [Abstract]  
Schedule of Environmental Reserves
The table below is a roll forward of our total environmental reserves.
(in Millions)Environmental Reserves Total
Balance as of December 31, 2022$7.0 
Change in reserves 0.8 
Cash payments(0.3)
Balance as of December 31, 2023$7.5 
Change in reserves 4.3 
Acquisitions - Allkem Livent Merger
2.8 
Cash payments(6.8)
Balance as of December 31, 2024$7.8 
Schedule of Accrual for Environmental Contingencies
The table below provides detail of current and long-term environmental reserves.
 December 31,
(in Millions)20242023
Environmental reserves, current (1)
$0.9 $0.5 
Environmental reserves, long-term (2)
6.9 7.0 
Total environmental reserves$7.8 $7.5 
______________
1.These amounts are included within "Accrued and other liabilities" on the consolidated balance sheets.
2.These amounts are included in "Environmental liabilities" on the consolidated balance sheets.
v3.25.0.1
Other (Gains)/Losses (Tables)
 12 Months Ended
Dec. 31, 2024
Other Income and Expenses [Abstract]  
Schedule of Other (Gains)/Losses
The following table shows amounts included in Other (Gains)/Losses in the consolidated statements of operations:
Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
Blue Chip Swap gains: (2)
Non-recurring - SDV and MdA Holdings LLC (3)
$(45.2)$(61.6)$(22.2)
Recurring - SDJ and MdA(22.6)(6.9)— 
Total Blue Chip Swap gains(67.8)(68.5)(22.2)
Foreign currency remeasurement (gains)/losses:
Foreign currency remeasurement (gains)/losses (4)
(171.3)68.9 7.0 
Remeasurement gains on U.S. dollar denominated cash held by foreign currency functional subsidiary(14.3)— — 
Total Foreign currency remeasurement (gains)/losses
(185.6)68.9 7.0 
Loss on trading securities and other
1.0 — — 
Total Other (gains)/losses
$(252.4)$0.4 $(15.2)
___________________________
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.See Note 2 for details.
3.Represents the non-recurring gain from the sale in Argentina pesos of Argentina Sovereign U.S. dollar-denominated bonds due to the divergence of Argentina's Blue Chip Swap market exchange rate from the official rate.
4.The twelve months ended December 31, 2024 primarily includes impact of currency fluctuations on deferred income tax assets and liabilities related to the Allkem Livent Merger.
v3.25.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Income before Income Tax, Domestic and Foreign
Domestic and foreign components of income from operations before income taxes are shown below:
 Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
Domestic$(21.5)$34.8 $133.2 
Foreign232.1 354.2 202.2 
Total$210.6 $389.0 $335.4 
Schedule of Components of Income Tax Expense (Benefit)
The provision for income taxes attributable to income from operations consisted of: 
 Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
Current:
Federal $9.5 $31.7 $43.7 
Foreign89.7 27.6 5.6 
State(0.4)0.6 1.3 
Total current$98.8 $59.9 $50.6 
Deferred:
Federal $6.5 $4.5 $(1.9)
Foreign(26.7)(5.9)13.3 
State0.3 0.4 (0.1)
Total deferred(19.9)(1.0)11.3 
Total$78.9 $58.9 $61.9 
____________________
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
Schedule of Effective Income Tax Rate Reconciliation
The effective income tax rate applicable to income from operations before income taxes was different from the statutory U.S. federal income tax rate due to the factors listed in the following table: 
 Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
U.S. Federal statutory rate$44.2 $81.7 $70.4 
Foreign earnings subject to different tax rates(9.6)(78.9)(30.0)
Foreign derived intangible income — (0.9)(2.1)
State and local income taxes, less federal income tax benefit(0.1)0.9 0.9 
Tax on intercompany dividends and deemed dividends for tax purposes 3.5 27.7 19.8 
Changes to unrecognized tax benefits6.8 0.4 (0.5)
Other non-deductible expenses (2)
23.5 6.2 0.1 
Other non-taxable income
(2.8)(4.9)(2.9)
Change in valuation allowance (3)
(44.6)66.0 (1.7)
Exchange gains and losses (4)
40.1 (43.0)6.9 
Withholding taxes net of credits7.3 4.7 0.6 
Tax on global activities (5)
5.4 — — 
Other 5.2 (1.0)0.4 
Total tax provision$78.9 $58.9 $61.9 
____________________ 
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.The year ended December 31, 2024 primarily includes the impact of management fees and transaction costs incurred by our parent company that are non-deductible.
3.For the year ended December 31, 2024, the Company released a valuation allowance of $(77.2) million to the statement of operations on the net deferred tax assets in Argentina. For the year ended December 31, 2023, the Company recorded a valuation allowance of $60.3 million to the statement of operations on the net deferred tax assets in Argentina. These adjustments were primarily due to the significant fluctuations in foreign currency impacts that occurred during both periods.
4.Includes the impact of foreign currency exchange gains or losses in Argentina on net monetary assets for which no corresponding tax expense or benefit is realized and the tax provision for statutory taxable gains or losses in foreign jurisdictions for which there is no corresponding amount in income before taxes. Additionally, the years ended December 31, 2024, 2023 and 2022 include an adjustment relating to inflation.
5.Represents additional expense for global minimum taxes at our parent company in accordance with the newly implemented Pillar Two rules.
Schedule of Deferred Tax Assets and Liabilities
Significant components of our deferred tax assets and liabilities were attributable to:
 Year Ended December 31,
(in Millions)2024
2023 (1)
Net operating loss carry-forwards and credits (2)
$203.9 $239.2 
Exploration and development expenses
11.2 12.0 
Disallowed interest expense (3)
88.9 8.8 
Other assets and reserves12.4 20.7 
Deferred tax assets$316.4 $280.7 
Valuation allowance, net (4)
(46.9)(83.1)
Deferred tax assets, net of valuation allowance$269.5 $197.6 
Property, plant and equipment, net (3)
(1,322.6)(281.8)
Intangibles(6.3)(11.8)
Deferred inflationary gain(49.0)(28.4)
Other liabilities(4.7)(0.6)
Deferred tax liabilities(1,382.6)(322.6)
Net deferred tax liabilities$(1,113.1)$(125.0)
___________________
1.Represents the results of predecessor Livent’s operations for the year ended December 31, 2023 which do not include the operations of Allkem.
2.The year ended December 31, 2024 primarily relates to net operating losses generated in Canada. The year ended December 31, 2023 primarily relates to net operating losses generated in Argentina and Canada. The net operating losses in Canada primarily relate to Nemaska Lithium, see Note 9 for details.
3.As part of the Allkem Livent Merger, the Company recorded deferred tax assets of $47.8 million related primarily to accrued interest, and deferred tax liabilities of $1,311.7 million related to property, plant and equipment, within the purchase price allocation for the year ended December 31, 2024. See Note 4 for details
4.For the year ended December 31, 2023, the Company recorded a valuation allowance in 2023 on the net deferred tax assets in Argentina, primarily relating to the net operating loss as a result of the significant fluctuations in foreign currency. These significant fluctuations in foreign currency impacts primarily occurred in December 2023. The balance at the end of the year was $80.2 million.
Schedule of Unrecognized Tax Benefits Roll Forward
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: 
Year Ended December 31,
(in Millions)202420232022
Balance at beginning of year
$4.7 $4.5 $2.9 
Increases related to positions taken in the current year4.5 0.4 3.3 
Decreases related to positions taken in prior years(3.7)— — 
Increases related to positions taken in prior years14.2 — — 
Decreases related to lapse of statutes of limitations(0.8)(0.2)(0.1)
Settlement of uncertain tax positions(4.2)— (1.6)
Balance at end of year$14.7 $4.7 $4.5 
v3.25.0.1
Debt (Tables)
 12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt
Long-term debt consists of the following:
Interest Rate
Percentage
Maturity
Date		December 31, 2024December 31, 2023
(in Millions)SOFR borrowingsBase rate borrowings
Revolving Credit Facility (1)
6.18%8.25%2027$344.0 $— 
4.125% Convertible Senior Notes due 2025
4.125%2025245.8 245.8 
Transaction costs - 2025 Notes(0.9)(2.4)
Nemaska - Prepayment agreement (2)
8.9%75.0 75.0 
Discount - Prepayment agreement(20.1)(19.8)
Nemaska - Prepayment agreement - tranche 2 (2)
9.4%150.0 — 
Discount - Prepayment agreement(52.8)— 
Nemaska - Other0.6 3.4 
Debt assumed in Allkem Livent Merger (3)
Project Loan Facility - Stage 2 of Olaroz Plant2.61%2029135.0 — 
Affiliate Loans with TTC14.30%203081.5 — 
Affiliate Loan with TLP10.03%20262.5 — 
Total debt assumed in Allkem Livent Merger219.0 — 
Subtotal long-term debt (including current maturities)960.6 302.0 
Less current maturities(288.9)(2.4)
Total long-term debt $671.7 $299.6 
______________________________
1.As of December 31, 2024 and December 31, 2023, there were $16.8 million and $15.5 million, respectively, in letters of credit outstanding under our Revolving Credit Facility and $139.2 million and $484.5 million available funds as of December 31, 2024 and December 31, 2023, respectively. Fund availability is subject to the Company meeting its debt covenants.
2.Represents advance payments in connection with customer supply agreement which do not have a contractual interest rate or bear any actual interest and are repayable in equal quarterly installments beginning in January 2027 and ending in October 2031. Represents U.S. GAAP imputed interest rate.
3.On March 7, 2024 SDJ paid $18.1 million to repay a portion of the outstanding balance of the Stage 1 and Stage 2 Olaroz Plan Project Loan Facility. On September 10, 2024, SDJ paid $9.1 million to repay the outstanding balance of the Stage 1 Olaroz Plan Project Loan Facility in its entirety, as well as $9.0 million to repay a portion of the outstanding of the Stage 2 Olaroz Plan Project Loan Facility. On May 30, 2024, SDV paid the outstanding principal balance of $47.0 million, a prepayment fee of $0.9 million and accrued interest and commitment fees of $1.3 million to repay the Sal de Vida Project Financing Facility in its entirety.
v3.25.0.1
Share-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan
We recognized the following share compensation expense for Legacy Livent Awards and awards under the Arcadium Plan:
Year Ended December 31,
(in Millions)2024
2023 (1)
2022 (1)
Share Option Expense, net of taxes of $0.4, $0.3 and $0.3
$3.0 $1.7 $1.8 
Restricted Share Expense, net of taxes of $(0.7), $0.9 and $0.7
24.7 4.5 3.6 
Performance-Based Restricted Share Expense, net of taxes of $0.1, $0.3, and $0.1
0.4 1.8 0.4 
Total Share Compensation Expense, net of taxes of $(0.2), $1.5 and $1.1 (2)
$28.1 $8.0 $5.8 
____________________ 
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.Gross share compensation charges of $12.2 million and $15.7 million were recorded to "Selling, general and administrative expenses" and "Restructuring and other charges", respectively, in our consolidated statement of operations for the year ended December 31, 2024. Gross share compensation charges of $8.4 million and $1.1 million were recorded to "Selling, general and administrative expenses" and "Restructuring and other charges", respectively, in our consolidated statement of operations for the year ended and December 31, 2023. Gross share compensation charges of $6.8 million and $0.1 million were recorded to "Selling, general and administrative expenses" and "Restructuring and other charges", respectively, in our consolidated statement of operations for the year ended December 31, 2022.
Schedule of Black Scholes Valuation Assumptions for Stock Option Grants
The following table contains Black Scholes valuation assumptions for share options granted for the years ended December 31, 2024, 2023 and 2022: 
202420232022
Grant date
3/6/20245/14/20246/28/20247/30/20249/1/20242/22/20232/23/2022
Expected dividend yield—%—%—%—%—%—%—%
Expected volatility31.18%31.97%33.00%33.22%35.06%30.19%28.89%
Expected life (in years)6.06.06.06.06.06.5
6.5
Risk-free interest rate4.08%4.41%4.28%4.00%3.72%4.04%1.95%
Schedule of Stock Option Activity
The following summary shows share option activity for the Allkem Livent Merger and the Arcadium Plan for the year ended December 31, 2024:
Number of Options Granted But Not ExercisedWeighted-Average Remaining Contractual Life
(in Years)		Weighted-Average Exercise Price Per ShareAggregate Intrinsic Value (in Millions)
Outstanding as of December 31, 2023
5,060,687 5.6$6.73 $6.5 
Granted4,055,748 $4.82 
Exercised(171,819)$3.58 $0.3 
Forfeited(275,656)$5.22 
Outstanding as of December 31, 2024
8,668,960 6.6$5.95 $2.9 
Exercisable as of December 31, 2024 (1)
4,069,419 4.1$6.30 $1.7 
_________________________
1.In December 2024, 706,975 share options of certain Arcadium executive officers vested on an accelerated basis.
Schedule of Restricted Award Activity The following table shows RSU activity for the Allkem Livent Merger and the Arcadium Plan for the year ended December 31, 2024:
Restricted Share Units
Number of
awards		Weighted-Average Grant Date Fair ValueAggregate Intrinsic Value (in Millions)
Nonvested December 31, 2023
2,287,088 $7.83 $17.1 
Granted (1)
5,217,604 $4.89 
Vested (2)
(2,634,791)$6.82 
Forfeited(290,380)$5.52 
Nonvested December 31, 2024 (3)
4,579,521 $5.21 $23.5 
___________________
1.The Company granted 1,080,825 Allkem Replacement Awards on January 12, 2024 pursuant to the Allkem Transaction Agreement.
2.Immediately prior to the Acquisition Date, 768,440 non-employee Director RSUs vested and were paid out in cash of $5.3 million pursuant to the Allkem Transaction Agreement. In December 2024, 347,361 RSUs of certain Arcadium executive officers vested on an accelerated basis.
The following table shows PRSU activity for the twelve months ended December 31, 2024.
Performance-Based Restricted Share Units
Number of
awards		Weighted-Average Grant Date Fair ValueAggregate Intrinsic Value (in Millions)
Nonvested as of December 31, 202396,885 $9.42 $0.7 
Vested(96,885)$9.42 
Nonvested as of December 31, 2024
— $— $— 
v3.25.0.1
Equity (Tables)
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Schedule of Stock by Class
IssuedTreasuryOutstanding
Balance as of December 31, 2022 (1)
432,243,013 (249,202)431,993,811 
RSU awards324,577 — 324,577 
PRSU awards126,421 — 126,421 
Share option awards
365,661 — 365,661 
Net purchases of treasury shares - NQSP
— (14,467)(14.467)
Issuance of ordinary shares - conversion of 2025 Notes
274 — 274 
Balance as of December 31, 2023 (1)
433,059,946 (263,669)432,796,277 
Issued to Allkem shareholders - Allkem Livent Merger641,337,840 — 641,337,840 
PRSU and RSU awards accelerated - Allkem Livent Merger648,969 — 648,969 
Arcadium RSU awards1,345,007 — 1,345,007 
Arcadium share option awards127,260 — 127,260 
Net sales of treasury shares - NQSP
— 3,525 3,525 
Balance as of December 31, 2024
1,076,519,022 (260,144)1,076,258,878 
_____________________
1.Balances outstanding as of December 31, 2023 and 2022, representing predecessor Livent, have been adjusted to reflect the 2.406 Exchange Ratio.
Schedule of Accumulated Other Comprehensive Income (Loss)
Summarized below is the roll forward of accumulated other comprehensive loss, net of tax.
(in Millions)Foreign currency adjustments
Derivative Instruments (1)
Total
Accumulated other comprehensive loss, net of tax as of December 31, 2022
$(51.0)$— $(51.0)
Other comprehensive income before reclassifications1.2 (0.5)$0.7 
Amounts reclassified from accumulated other comprehensive loss— 0.5 0.5 
Accumulated other comprehensive loss, net of tax as of December 31, 2023
$(49.8)$— $(49.8)
Other comprehensive income before reclassifications
(40.6)(0.6)(41.2)
Amounts reclassified from accumulated other comprehensive loss— 0.6 0.6 
Accumulated other comprehensive loss, net of tax as of December 31, 2024
$(90.4)$— $(90.4)
______________
1.See Note 21 for more information.
Reclassifications of Accumulated Other Comprehensive Income
The table below provides details about the reclassifications from accumulated other comprehensive loss and the affected line items in the consolidated statement of operations for each of the periods presented.
Details about Accumulated Other Comprehensive Loss ComponentsAmounts Reclassified from Accumulated Other Comprehensive LossAffected Line Item in the Consolidated Statements of Income
(in Millions)Year ended December 31, 2024Year ended December 31, 2023Year ended December 31, 2022
Derivative instruments
Foreign currency contracts$0.6 $0.5 $0.9 Costs of sales
Total before tax0.6 0.5 0.9 
— — (0.2)Provision for income taxes
Amount included in net income$0.6 $0.5 $0.7 
Total reclassifications for the period$0.6 $0.5 $0.7 Amount included in net income
v3.25.0.1
Earnings Per Share (Tables)
 12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Calculation of Basic and Diluted Earnings Per Share
Earnings applicable to ordinary shares and ordinary shares used in the calculation of basic and diluted earnings per share are as follows:
(in Millions, Except Per Share Data)Year Ended December 31,
2024
2023 (1)
2022 (1)
Numerator:
Net income attributable to Arcadium Lithium plc$103.2 $330.1 $273.5 
Denominator:
Weighted average ordinary shares outstanding - basic
1,069.8 432.4 413.4 
Dilutive share equivalents from share-based plans 1.2 3.3 4.1 
Dilutive share equivalents from 2025 Notes67.7 67.7 67.7 
Weighted average ordinary shares outstanding - diluted
1,138.7 503.4 485.2 
Basic earnings per ordinary share
$0.10 $0.76 $0.66 
Diluted earnings per ordinary share
$0.09 $0.66 $0.56 
_______________________________
1.For the years ended December 31, 2023 and 2022 weighted average ordinary shares outstanding - basic and diluted, dilutive share equivalents and basic and diluted earnings per ordinary share amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio.
v3.25.0.1
Financial Instruments, Risk Management and Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Financial Instrument Valuation Methods Our other financial instruments include the following:
Financial InstrumentValuation Method
Foreign exchange forward contractsEstimated amounts that would be received or paid to terminate the contracts at the reporting date based on current market prices for applicable currencies.
Schedule of Derivatives in Cash Flow Hedging Relationships
The following tables summarize the gains or losses related to our cash flow hedges and derivatives not designated as cash flow hedging instruments.

Derivatives in Cash Flow Hedging Relationships
(in Millions)Total Foreign Exchange Contracts
Accumulated other comprehensive loss, net of tax at December 31, 2022$— 
Unrealized hedging losses, net of tax(0.5)
Reclassification of deferred hedging losses, net of tax (1)
0.5 
Total derivative instrument impact on comprehensive income, net of tax— 
Accumulated other comprehensive loss, net of tax at December 31, 2023$— 
Unrealized hedging losses, net of tax
(0.6)
Reclassification of deferred hedging losses, net of tax (1)
0.6 
Total derivative instrument impact on comprehensive loss, net of tax— 
Accumulated other comprehensive loss, net of tax at December 31, 2024$— 
____________________
1.Amounts are included in "Cost of sales" on the consolidated statement of operations.
Schedule of Derivatives Not Designated as Cash Flow Hedging Instruments
Location of Loss
Recognized in Income on Derivatives
Amount of Pre-tax Loss
Recognized in Income on Derivatives (1)
Year Ended December 31,
(in Millions) 202420232022
Foreign Exchange contractsCost of sales $18.9 $(2.8)$(5.2)
Total$18.9 $(2.8)$(5.2)
____________________
1.Amounts in the columns represent the gain or loss on the derivative instrument offset by the gain or loss on the hedged item.
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis
The following tables present our fair-value hierarchy for those assets and liabilities measured at fair-value on a recurring basis in our consolidated balance sheets as of December 31, 2024 and 2023.  
(in Millions)December 31, 2024Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets
Investments in deferred compensation plan (1)
$6.3 $6.3 $— $— 
JEMSE Receivable5.0 — — 5.0 
Equity securities (2)
0.30.3 — — 
Total Assets
$11.6 $6.6 $— $5.0 
Liabilities
Deferred compensation plan obligation (3)
$7.6 $7.6 $— $— 
Total Liabilities
$7.6 $7.6 $— $— 

(in Millions)December 31, 2023Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets
Investments in deferred compensation plan (1)
$4.1 $4.1 $— — 
Total Assets$4.1 $4.1 $— $— 
Liabilities
Deferred compensation plan obligation (3)
$6.7 $6.7 $— $— 
Total Liabilities (4)
$6.7 $6.7 $— $— 
____________________
1.Balance is included in "Other assets" in the consolidated balance sheets. Arcadium NQSP investments in Arcadium ordinary shares are recorded as Treasury shares in the consolidated balance sheets and carried at historical cost. A mark-to-market gain of $0.6 million and a
mark-to-market gain of $0.2 million related to the Arcadium ordinary shares was recorded in "Selling, general and administrative expense" in the consolidated statements of operations for the years ended December 31, 2024 and December 31, 2023, respectively, with a corresponding offset to the deferred compensation plan obligation in the consolidated balance sheets.
2.Mark-to-market gains and losses are recorded to Other gain/loss in the consolidated statement of operations.
3.Balance is included in "Other long-term liabilities" in the consolidated balance sheets.
4.The Company had no open cash flow hedge contracts as of December 31, 2023.
v3.25.0.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Lease Cost
Disclosures about our leases under ASC 842 are summarized in the table below.
Year ended December 31,
(in Millions)
2024
2023 (1)
2022 (1)
Lease Cost
Operating lease cost (2)
$15.5 $1.4 $1.3 
Short-term lease cost0.5 0.4 0.4 
Total lease cost (2)
$16.0 $1.8 $1.7 
Other information
Cash paid for amounts included in the measurement of lease liabilities:
Cash paid for operating leases $14.9 $1.4 $1.3 
____________________________
1.Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
2.Lease expense is classified as "Selling, general and administrative expenses" in our consolidated statements of operations.
Schedule of Maturity Analysis of Operating Lease Liabilities
The table below presents a maturity analysis of our operating lease liabilities for each of the next five years and a total of the amounts for the remaining years.
(in Millions)Undiscounted cash flows
2025$10.2 
20269.4 
20278.7 
20288.5 
2029
9.0 
Thereafter26.0 
       Total future minimum lease payments71.8 
Less: Imputed interest(25.0)
       Total$46.8 
v3.25.0.1
Supplemental Information (Tables)
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Other Assets
The following tables present details of prepaid and other current assets, other assets, accrued and other liabilities and other long-term liabilities as presented on the consolidated balance sheets:
(in Millions) December 31,
20242023
Prepaid and other current assets
Income tax receivable - refunds and prepayments$82.2 $29.5 
Argentina government receivable (1)
40.6 7.9 
Prepaid expenses42.8 16.9 
Other receivables47.8 28.2 
Bank Acceptance Drafts (2)
1.1 — 
Other current assets4.2 3.9 
Total$218.7 $86.4 
(in Millions) December 31,
20242023
Other assets
Argentina government receivable (1)(3)
$131.8 $71.3 
Advance to contract manufacturers (4)
27.9 27.6 
Long-term semi-finished goods inventory105.0 1.0 
Tax related items4.3 4.0 
Capitalized software, net2.3 1.1 
Investment in transit - Nemaska Lithium (5)
96.7 — 
Deposits
23.4 — 
Other long-term assets20.9 22.7 
Total$412.3 $127.7 
____________________
1.We have various subsidiaries that conduct business within Argentina. At December 31, 2024 and 2023, $42.0 million and $38.8 million of outstanding receivables due from the Argentina government, which primarily represent export tax and export rebate receivables, were denominated in U.S. dollars. A judicial decision relating to the U.S. dollar-denominated export tax receivable portion $34.8 million permits the Argentina government to reimburse us in Argentine pesos at the historical foreign exchange rate applicable at each past payment date, adjusted by a bank deposit interest rate. While the Company filed an appeal on November 6, 2023 and believes it has valid defenses on the technical merits, the ultimate resolution of this matter could result in a possible loss of up to $34.4 million. We continually review the recoverability of all outstanding receivables by analyzing historical experience, current collection trends and regional business and political factors among other factors.
2.Bank Acceptance Drafts are a common Chinese finance note used to settle trade transactions. The Company accepts these notes from Chinese customers based on criteria intended to ensure collectability and limit working capital usage.
3.In June 2023, the Company decided to pay $21.7 million for the export duties and interest claimed by the Customs Authorities of Buenos Aires, Ezeiza and Salta related to exports made between the years 2018 – 2022 registered in those locations. This payment stops the accrual of any further interest. It was a deposit made under protest, and was not an admission of any of the claims made by the Customs Authorities or a waiver of any of the Company's defenses, including recovery of the deposit plus interest. The cases remain in discussion. See Note 22 for more information.
4.We record deferred charges related to certain contract manufacturing agreements which we amortize over the term of the underlying contract.
5.Represents the Company's cash contributed to Nemaska Lithium in the fourth quarter of 2024 which, due to one-quarter lag reporting, are not yet recorded in our consolidation of Nemaska. The balance is recorded to Other assets - noncurrent because the cash is expected to be used by Nemaska primarily for capital expenditures. IQ contemporaneously made an equal contribution in the fourth quarter of 2024 which, due to one-quarter lag reporting, is not recorded in our consolidation of Nemaska. See Note 9 for details.
Schedule of Other Liabilities
(in Millions) December 31,
20242023
Accrued and other current liabilities
Accrued payroll$46.2 $20.3 
Restructuring reserves1.4 1.7 
Retirement liability - 401k3.5 3.2 
Environmental reserves, current0.9 0.5 
Accrued investment in unconsolidated affiliates— 27.0 
Accrued capital expenditures137.8 84.1 
Total$189.8 $136.8 

(in Millions) December 31,
20242023
Other long-term liabilities
Deferred compensation plan obligation$7.6 $6.7 
Contingencies related to uncertain tax positions (1)
22.2 6.2 
Self insurance reserves1.1 1.1 
Asset retirement obligations14.2 3.7 
Affiliate Loans with TTC - accrued interest
53.4 — 
Other long-term liabilities13.2 3.6 
Total$111.7 $21.3 
____________________
1.As of December 31, 2024, we have recorded a liability for uncertain tax positions of $21.8 million and a $0.4 million indemnification liability to FMC for assets where the offsetting uncertain tax position is with FMC.
v3.25.0.1
Description of the Business (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Oct. 09, 2024
Jan. 04, 2024
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Common stock, par value (in dollars per share) $ 1.00 $ 1.00 $ 1.00   $ 1.00 $ 1.00
Rio Tinto            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Common stock, par value (in dollars per share)       $ 1.00    
Exchange right without interest (in dollars per share)       $ 5.85    
Rio Tinto            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Termination fees $ 200.0          
Transaction costs 129.0          
Cost related to the Allkem Livent Merger $ 23.2 $ 0.0 $ 0.0      
v3.25.0.1
Principal Accounting Policies and Related Financial Information - Restrictions on Cash and Cash Equivalents (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
 [2]
Dec. 31, 2021
 [2]
Significant Accounting Policies [Line Items]        
Cash and cash equivalents $ 93.2 $ 237.6 [1]    
Total Cash and cash equivalents and restricted cash 93.2 237.6 [2] $ 189.0 $ 113.0
Cash Reconciliation        
Significant Accounting Policies [Line Items]        
Cash and cash equivalents 93.2 237.6    
Restricted cash - Other non-current assets 23.4 0.0    
Total Cash and cash equivalents and restricted cash $ 116.6 $ 237.6    
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
[2] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Principal Accounting Policies and Related Financial Information - Narrative (Details)
$ in Millions
 12 Months Ended
Jan. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
segment
remediation_site
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jan. 22, 2025
USD ($)
Dec. 31, 2021
USD ($)
 [1]
Dec. 31, 2020
USD ($)
Significant Accounting Policies [Line Items]              
Cash and cash equivalents and restricted cash   $ 93.2 $ 237.6 [1] $ 189.0 [1]   $ 113.0  
Net cash (used in)/provided by operating activities   (176.0) 297.3 [1] 454.7 [1]      
Cash (used in)/provided by investing activities   (445.3) (228.3) [1] (364.7) [1]      
Capitalized interest costs   24.9 16.8 15.8      
Non-cash impairment charge   $ 51.7          
Number of reportable segments | segment   1          
Number of environmental remediation sites | remediation_site   2          
Remediation charges   $ 4.3 $ 0.8 $ 1.2      
Environmental Remediation Expense, before Recovery, Statement of Income or Comprehensive Income [Extensible Enumeration]   Restructuring and other charges Restructuring and other charges Restructuring and other charges      
Accrual for environmental loss contingencies   $ 7.8 $ 7.5 $ 7.0      
Unrealized (gain)/loss, foreign currency transaction, before tax   (185.6) 68.9 7.0      
Asset retirement obligation   14.2 3.7        
Realized foreign currency transaction gain   $ 67.8 68.5 $ 22.2      
Minimum              
Significant Accounting Policies [Line Items]              
Payment term (in days)   30 days          
Maximum              
Significant Accounting Policies [Line Items]              
Payment term (in days)   180 days          
Patents              
Significant Accounting Policies [Line Items]              
Finite-lived intangible assets amortization period (in years)   15 years          
Convertible Debt              
Significant Accounting Policies [Line Items]              
Debt interest rate   4.125%          
Pari Passu Term Loan | Subsequent Event              
Significant Accounting Policies [Line Items]              
Proceeds from issuance of debt $ 199.5            
Debt instrument, fee amount 0.5            
Convertible Senior Notes Due 2025 | Convertible Debt              
Significant Accounting Policies [Line Items]              
Aggregate principal amount of debt             $ 245.8
Debt interest rate   4.125%         4.125%
Project Financing Facility - Mizuho              
Significant Accounting Policies [Line Items]              
Restricted cash, noncurrent   $ 18.1          
Letter of Credit              
Significant Accounting Policies [Line Items]              
Restricted cash, noncurrent   5.3          
Revolving Credit Facility              
Significant Accounting Policies [Line Items]              
Line of credit, remaining borrowing capacity   $ 139.2 $ 484.5        
Secured Debt | Pari Passu Term Loan | Subsequent Event              
Significant Accounting Policies [Line Items]              
Proceeds from issuance of debt 199.5            
Debt instrument, fee amount $ 0.5            
Secured Debt | Pari Passu Term Loan | First Lien Secured Term Loan Facility | Subsequent Event              
Significant Accounting Policies [Line Items]              
Aggregate principal amount of debt         $ 200.0    
Secured Debt | Pari Passu Term Loan | Second Lien Secured Term Loan Facility | Subsequent Event              
Significant Accounting Policies [Line Items]              
Aggregate principal amount of debt         $ 300.0    
[1] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Principal Accounting Policies and Related Financial Information - Property, Plant and Equipment (Details)
Dec. 31, 2024
Land improvements  
Significant Accounting Policies [Line Items]  
Useful life (in years) 20 years
Buildings | Minimum  
Significant Accounting Policies [Line Items]  
Useful life (in years) 20 years
Buildings | Maximum  
Significant Accounting Policies [Line Items]  
Useful life (in years) 40 years
Mining rights  
Significant Accounting Policies [Line Items]  
Useful life (in years) 33 years
Machinery and Equipment | Minimum  
Significant Accounting Policies [Line Items]  
Useful life (in years) 3 years
Machinery and Equipment | Maximum  
Significant Accounting Policies [Line Items]  
Useful life (in years) 18 years
Software | Minimum  
Significant Accounting Policies [Line Items]  
Useful life (in years) 3 years
Software | Maximum  
Significant Accounting Policies [Line Items]  
Useful life (in years) 10 years
v3.25.0.1
Principal Accounting Policies and Related Financial Information - Schedule of Impact of Reclassifications (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Significant Accounting Policies [Line Items]      
Cost of sales $ 719.2 $ 344.1 [1] $ 410.7 [1]
Restructuring and other charges   56.9 7.3
Other (gains)/losses $ (252.4) 0.4 [1] (15.2) [1]
Prior Presentation      
Significant Accounting Policies [Line Items]      
Cost of sales   413.2 417.5
Restructuring and other charges   56.7 7.5
Other (gains)/losses   (68.5) (22.2)
Loss/(gain) Reclassified      
Significant Accounting Policies [Line Items]      
Cost of sales   69.1 6.8
Restructuring and other charges   (0.2) 0.2
Other (gains)/losses   $ 68.9 $ 7.0
[1] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Allkem Livent Merger - Narrative (Details)
$ / shares in Units, $ in Millions
 12 Months Ended
Jan. 04, 2024
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
$ / shares
Dec. 31, 2021
$ / shares
Business Acquisition [Line Items]          
Common stock, par value (in dollars per share) | $ / shares $ 1.00 $ 1.00 $ 1.00 $ 1.00 $ 1.00
Conversion ratio 2.406        
Decrease to deferred income tax liabilities   $ 31.1 $ 4.7 [1] $ (10.5) [1]  
Allkem Livent Merger          
Business Acquisition [Line Items]          
Cost related to the Allkem Livent Merger   103.9      
Livent Corporation          
Business Acquisition [Line Items]          
Common stock, par value (in dollars per share) | $ / shares $ 0.001        
Allkem Livent Merger          
Business Acquisition [Line Items]          
Decrease to property, plant and equipment   46.6      
Increase to deferred income tax assets   4.6      
Increase to accounts payable trade and other   1.8      
Decrease in income taxes   0.3      
Decrease to environmental liabilities   7.0      
Decrease to deferred income tax liabilities   49.3      
Increase to other long term liabilities   8.7      
Increase in goodwill   54.5      
Cost related to the Allkem Livent Merger   $ 103.9 $ 54.1 $ 2.9  
Trade receivables $ 64.2        
Property, plant and equipment 4,278.9        
Allkem Livent Merger | Mineral rights          
Business Acquisition [Line Items]          
Property, plant and equipment 2,675.0        
Allkem Livent Merger | Non Mining Properties and Mineral Rights          
Business Acquisition [Line Items]          
Property, plant and equipment $ 1,603.9        
Allkem Livent Merger | Former Livent Stockholders          
Business Acquisition [Line Items]          
Number of shares issued in transaction (in shares) | shares 433,156,855        
Allkem Livent Merger | Former Allkem Shareholders          
Business Acquisition [Line Items]          
Number of shares issued in transaction (in shares) | shares 641,337,840        
Allkem Livent Merger | CHESS Depositary Instrument          
Business Acquisition [Line Items]          
Equity interest issued or issuable, share exchange ratio 1        
Allkem Livent Merger | CHESS Depositary Instrument | Former Allkem Shareholders          
Business Acquisition [Line Items]          
Number of shares issued in transaction (in shares) | shares 542,612,224        
Allkem Livent Merger | Common Stock          
Business Acquisition [Line Items]          
Equity interest issued or issuable, share exchange ratio 1        
Allkem Livent Merger | Common Stock | Former Allkem Shareholders          
Business Acquisition [Line Items]          
Number of shares issued in transaction (in shares) | shares 98,725,616        
Allkem Livent Merger | PRSU awards | Former Livent Stockholders          
Business Acquisition [Line Items]          
Number of shares issued in transaction (in shares) | shares 96,909        
[1] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Allkem Livent Merger - Consideration Transferred (Details) - Allkem Livent Merger
$ in Millions
Jan. 04, 2024
USD ($)
Business Acquisition [Line Items]  
Fair value of Arcadium ordinary shares issued to Allkem shareholders $ 4,385.6
Fair value of converted Allkem performance rights attributable to pre-combination service 4.8
Total consideration $ 4,390.4
v3.25.0.1
Allkem Livent Merger - Purchase Price Allocation (Details) - USD ($)
$ in Millions
Jan. 04, 2024
Dec. 31, 2024
Dec. 31, 2023
 [1]
Liabilities assumed:      
Goodwill   $ 1,362.9 $ 120.7
Allkem Livent Merger      
Business Acquisition [Line Items]      
Total consideration $ 4,390.4    
Assets acquired:      
Cash and cash equivalents 681.4    
Trade receivables 64.2    
Inventories 127.6    
Prepaid and other current assets 87.2    
Property, plant and equipment 4,278.9    
Right of use assets - operating leases, net 53.4    
Deferred income tax assets 30.9    
Other assets 174.0    
Total assets acquired 5,497.6    
Liabilities assumed:      
Accounts payable, trade and other 223.7    
Accrued and other current liabilities 35.1    
Income taxes 78.5    
Long-term debt including current portion 301.7    
Operating lease liabilities 53.4    
Environmental liabilities 11.9    
Deferred income tax liabilities 1,267.4    
Other long-term liabilities 58.2    
Total liabilities assumed 2,029.9    
Fair value of net assets acquired 3,467.7    
Add: Fair value of noncontrolling interests acquired 321.0    
Fair value of net assets acquired less noncontrolling interests acquired 3,146.7    
Goodwill $ 1,243.7    
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
v3.25.0.1
Allkem Livent Merger - Earnings Subsequent to the Closing Date of Transaction (Details) - Allkem Livent Merger
$ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
Business Acquisition [Line Items]  
Revenue $ 337.5
Income from operations before income taxes $ 115.3
v3.25.0.1
Allkem Livent Merger - Pro Forma Information (Details) - Allkem Livent Merger
$ in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]  
Revenue $ 2,001.7
Net income $ 374.0
v3.25.0.1
Goodwill (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
Goodwill [Roll Forward]  
Beginning balance $ 120.7 [1]
Acquisitions - Allkem Livent Merger 1,243.7
Purchase price adjustments - Nemaska Lithium (1.5)
Ending balance $ 1,362.9
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
v3.25.0.1
Segment Reporting (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
segment
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Segment Reporting [Abstract]      
Number of reportable segments | segment 1    
Segment Reporting Information [Line Items]      
Revenue $ 1,007.8 $ 882.5 $ 813.2
Less:      
Cost of sales - as reviewed by chief operating decision maker 719.2 344.1 [1] 410.7 [1]
Depreciation and amortization 124.0 29.6 [2] 27.7 [2]
Net income 131.7 330.1 [2] 273.5 [2]
Reportable Segment      
Segment Reporting Information [Line Items]      
Revenue 1,007.8 882.5 [1] 813.2 [1]
Less:      
Cost of sales - as reviewed by chief operating decision maker 670.3 344.1 410.1
Selling, administration and research costs 133.2 69.0 59.1
Depreciation and amortization 113.7 29.6 27.7
Other segment items (41.1) 109.7 42.8
Net income $ 131.7 $ 330.1 [1] $ 273.5 [1]
[1] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
[2] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Revenue Recognition - Revenue By Major Geographical Region (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue [Line Items]      
Revenue $ 1,007.8 $ 882.5 $ 813.2
Asia Pacific      
Disaggregation of Revenue [Line Items]      
Revenue 860.1 649.7 566.5
North America      
Disaggregation of Revenue [Line Items]      
Revenue 84.4 143.8 145.7
Europe, Middle East & Africa      
Disaggregation of Revenue [Line Items]      
Revenue 61.2 87.2 98.1
Latin America      
Disaggregation of Revenue [Line Items]      
Revenue 2.1 1.8 2.9
CHINA      
Disaggregation of Revenue [Line Items]      
Revenue 564.8 364.8 304.9
UNITED STATES      
Disaggregation of Revenue [Line Items]      
Revenue   138.7 139.1
JAPAN      
Disaggregation of Revenue [Line Items]      
Revenue 142.1 136.9 $ 167.6
South Korea      
Disaggregation of Revenue [Line Items]      
Revenue $ 138.5 $ 123.0  
v3.25.0.1
Revenue Recognition - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jul. 25, 2022
Disaggregation of Revenue [Line Items]          
Contract liability - long-term $ 238.1 $ 217.8 [1]   $ 198.0  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01          
Disaggregation of Revenue [Line Items]          
Expected timing of satisfaction of performance obligations 4 years       6 years
Minimum          
Disaggregation of Revenue [Line Items]          
Contract payment term (in days) 30 days        
Maximum          
Disaggregation of Revenue [Line Items]          
Contract payment term (in days) 180 days        
Customer One | Total Revenue | Customer Concentration Risk          
Disaggregation of Revenue [Line Items]          
Concentration risk, percentage 25.00% 28.00% 24.00%    
Customer Two | Total Revenue | Customer Concentration Risk          
Disaggregation of Revenue [Line Items]          
Concentration risk, percentage 22.00% 22.00%      
Ten Largest Customers | Total Revenue | Customer Concentration Risk          
Disaggregation of Revenue [Line Items]          
Concentration risk, percentage 74.00% 72.00% 63.00%    
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
v3.25.0.1
Revenue Recognition - Revenue By Major Product Category (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue [Line Items]      
Revenue $ 1,007.8 $ 882.5 $ 813.2
Lithium Hydroxide      
Disaggregation of Revenue [Line Items]      
Revenue 437.2 564.4 415.5
Lithium Carbonate      
Disaggregation of Revenue [Line Items]      
Revenue 291.7 44.8 68.7
Butyllithium and Other Lithium Specialties      
Disaggregation of Revenue [Line Items]      
Revenue 169.2 273.3 329.0
Spodumene Concentrate      
Disaggregation of Revenue [Line Items]      
Revenue $ 109.7 $ 0.0 $ 0.0
v3.25.0.1
Revenue Recognition - Assets and Liabilities (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
 [2]
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]        
Receivables from contracts with customers, net of allowances $ 130.3 $ 106.7 [1]    
Contract liability - short-term 42.3 4.4 [1]    
Contract liability - long-term 238.1 217.8 [1]   $ 198.0
Increase, receivables from contracts with customers, net of allowances 23.6      
Increase, contract liability - short-term 37.9 $ (11.1) [2] $ 15.5  
Increase, contract liability - long-term $ 20.3      
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
[2] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Revenue Recognition - Performance Obligations (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 - USD ($)
$ in Billions
Dec. 31, 2024
Jul. 25, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Remaining performance obligation $ 1.4  
Expected timing of satisfaction of performance obligations 4 years 6 years
v3.25.0.1
Inventories, Net (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Finished goods $ 99.8 $ 59.1
Semi-finished goods 202.5 108.8
Raw materials, supplies, and other 115.3 49.6
FIFO inventory, net $ 417.6 $ 217.5
v3.25.0.1
Partially-Owned Subsidiaries and Noncontrolling Interests - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 06, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Jan. 03, 2025
Sep. 30, 2024
Dec. 31, 2020
Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]                
Cash and cash equivalents   $ 93.2 $ 237.6 [1]          
Total long-term debt   960.6 302.0          
Investment in-transit - Nemaska Lithium [2]   96.7 0.0 [3] $ 0.0 [3]        
Equity in net loss of unconsolidated affiliates   7.5 $ 23.1 [3],[4] 15.1 [3],[4]        
Cash held in subsidiary entities   $ 21.1            
Investment interest-free loan repaid dividends percentage   33.00%            
Significant Unobservable Inputs (Level 3)                
Schedule of Equity Method Investments [Line Items]                
JEMSE Receivable   $ 5.0            
Line of Credit                
Schedule of Equity Method Investments [Line Items]                
Restricted cash, noncurrent   $ 18.1            
Sales De Jujuy Pte Ltd                
Schedule of Equity Method Investments [Line Items]                
Ownership percentage   72.68%            
Sales De Jujuy Pte Ltd | Toyota Tsusho Corporation                
Schedule of Equity Method Investments [Line Items]                
Subsidiary, ownership percentage, noncontrolling owner   27.32%            
Sales De Jujuy S.A                
Schedule of Equity Method Investments [Line Items]                
Ownership percentage   66.50%            
Sales De Jujuy S.A | Jujuy Energia y Minera Sociedad del Estado                
Schedule of Equity Method Investments [Line Items]                
Subsidiary, ownership percentage, noncontrolling owner   8.50%            
Olaroz                
Schedule of Equity Method Investments [Line Items]                
Ownership percentage   66.50%            
Olaroz | Toyota Tsusho Corporation                
Schedule of Equity Method Investments [Line Items]                
Subsidiary, ownership percentage, noncontrolling owner   25.00%            
Olaroz | Jujuy Energia y Minera Sociedad del Estado                
Schedule of Equity Method Investments [Line Items]                
Subsidiary, ownership percentage, noncontrolling owner   8.50%            
Sales De Jujuy Pte Ltd | Sales De Jujuy S.A                
Schedule of Equity Method Investments [Line Items]                
Ownership percentage   91.50%            
Nemaska Lithium                
Schedule of Equity Method Investments [Line Items]                
Equity interest percentage 50.00%           25.00%  
Equity method investments       $ 437.1        
Nemaska Lithium | Canadian Government                
Schedule of Equity Method Investments [Line Items]                
Equity interest percentage 50.00%              
Nemaska Lithium Inc.                
Schedule of Equity Method Investments [Line Items]                
Cash and cash equivalents           $ 11.4    
Cumulative proceeds from supply agreement   $ 225.0            
Total long-term debt   152.1            
Contract with customer, liability   72.9            
Contract with customer, asset, after allowance for credit loss   $ 350.0            
Nemaska Lithium Inc. | Subsequent Event                
Schedule of Equity Method Investments [Line Items]                
Contract with customer, asset, after allowance for credit loss         $ 125.0      
Quebec Lithium Partners UK                
Schedule of Equity Method Investments [Line Items]                
Voting interest percentage 50.00%           50.00% 50.00%
Number of shares issued in transaction (in shares) 17,500,000              
Equity method investments $ 387.1              
Cash and cash equivalents 0.3              
Short-term debt 13.5              
Issuance of common stock $ 373.9              
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
[2] Represents the Company's cash contributed to Nemaska Lithium in the fourth quarter of 2024 which, due to one-quarter lag reporting, is not yet recorded in our consolidation of Nemaska. The balance is recorded to Other assets - noncurrent because the cash is expected to be used by Nemaska primarily for capital expenditures. See Note 9 for details.
[3] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
[4] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Partially-Owned Subsidiaries and Noncontrolling Interests - Summarized Financial Information (Details) - USD ($)
$ in Millions
Oct. 18, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
 [2]
Sep. 30, 2022
Dec. 31, 2021
 [2]
ASSETS            
Cash and cash equivalents   $ 93.2 $ 237.6 [1]      
Prepaid expenses   42.8 16.9      
Total current assets   859.8 648.2 [1]      
Property, plant and equipment   7,371.2 2,237.1 [1]      
Goodwill   1,362.9 120.7 [1]      
Other non-current assets   412.3 127.7 [1]      
Total assets   10,190.1 3,230.1 [1]      
LIABILITIES AND EQUITY            
Current portion of long-term debt   288.9 2.4 [1]      
Total current liabilities   789.0 268.6 [1]      
Long-term debt   671.7 299.6 [1]      
Contract liability - long-term   238.1 217.8 [1]   $ 198.0  
Asset retirement obligations   14.2 3.7      
Deferred income taxes   1,151.0 126.4 [1]      
Other non-current liabilities   111.7 21.3 [1]      
Total current and long-term liabilities   3,009.3 946.3 [1]      
Arcadium shareholders’ equity   6,261.9 1,784.2 [1]      
Noncontrolling interest   918.9 499.6 [1]      
Total equity   7,180.8 2,283.8 [1],[2] $ 1,443.0   $ 795.4
Total liabilities and equity   10,190.1 3,230.1 [1]      
Debt discount   $ 0.9 $ 2.4      
Nemaska Lithium            
ASSETS            
Cash and cash equivalents $ 133.5          
Sales tax receivable 9.2          
Prepaid expenses 3.4          
Total current assets 146.1          
In-trust deposits 9.9          
Property, plant and equipment 932.2          
Goodwill 119.2          
Intangible assets 45.0          
Other non-current assets 0.5          
Total non-current assets 1,106.8          
Total assets 1,252.9          
LIABILITIES AND EQUITY            
Current portion of long-term debt 2.4          
Accounts payable and accrued liabilities 59.8          
Total current liabilities 62.2          
Long-term debt 56.1          
Contract liability - long-term 19.8          
Asset retirement obligations 3.4          
Deferred income taxes 111.9          
Other non-current liabilities 0.3          
Total non-current liabilities 191.5          
Total current and long-term liabilities 253.7          
Arcadium shareholders’ equity 499.6          
Noncontrolling interest 499.6          
Total equity 999.2          
Total liabilities and equity $ 1,252.9          
Weighted average amortization period 15 years          
Proceeds from Nemaska supply agreement prepayment $ 75.0          
Nemaska Lithium | Prepayment Agreement            
LIABILITIES AND EQUITY            
Debt discount $ 19.8          
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
[2] Represents the financial position of predecessor Livent as of December 31, 2023, 2022 and 2021 which does not include the financial position of Allkem.
v3.25.0.1
Investments - Equity Method Investments (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]    
Investments $ 36.9 $ 34.8 [1]
ESM ILiAD, LLC    
Schedule of Equity Method Investments [Line Items]    
Investments 30.1 30.1
Arcadium NQSP    
Schedule of Equity Method Investments [Line Items]    
Investments 6.3 4.7
Other    
Schedule of Equity Method Investments [Line Items]    
Investments $ 0.5 $ 0.0
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
v3.25.0.1
Investments - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
 [2],[3]
Schedule of Equity Method Investments [Line Items]      
Investments $ 36,900,000 $ 34,800,000 [1]  
Equity in net loss of unconsolidated affiliates $ 7,500,000 23,100,000 [2],[3] $ 15,100,000
Toyotsu Lithium Corporation      
Schedule of Equity Method Investments [Line Items]      
Ownership percentage 75.00%    
Subsidiary, economic ownership percentage, noncontrolling owner 51.00%    
Toyotsu Lithium Corporation | Class A Voting Shares      
Schedule of Equity Method Investments [Line Items]      
Ownership percentage 49.00%    
Toyotsu Lithium Corporation | Class B Nonvoting Shares      
Schedule of Equity Method Investments [Line Items]      
Ownership percentage 100.00%    
Toyota Tsusho Corporation      
Schedule of Equity Method Investments [Line Items]      
Ownership percentage 49.00%    
Subsidiary, economic ownership percentage, noncontrolling owner 25.00%    
Toyota Tsusho Corporation | Class A Voting Shares      
Schedule of Equity Method Investments [Line Items]      
Ownership percentage 51.00%    
ESM ILiAD, LLC      
Schedule of Equity Method Investments [Line Items]      
Investments $ 30,100,000 $ 30,100,000  
Toyotsu Lithium Corporation      
Schedule of Equity Method Investments [Line Items]      
Equity method investments 0    
Financing receivable, after allowance for credit loss $ 0    
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
[2] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
[3] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Total cost $ 7,722.4 $ 2,506.2
Accumulated depreciation (351.2) (269.1)
Property, plant and equipment, net 7,371.2 2,237.1 [1]
Land and land improvements    
Property, Plant and Equipment [Line Items]    
Total cost 337.0 106.2
Buildings    
Property, Plant and Equipment [Line Items]    
Total cost $ 1,006.8 134.9
Buildings | Minimum    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 20 years  
Buildings | Maximum    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 40 years  
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Total cost $ 1,011.8 420.7
Machinery and equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 3 years  
Machinery and equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 18 years  
Mineral rights    
Property, Plant and Equipment [Line Items]    
Total cost $ 3,184.9 560.0
Construction in progress    
Property, Plant and Equipment [Line Items]    
Total cost $ 2,181.9 $ 1,284.4
Land improvements    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 20 years  
Leased plant and equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 1 year  
Leased plant and equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 10 years 6 months  
Other machinery and equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 3 years  
Other machinery and equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 18 years  
Software | Minimum    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 3 years  
Software | Maximum    
Property, Plant and Equipment [Line Items]    
Useful life (in years) 10 years  
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
v3.25.0.1
Property, Plant, and Equipment, Net - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Abstract]      
Depreciation $ 120.2 $ 26.6 $ 25.1
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring and other charges    
Non-cash impairment charge $ 51.7    
v3.25.0.1
Restructuring and Other Charges (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Restructuring charges:      
Severance-related and exit costs $ 19.0 $ 2.4 $ 1.8
Other charges:      
Loss on asset replacement 6.9 0.0 0.0
Other 4.2 0.4 2.6
Total restructuring and other charges 157.2 56.9 [1] 7.3 [1]
Rio Tinto      
Other charges:      
Acquisition related costs 23.2 0.0 0.0
Allkem Livent Merger      
Other charges:      
Acquisition related costs $ 103.9 $ 54.1 $ 2.9
[1] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Environmental Obligations - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Environmental Remediation Obligations [Abstract]      
Accrual for environmental loss contingencies $ 7.8 $ 7.5 $ 7.0
Loss exposure in excess of accrual $ 1.3    
v3.25.0.1
Environmental Obligations - Environmental Reserve Rollforward (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Accrual for Environmental Loss Contingencies [Roll Forward]    
Total environmental reserves, net of recoveries, beginning balance $ 7.5 $ 7.0
Change in reserves 4.3 0.8
Acquisitions - Allkem Livent Merger 2.8  
Cash payments (6.8) (0.3)
Total environmental reserves, net of recoveries, ending balance $ 7.8 $ 7.5
v3.25.0.1
Environmental Obligations - Reserves (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Environmental Remediation Obligations [Abstract]      
Environmental reserves, current $ 0.9 $ 0.5  
Environmental Loss Contingency, Current, Statement of Financial Position [Extensible Enumeration] Accrued and other liabilities Accrued and other liabilities  
Environmental reserves, long-term $ 6.9 $ 7.0 [1]  
Total environmental reserves $ 7.8 $ 7.5 $ 7.0
Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration] Environmental reserves, long-term, Accrued and other liabilities Environmental reserves, long-term, Accrued and other liabilities  
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
v3.25.0.1
Other (Gains)/Losses (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Other Income and Expenses [Abstract]      
Non-recurring - SDV and MdA Holdings LLC $ (45.2) $ (61.6) $ (22.2)
Recurring - SDJ and MdA (22.6) (6.9) 0.0
Total Blue Chip Swap gains (67.8) (68.5) (22.2)
Foreign currency remeasurement (gains)/losses:      
Foreign currency remeasurement (gains)/losses (171.3) 68.9 7.0
Remeasurement gains on U.S. dollar denominated cash held by foreign currency functional subsidiary (14.3) 0.0 0.0
Total Foreign currency remeasurement (gains)/losses (185.6) 68.9 7.0
Loss on trading securities and other 1.0 0.0 0.0
Total Other (gains)/losses $ (252.4) $ 0.4 [1] $ (15.2) [1]
[1] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Income Taxes - Domestic and Foreign Income Tax Components (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
Domestic $ (21.5) $ 34.8 $ 133.2
Foreign 232.1 354.2 202.2
Income from operations before income taxes $ 210.6 $ 389.0 [1] $ 335.4 [1]
[1] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Income Taxes - Provision (Benefit) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Current:      
Federal $ 9.5 $ 31.7 $ 43.7
Foreign 89.7 27.6 5.6
State (0.4) 0.6 1.3
Total current 98.8 59.9 50.6
Deferred:      
Federal 6.5 4.5 (1.9)
Foreign (26.7) (5.9) 13.3
State 0.3 0.4 (0.1)
Total deferred (19.9) (1.0) 11.3
Total $ 78.9 $ 58.9 [1] $ 61.9 [1]
[1] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
U.S. Federal statutory rate $ 44.2 $ 81.7 $ 70.4
Foreign earnings subject to different tax rates (9.6) (78.9) (30.0)
Foreign derived intangible income 0.0 (0.9) (2.1)
State and local income taxes, less federal income tax benefit (0.1) 0.9 0.9
Tax on intercompany dividends and deemed dividends for tax purposes 3.5 27.7 19.8
Changes to unrecognized tax benefits 6.8 0.4 (0.5)
Other non-deductible expenses 23.5 6.2 0.1
Other non-taxable income (2.8) (4.9) (2.9)
Change in valuation allowance (44.6) 66.0 (1.7)
Exchange gains and losses 40.1 (43.0) 6.9
Withholding taxes net of credits 7.3 4.7 0.6
Tax on global activities 5.4 0.0 0.0
Other 5.2 (1.0) 0.4
Total 78.9 58.9 [1] $ 61.9 [1]
Argentina      
Effective Income Tax Rate Reconciliation [Line Items]      
Increase (decrease) in valuation allowance $ (77.2) $ 60.3  
[1] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Effective Income Tax Rate Reconciliation [Line Items]    
Net operating loss carry-forwards and credits $ 203.9 $ 239.2
Exploration and development expenses 11.2 12.0
Disallowed interest expense 88.9 8.8
Other assets and reserves 12.4 20.7
Deferred tax assets 316.4 280.7
Valuation allowance, net (46.9) (83.1)
Deferred tax assets, net of valuation allowance 269.5 197.6
Property, plant and equipment, net (1,322.6) (281.8)
Intangibles (6.3) (11.8)
Deferred inflationary gain (49.0) (28.4)
Other liabilities (4.7) (0.6)
Deferred tax liabilities (1,382.6) (322.6)
Net deferred tax liabilities (1,113.1) (125.0)
Argentina    
Effective Income Tax Rate Reconciliation [Line Items]    
Valuation allowance, net (3.4)  
Argentina | Foreign Tax Jurisdiction    
Effective Income Tax Rate Reconciliation [Line Items]    
Valuation allowance, net   $ (80.2)
Allkem Livent Merger    
Effective Income Tax Rate Reconciliation [Line Items]    
Disallowed interest expense 47.8  
Property, plant and equipment, net $ (1,311.7)  
v3.25.0.1
Income Taxes - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Contingency [Line Items]        
Valuation allowance $ 46,900,000 $ 83,100,000    
Unrecognized tax benefits 14,700,000 4,700,000 $ 4,500,000 $ 2,900,000
Unrecognized tax benefits that would impact effective tax rate 11,900,000      
Interest and penalties recognized 9,200,000 300,000 $ 200,000  
Interest and penalties accrued 7,100,000 1,100,000    
Minimum        
Income Tax Contingency [Line Items]        
Possible increase in unrecognized tax benefits 0      
Maximum        
Income Tax Contingency [Line Items]        
Possible increase in unrecognized tax benefits 400,000      
IRELAND        
Income Tax Contingency [Line Items]        
Valuation allowance 28,900,000      
Argentina        
Income Tax Contingency [Line Items]        
Valuation allowance 3,400,000      
Operating loss carryforwards 153,300,000 $ 233,100,000    
Operating loss carryforwards, expiring period   5 years    
Canada        
Income Tax Contingency [Line Items]        
Operating loss carryforwards $ 153,300,000 $ 233,100,000    
Operating loss carryforwards, expiring period 20 years 20 years    
v3.25.0.1
Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Unrecognized Tax Benefits [Roll Forward]      
Balance at beginning of year $ 4.7 $ 4.5 $ 2.9
Increases related to positions taken in the current year 4.5 0.4 3.3
Decreases related to positions taken in prior years (3.7) 0.0 0.0
Increases related to positions taken in prior years 14.2 0.0 0.0
Decreases related to lapse of statutes of limitations (0.8) (0.2) (0.1)
Settlement of uncertain tax positions (4.2) 0.0 (1.6)
Balance at end of year $ 14.7 $ 4.7 $ 4.5
v3.25.0.1
Asset Retirement Obligations (Details) - Allkem Livent Merger
$ in Millions
Dec. 31, 2024
USD ($)
Mt Cattlin Spodumene Mine  
Business Acquisition [Line Items]  
Asset retirement obligations acquired $ 9.4
Olaroz  
Business Acquisition [Line Items]  
Asset retirement obligations acquired 1.5
Galaxy Lithium (SAL DE VIDA) S.A  
Business Acquisition [Line Items]  
Asset retirement obligations acquired $ 1.0
v3.25.0.1
Debt - Long-term Debt (Details) - USD ($)
$ in Millions
May 30, 2024
Dec. 31, 2024
Sep. 10, 2024
Dec. 31, 2023
Oct. 18, 2023
Debt Instrument [Line Items]          
Transaction costs/discount   $ (0.9)   $ (2.4)  
Subtotal long-term debt (including current maturities)   960.6   302.0  
Less current maturities   (288.9)   (2.4) [1]  
Total long-term debt   $ 671.7   299.6 [1]  
Nemaska Lithium          
Debt Instrument [Line Items]          
Less current maturities         $ (2.4)
Total long-term debt         $ 56.1
Prepayment Agreement Tranche One | Nemaska Lithium          
Debt Instrument [Line Items]          
Debt interest rate   8.90%      
Transaction costs/discount   $ (20.1)   (19.8)  
Nemaska - Prepayment agreement/Other   $ 75.0   75.0  
Prepayment Agreement Tranche Two | Nemaska Lithium          
Debt Instrument [Line Items]          
Debt interest rate   9.40%      
Transaction costs/discount   $ (52.8)   0.0  
Nemaska - Prepayment agreement/Other   150.0   0.0  
Other | Nemaska Lithium          
Debt Instrument [Line Items]          
Nemaska - Prepayment agreement/Other   0.6   3.4  
Total debt assumed in Allkem Livent Merger          
Debt Instrument [Line Items]          
Subtotal long-term debt (including current maturities)   219.0   0.0  
Convertible Debt          
Debt Instrument [Line Items]          
Long-term debt, gross   $ 245.8   245.8  
Debt interest rate   4.125%      
Line of Credit | Project Loan Facility - Stage 2 of Olaroz Plant          
Debt Instrument [Line Items]          
Long-term debt, gross   $ 135.0 $ 9.0 0.0  
Debt interest rate   2.6119%      
Line of Credit | Affiliate Loans with TTC          
Debt Instrument [Line Items]          
Long-term debt, gross   $ 81.5   0.0  
Debt interest rate   14.30%      
Line of Credit | Affiliate Loan with TLP          
Debt Instrument [Line Items]          
Long-term debt, gross   $ 2.5   0.0  
Debt interest rate   10.03%      
Line of Credit | Project Loan Facility - Stage 1 of Olaroz Plant          
Debt Instrument [Line Items]          
Long-term debt, gross     $ 9.1    
Line of Credit | Project Financing Facility - Sal de Vida          
Debt Instrument [Line Items]          
Long-term debt, gross $ 47.0        
Payment for debt extinguishment or debt prepayment cost 0.9        
Deferred financing costs $ 1.3        
Revolving Credit Facility          
Debt Instrument [Line Items]          
Letters of credit outstanding, amount   $ 16.8   15.5  
Line of credit, remaining borrowing capacity   139.2   484.5  
Revolving Credit Facility | Line of Credit          
Debt Instrument [Line Items]          
Long-term debt, gross   $ 344.0   $ 0.0  
Revolving Credit Facility | Line of Credit | SOFR borrowings          
Debt Instrument [Line Items]          
Credit facility, interest rate   6.18%      
Revolving Credit Facility | Line of Credit | Base rate borrowings          
Debt Instrument [Line Items]          
Credit facility, interest rate   8.25%      
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
v3.25.0.1
Debt - Narrative (Details)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Jan. 30, 2025
USD ($)
Jan. 22, 2025
USD ($)
May 30, 2024
USD ($)
Jan. 04, 2024
USD ($)
$ / shares
Mar. 31, 2024
day
Dec. 31, 2024
USD ($)
loan
shares
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
 [1]
Dec. 31, 2020
USD ($)
day
$ / shares
shares
Sep. 10, 2024
USD ($)
Mar. 07, 2024
USD ($)
Debt Instrument [Line Items]                      
Loss on debt extinguishment           $ 1.1 $ 0.0 [1] $ 0.1      
Cash and cash equivalents           $ 93.2 237.6 [2]        
Convertible Debt                      
Debt Instrument [Line Items]                      
Debt interest rate           4.125%          
Long-term debt, gross           $ 245.8 245.8        
Convertible Debt | Conversion Circumstance One                      
Debt Instrument [Line Items]                      
Percentage of conversion price         130.00%            
Trading days | day         20            
Consecutive trading days | day         30            
Line of Credit                      
Debt Instrument [Line Items]                      
Restricted cash, noncurrent           $ 18.1          
Pari Passu Term Loan | Subsequent Event                      
Debt Instrument [Line Items]                      
Proceeds from issuance of debt $ 199.5                    
Debt instrument, fee amount 0.5                    
Convertible Senior Notes Due 2025                      
Debt Instrument [Line Items]                      
Debt discount, excluding amortization             10.1        
Convertible Senior Notes Due 2025 | Convertible Debt                      
Debt Instrument [Line Items]                      
Aggregate principal amount of debt                 $ 245.8    
Debt interest rate           4.125%     4.125%    
Conversion ratio (in shares) | shares           0.275459331     0.1144885    
Initial conversion price per share (in dollars per share) | $ / shares       $ 3.63         $ 8.73    
Percentage of conversion price                 130.00%    
Trading days | day                 20    
Consecutive trading days | day                 30    
Redemption price, percentage of principal amount                 100.00%    
Amortization of discount and transaction costs           $ 1.5 1.5        
Convertible Senior Notes, Over-Allotment Option | Convertible Debt                      
Debt Instrument [Line Items]                      
Net cash proceeds from debt                 $ 238.2    
Payments of debt issuance costs                 $ 7.6    
Project Financing Facility - Sal de Vida | Line of Credit                      
Debt Instrument [Line Items]                      
Maximum borrowing capacity     $ 180.0                
Deferred financing costs     1.3                
Debt instruments, ownership percentage           1          
Long-term debt, gross     47.0                
Payment for debt extinguishment or debt prepayment cost     $ 0.9                
Project Loan Facility - Stage 1 And Stage 2 of Olaroz Plant | Line of Credit                      
Debt Instrument [Line Items]                      
Long-term debt, gross                     $ 18.1
Project Loan Facility - Stage 1 of Olaroz Plant | Line of Credit                      
Debt Instrument [Line Items]                      
Long-term debt, gross                   $ 9.1  
Project Loan Facility - Stage 2 of Olaroz Plant | Line of Credit                      
Debt Instrument [Line Items]                      
Debt interest rate           2.6119%          
Long-term debt, gross           $ 135.0 0.0     $ 9.0  
Cash and cash equivalents           $ 101.3          
Permitted reduction fee           0.025          
Project Financing Facility - Mizuho                      
Debt Instrument [Line Items]                      
Restricted cash, noncurrent           $ 18.1          
Affiliate Loans with TTC | Line of Credit                      
Debt Instrument [Line Items]                      
Aggregate principal amount of debt           $ 93.0          
Debt interest rate           14.30%          
Long-term debt, gross           $ 81.5 0.0        
Number of loans | loan           11          
Revolving Credit Facility | Line of Credit                      
Debt Instrument [Line Items]                      
Long-term debt, gross           $ 344.0 $ 0.0        
Revolving Credit Facility | Credit Agreement | Line of Credit                      
Debt Instrument [Line Items]                      
Basis spread on variable rate       0.10%              
Floor rate       0.00%              
Maximum borrowing capacity       $ 500.0              
Maximum increase in revolving credit commitments       $ 700.0              
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]       SOFR borrowings              
Commitment fee percentage       0.25%              
Deferred financing costs           0.8          
Loss on debt extinguishment           0.2          
Deferred financing costs           $ 2.1          
Net leverage ratio           3.5          
Minimum interest coverage ratio           3.5          
Letter of Credit | Credit Agreement | Line of Credit                      
Debt Instrument [Line Items]                      
Maximum borrowing capacity       $ 50.0              
Secured Debt | Pari Passu Term Loan | Subsequent Event                      
Debt Instrument [Line Items]                      
Basis spread on variable rate   0.10%                  
Floor rate   0.00%                  
Proceeds from issuance of debt 199.5                    
Debt instrument, fee amount $ 0.5                    
Secured Debt | Pari Passu Term Loan | First Lien Secured Term Loan Facility | Subsequent Event                      
Debt Instrument [Line Items]                      
Aggregate principal amount of debt   $ 200.0                  
Secured Debt | Pari Passu Term Loan | Second Lien Secured Term Loan Facility | Subsequent Event                      
Debt Instrument [Line Items]                      
Aggregate principal amount of debt   $ 300.0                  
[1] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
[2] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
v3.25.0.1
Share-Based Compensation - Narrative (Details)
$ / shares in Units, $ in Millions
 12 Months Ended
Jan. 04, 2024
shares
Jan. 03, 2024
USD ($)
Dec. 31, 2024
USD ($)
publicly_traded_peer
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Right to receive per share amount (in dollars per share) | $ / shares     $ 5.85    
Number of publicly traded peers | publicly_traded_peer     10    
Weighted average grant date fair value (in dollars per share) | $ / shares     $ 1.89 $ 9.22 $ 7.01
Exercised     $ 0.3 $ 1.4 $ 4.9
Legacy Livent Awards          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Common stock, shares authorized (in shares) | shares     6,579,305    
Share option awards          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based payment award, expiration period (in years)     10 years    
Unrecognized compensation cost     $ 5.7 $ 1.8  
Requisite service period (in years)     2 years 2 months 12 days    
RSU awards          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Weighted average grant date fair value (in dollars per share) | $ / shares       $ 9.51 $ 9.44
Unrecognized compensation cost     $ 15.4    
Requisite service period (in years)     2 years 1 month 6 days    
Accelerated vesting, number (in shares) | shares     927,510    
Intrinsic value of awards vested   $ 5.3 $ 10.4 $ 1.8 $ 4.7
Fair value of awards vested     $ 14.1 $ 0.8 $ 2.5
PRSU awards          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Accelerated vesting, number (in shares) | shares 96,885        
PRSU awards | Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage 0.00%        
PRSU awards | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage 100.00%        
Arcadium Lithium Omnibus Incentive Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Common stock, shares authorized (in shares) | shares     64,548,000    
Share-based payment award, expiration period (in years)     10 years    
v3.25.0.1
Share-Based Compensation - Share Compensation (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock compensation expense, tax $ (0.2) $ 1.5 $ 1.1
Stock compensation expense 28.1 8.0 5.8
Selling, General and Administrative Expenses      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Gross stock compensation charges 12.2 8.4 6.8
Restructuring Charges      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Gross stock compensation charges 15.7 1.1 0.1
Share option awards      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock compensation expense, tax 0.4 0.3 0.3
Stock compensation expense 3.0 1.7 1.8
RSU awards      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock compensation expense, tax (0.7) 0.9 0.7
Stock compensation expense 24.7 4.5 3.6
PRSU awards      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock compensation expense, tax 0.1 0.3 0.1
Stock compensation expense $ 0.4 $ 1.8 $ 0.4
v3.25.0.1
Share-Based Compensation - Black Scholes Assumptions (Details) - Share option awards
Sep. 01, 2024
Jul. 30, 2024
Jun. 28, 2024
May 14, 2024
Mar. 06, 2024
Feb. 22, 2023
Feb. 23, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Expected dividend yield 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Expected volatility 35.06% 33.22% 33.00% 31.97% 31.18% 30.19% 28.89%
Expected life (in years) 6 years 6 years 6 years 6 years 6 years 6 years 6 months 6 years 6 months
Risk-free interest rate 3.72% 4.00% 4.28% 4.41% 4.08% 4.04% 1.95%
v3.25.0.1
Share-Based Compensation - Share Option Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 12 Months Ended
Dec. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Number of Options Granted But Not Exercised        
Beginning balance (in shares)   5,060,687    
Granted (in shares)   4,055,748    
Exercised (in shares)   (171,819)    
Forfeited (in shares)   (275,656)    
Ending balance (in shares) 8,668,960 8,668,960 5,060,687  
Exercisable (in shares) 4,069,419,000 4,069,419,000    
Weighted-Average Remaining Contractual Life (in Years)        
Outstanding   6 years 7 months 6 days 5 years 7 months 6 days  
Exercisable   4 years 1 month 6 days    
Weighted-Average Exercise Price Per Share        
Outstanding (in dollars per share)   $ 6.73    
Granted (in dollars per share)   4.82    
Exercised (in dollars per share)   3.58    
Forfeited (in dollars per share)   5.22    
Outstanding (in dollars per share) $ 5.95 5.95 $ 6.73  
Exercisable (in dollars per share) $ 6.30 $ 6.30    
Aggregate Intrinsic Value (in Millions)        
Outstanding $ 2.9 $ 2.9 $ 6.5  
Exercised   0.3 $ 1.4 $ 4.9
Exercisable $ 1.7 $ 1.7    
Vested (in shares) 706,975      
v3.25.0.1
Share-Based Compensation - RSU and PRSU Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 12 Months Ended
Jan. 12, 2024
Jan. 03, 2024
Dec. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
RSU awards            
Number of awards            
Nonvested, beginning balance (in shares)       2,287,088    
Granted (in shares) 1,080,825     5,217,604    
Vested (in shares)   (768,440) (347,361) (2,634,791)    
Forfeited (in shares)       (290,380)    
Nonvested, ending balance (in shares)     4,579,521 4,579,521 2,287,088  
Weighted-Average Grant Date Fair Value            
Nonvested, beginning balance (in dollars per share)       $ 7.83    
Granted (in dollars per share)       4.89    
Vested (in dollars per share)       6.82    
Forfeited (in dollars per share)       5.52    
Nonvested, ending balance (in dollars per share)     $ 5.21 $ 5.21 $ 7.83  
Aggregate Intrinsic Value (in Millions)            
Aggregate intrinsic value     $ 23.5 $ 23.5 $ 17.1  
Intrinsic value of awards vested   $ 5.3   $ 10.4 $ 1.8 $ 4.7
PRSU awards            
Number of awards            
Nonvested, beginning balance (in shares)       96,885    
Vested (in shares)       (96,885)    
Nonvested, ending balance (in shares)     0 0 96,885  
Weighted-Average Grant Date Fair Value            
Nonvested, beginning balance (in dollars per share)       $ 9.42    
Vested (in dollars per share)       9.42    
Nonvested, ending balance (in dollars per share)     $ 0 $ 0 $ 9.42  
Aggregate Intrinsic Value (in Millions)            
Aggregate intrinsic value     $ 0.0 $ 0.0 $ 0.7  
v3.25.0.1
Equity - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Jan. 04, 2024
Dec. 31, 2021
Equity [Abstract]          
Common stock, authorized (in shares) 5,000,000,000 5,000,000,000   5,000,000,000  
Common stock, par value (in dollars per share) $ 1.00 $ 1.00 $ 1.00 $ 1.00 $ 1.00
Preferred Stock, Shares Authorized 125,000,000     125,000,000  
Preferred stock, par value (in dollars per share) $ 1.00     $ 1.00  
Dividends paid $ 0 $ 0 $ 0    
v3.25.0.1
Equity - Summary of Common Stock Activity (Details)
 12 Months Ended
Dec. 31, 2024
shares
Dec. 31, 2023
shares
Jan. 04, 2024
Dec. 31, 2022
Issued        
Beginning balance (in shares) 433,059,946 432,243,013    
Arcadium share option awards (in shares) 4,055,748      
Ending balance (in shares) 1,076,519,022 433,059,946    
Treasury        
Beginning balance (in shares) (263,669) (249,202)    
Net purchases of treasury shares - NQSP (in shares)   (14,467)    
Net sales of treasury shares - Arcadium NQSP (in shares) 3,525      
Ending balance (in shares) (260,144) (263,669)    
Outstanding        
Beginning balance (in shares) 432,796,277 431,993,811    
Net purchases of treasury shares - NQSP (in shares)   (14,467)    
Ending balance (in shares) 1,076,258,878 432,796,277    
Exchange ratio   2.406   2.406
Allkem Livent Merger        
Outstanding        
Exchange ratio     2.406  
Allkem Livent Merger | Common Stock        
Outstanding        
Exchange ratio   2.406   2.406
Common Stock        
Issued        
Stock issued during period (in shares)   274    
Issued to Allkem shareholders - Allkem Livent Merger (in shares) 641,337,840      
Outstanding        
Stock issued during period (in shares)   274    
Livent Plan | Common Stock        
Issued        
Stock issued during period (in shares) 641,337,840      
Outstanding        
Stock issued during period (in shares) 641,337,840      
RSU awards        
Issued        
Stock issued during period (in shares)   324,577    
PRSU and RSU awards (in shares) 1,345,007      
Outstanding        
Stock issued during period (in shares)   324,577    
RSU awards | Arcadium        
Issued        
Stock issued during period (in shares) 1,345,007      
Outstanding        
Stock issued during period (in shares) 1,345,007      
PRSU awards        
Issued        
Stock issued during period (in shares)   126,421    
Outstanding        
Stock issued during period (in shares)   126,421    
Share option awards        
Issued        
Stock issued during period (in shares)   365,661    
Outstanding        
Stock issued during period (in shares)   365,661    
Share option awards | Arcadium        
Issued        
Stock issued during period (in shares) 127,260      
Arcadium share option awards (in shares) 127,260      
Outstanding        
Stock issued during period (in shares) 127,260      
Performance Share and Restricted Stock Units        
Issued        
PRSU and RSU awards (in shares) 648,969      
Performance Share and Restricted Stock Units | Livent Plan        
Issued        
Stock issued during period (in shares) 648,969      
Outstanding        
Stock issued during period (in shares) 648,969      
v3.25.0.1
Equity - Schedule of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance [1] $ 1,784.2  
Other comprehensive income before reclassifications (41.2) $ 0.7
Amounts reclassified from accumulated other comprehensive loss 0.6 0.5
Ending balance 6,261.9 1,784.2 [1]
Total    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (49.8) (51.0)
Ending balance (90.4) (49.8)
Foreign currency adjustments    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (49.8) (51.0)
Other comprehensive income before reclassifications (40.6) 1.2
Amounts reclassified from accumulated other comprehensive loss 0.0 0.0
Ending balance (90.4) (49.8)
Derivative Instruments    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 0.0 0.0
Other comprehensive income before reclassifications (0.6) (0.5)
Amounts reclassified from accumulated other comprehensive loss 0.6 0.5
Ending balance $ 0.0 $ 0.0
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
v3.25.0.1
Equity - Reclassification Out of Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Total before tax $ (210.6) $ (389.0) [1] $ (335.4) [1]
Income tax expense 78.9 58.9 [1] 61.9 [1]
Net income (131.7) (330.1) [2] (273.5) [2]
Amounts Reclassified from Accumulated Other Comprehensive Loss      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Net income 0.6 0.5 0.7
Derivative Instruments | Amounts Reclassified from Accumulated Other Comprehensive Loss      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Total before tax 0.6 0.5 0.9
Income tax expense 0.0 0.0 (0.2)
Net income 0.6 0.5 0.7
Foreign currency contracts | Derivative Instruments | Amounts Reclassified from Accumulated Other Comprehensive Loss      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Costs of sales $ 0.6 $ 0.5 $ 0.9
[1] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
[2] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Earnings Per Share - EPS Computation (Details)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Numerator:      
Net income attributable to Arcadium Lithium plc | $ $ 103.2 $ 330.1 [1],[2] $ 273.5 [1],[2]
Denominator:      
Weighted average ordinary shares outstanding - basic (in shares) 1,069.8 432.4 [1] 413.4 [1]
Dilutive share equivalents from share-based plans (in shares) 1.2 3.3 4.1
Dilutive share equivalents from 2025 Notes (in shares) 67.7 67.7 67.7
Weighted average ordinary shares outstanding - diluted (in shares) 1,138.7 503.4 [1] 485.2 [1]
Basic earnings per ordinary share (in dollars per share) | $ / shares $ 0.10 $ 0.76 [1] $ 0.66 [1]
Diluted earnings per ordinary share (in dollars per share) | $ / shares $ 0.09 $ 0.66 [1] $ 0.56 [1]
Exchange ratio   2.406 2.406
[1] For the years ended ended December 31, 2023 and 2022, basic and diluted earnings per ordinary share and weighted average ordinary shares outstanding - basic and diluted amounts represent predecessor Livent and have been adjusted to reflect the 2.406 Exchange Ratio. Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
[2] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Earnings Per Share - Narrative (Details) - $ / shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive securities, exercise price (in dollars per share) $ 4.82    
Share option awards      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Total antidilutive weighted average share equivalents (in shares) 8,162,842 373,901 0
Antidilutive securities, exercise price (in dollars per share) $ 6.25 $ 9.70  
v3.25.0.1
Financial Instruments, Risk Management and Fair Value Measurements - Narrative (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
 [1]
Derivative [Line Items]    
Long-term debt $ 671.7 $ 299.6
Estimate of Fair Value Measurement    
Derivative [Line Items]    
Debt value 1,146.2  
Foreign currency contracts | Not Designated as Hedging Instrument    
Derivative [Line Items]    
Notional amount $ 145.6  
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
v3.25.0.1
Financial Instruments, Risk Management and Fair Value Measurements - Derivatives in Cash Flow Hedging Relationships (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance [1] $ 1,784.2    
Unrealized hedging losses, net of tax (41.2) $ 0.7  
Reclassification of deferred hedging losses, net of tax 0.6 0.5  
Other comprehensive (loss)/income, net of tax (40.6) 1.2 [2] $ (8.1) [2]
Ending balance 6,261.9 1,784.2 [1]  
Derivative Instruments      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance 0.0 0.0  
Unrealized hedging losses, net of tax (0.6) (0.5)  
Reclassification of deferred hedging losses, net of tax 0.6 0.5  
Other comprehensive (loss)/income, net of tax 0.0 0.0  
Ending balance $ 0.0 $ 0.0 $ 0.0
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
[2] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Financial Instruments, Risk Management and Fair Value Measurements - Derivatives Not Designated As Cash Flow Hedging Instruments (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Derivative [Line Items]      
Amount of pre-tax loss recognized in income on derivatives $ 18.9 $ (2.8) $ (5.2)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of sales Cost of sales Cost of sales
Foreign Exchange contracts      
Derivative [Line Items]      
Amount of pre-tax loss recognized in income on derivatives $ 18.9 $ (2.8) $ (5.2)
v3.25.0.1
Financial Instruments, Risk Management and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Assets    
Investments in deferred compensation plan $ 6,300,000 $ 4,100,000
Equity securities 300,000  
Total Assets 11,600,000 4,100,000
Liabilities    
Deferred compensation plan obligation 7,600,000 6,700,000
Total Liabilities 7,600,000 6,700,000
Cash Flow Hedging | Designated as Hedging Instrument    
Liabilities    
Total Liabilities   0
Selling, General and Administrative Expenses    
Liabilities    
Mark-to-market gains (loss) on deferred compensation plan 600,000 200,000
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets    
Investments in deferred compensation plan 6,300,000 4,100,000
JEMSE Receivable 0  
Equity securities 300,000  
Total Assets 6,600,000 4,100,000
Liabilities    
Deferred compensation plan obligation 7,600,000 6,700,000
Total Liabilities 7,600,000 6,700,000
Significant Other Observable Inputs (Level 2)    
Assets    
Investments in deferred compensation plan 0 0
JEMSE Receivable 0  
Equity securities 0  
Total Assets 0 0
Liabilities    
Deferred compensation plan obligation 0 0
Total Liabilities 0 0
Significant Unobservable Inputs (Level 3)    
Assets    
Investments in deferred compensation plan 0 0
JEMSE Receivable 5,000,000  
Equity securities 0  
Total Assets 5,000,000.0 0
Liabilities    
Deferred compensation plan obligation 0 0
Total Liabilities $ 0 $ 0
v3.25.0.1
Commitments and Contingencies - Narrative (Details)
$ in Millions, $ in Millions
Jan. 16, 2025
CAD ($)
Dec. 31, 2024
USD ($)
Sep. 06, 2024
lawsuit
Jan. 04, 2024
USD ($)
Oct. 31, 2023
Oct. 26, 2023
Feb. 28, 2023
Feb. 08, 2023
Lessor, Lease, Description [Line Items]                
Operating lease, weighted average remaining lease term (in years)   8 years 4 months 24 days            
Operating lease, weighted average discount rate (as a percent)   8.70%            
Export rate, percent of FOB value           1.50% 4.00%  
Export LA Puna rate, percent of FOB value               0.025
Remaining export rate, percent of FOB value         0.015     0.015
Number of class action lawsuits | lawsuit     2          
Subsequent Event                
Lessor, Lease, Description [Line Items]                
Monetary damages $ 30.0              
Minera Del Altiplano                
Lessor, Lease, Description [Line Items]                
Export rebate receivable   $ 5.4            
Sales De Jujuy S.A                
Lessor, Lease, Description [Line Items]                
Export rebate receivable   $ 1.7            
Allkem Livent Merger                
Lessor, Lease, Description [Line Items]                
Operating lease liabilities       $ 53.4        
Right of use assets - operating leases, net       $ 53.4        
Minimum                
Lessor, Lease, Description [Line Items]                
Lessee, operating lease, remaining lease term   2 years            
Maximum                
Lessor, Lease, Description [Line Items]                
Lessee, operating lease, remaining lease term   26 years            
v3.25.0.1
Commitments and Contingencies - Lease Cost (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Lease Cost      
Operating lease cost $ 15.5 $ 1.4 $ 1.3
Short-term lease cost 0.5 0.4 0.4
Total lease cost 16.0 1.8 1.7
Cash paid for amounts included in the measurement of lease liabilities:      
Cash paid for operating leases $ 14.9 $ 1.4 $ 1.3
v3.25.0.1
Commitments and Contingencies - Maturity of Operating Lease Liabilities (Details)
$ in Millions
Dec. 31, 2024
USD ($)
Undiscounted cash flows  
2025 $ 10.2
2026 9.4
2027 8.7
2028 8.5
2029 9.0
Thereafter 26.0
Total future minimum lease payments 71.8
Less: Imputed interest (25.0)
Total $ 46.8
v3.25.0.1
Supplemental Information - Prepaid and Other Current Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Prepaid and other current assets    
Income tax receivable - refunds and prepayments $ 82.2 $ 29.5
Argentina government receivable 40.6 7.9
Prepaid expenses 42.8 16.9
Other receivables 47.8 28.2
Bank Acceptance Drafts 1.1 0.0
Other Assets, Current 4.2 3.9
Total $ 218.7 $ 86.4 [1]
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
v3.25.0.1
Supplemental Information - Other Assets (Details) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
 [2]
Nov. 06, 2023
Other assets          
Argentina government receivable   $ 131.8 $ 71.3    
Advance to contract manufacturers   27.9 27.6    
Long-term semi-finished goods inventory   105.0 1.0    
Tax related items   4.3 4.0    
Capitalized software, net   2.3 1.1    
Investment in transit - Nemaska Lithium   96.7 0.0    
Deposits   23.4 0.0    
Other long-term assets   20.9 22.7    
Total   412.3 127.7 [1]    
Condensed Balance Sheet Statements, Captions [Line Items]          
Export tax receivable portion   34.8      
Payment of deposit to customs authorities $ 21.7 0.0 21.7 [2] $ 0.0  
Argentina Government          
Condensed Balance Sheet Statements, Captions [Line Items]          
Export tax and export rebate receivable   $ 42.0 $ 38.8    
Settlement amount to be paid         $ 34.4
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
[2] Represents the results of predecessor Livent’s operations for the years ended December 31, 2023 and 2022 which do not include the operations of Allkem.
v3.25.0.1
Supplemental Information - Accrued and Other Current Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Accrued and other current liabilities    
Accrued payroll $ 46.2 $ 20.3
Restructuring reserves 1.4 1.7
Retirement liability - 401k 3.5 3.2
Environmental reserves, current 0.9 0.5
Accrued investment in unconsolidated affiliates 0.0 27.0
Accrued capital expenditures 137.8 84.1
Accrued and other liabilities $ 189.8 $ 136.8 [1]
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.
v3.25.0.1
Supplemental Information - Other Long-Term Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Other long-term liabilities    
Deferred compensation plan obligation $ 7.6 $ 6.7
Contingencies related to uncertain tax positions 22.2 6.2
Self-insurance reserves 1.1 1.1
Asset retirement obligations 14.2 3.7
Affiliate Loans with TTC - accrued interest 53.4 0.0
Other long-term liabilities 13.2 3.6
Total 111.7 $ 21.3 [1]
TMA Agreement, Uncertain Tax Positions    
Other long-term liabilities    
Contingencies related to uncertain tax positions 21.8  
TMA Agreement, Indemnification Liability    
Other long-term liabilities    
Contingencies related to uncertain tax positions $ 0.4  
[1] Represents the financial position of predecessor Livent as of December 31, 2023 which does not include the financial position of Allkem.